BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. The Lancet 2003;362:1907-17. [DOI: 10.1016/s0140-6736(03)14964-1] [Cited by in Crossref: 3076] [Cited by in F6Publishing: 1246] [Article Influence: 170.9] [Reference Citation Analysis]
Number Citing Articles
1 Tschida BR, Largaespada DA, Keng VW. Mouse models of cancer: Sleeping Beauty transposons for insertional mutagenesis screens and reverse genetic studies. Semin Cell Dev Biol 2014;27:86-95. [PMID: 24468652 DOI: 10.1016/j.semcdb.2014.01.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
2 Gao F, Xia Y, Wang J, Lin Z, Ou Y, Liu X, Liu W, Zhou B, Luo H, Zhou B, Wen B, Zhang X, Huang J. Integrated analyses of DNA methylation and hydroxymethylation reveal tumor suppressive roles of ECM1, ATF5, and EOMES in human hepatocellular carcinoma. Genome Biol 2014;15:533. [PMID: 25517360 DOI: 10.1186/s13059-014-0533-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
3 Napel SA, Beaulieu CF, Rodriguez C, Cui J, Xu J, Gupta A, Korenblum D, Greenspan H, Ma Y, Rubin DL. Automated retrieval of CT images of liver lesions on the basis of image similarity: method and preliminary results. Radiology 2010;256:243-52. [PMID: 20505065 DOI: 10.1148/radiol.10091694] [Cited by in Crossref: 81] [Cited by in F6Publishing: 43] [Article Influence: 7.4] [Reference Citation Analysis]
4 Mason MC, Massarweh NN, Salami A, Sultenfuss MA, Anaya DA. Post-embolization syndrome as an early predictor of overall survival after transarterial chemoembolization for hepatocellular carcinoma. HPB (Oxford) 2015;17:1137-44. [PMID: 26374137 DOI: 10.1111/hpb.12487] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
5 Wang YB, Chen MH, Yan K, Yang W, Dai Y, Yin SS. Quality of life after radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinoma: comparison with transcatheter arterial chemoembolization alone. Qual Life Res. 2007;16:389-397. [PMID: 17111232 DOI: 10.1007/s11136-006-9133-9] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 3.7] [Reference Citation Analysis]
6 Jung KS, Park KH, Chon YE, Lee SR, Park YN, Lee DY, Seong JS, Park JY. A case of isolated metastatic hepatocellular carcinoma arising from the pelvic bone. Korean J Hepatol 2012;18:89-93. [PMID: 22511908 DOI: 10.3350/kjhep.2012.18.1.89] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
7 Hanaoka H, Nakajima T, Sato K, Watanabe R, Phung Y, Gao W, Harada T, Kim I, Paik CH, Choyke PL, Ho M, Kobayashi H. Photoimmunotherapy of hepatocellular carcinoma-targeting Glypican-3 combined with nanosized albumin-bound paclitaxel. Nanomedicine (Lond) 2015;10:1139-47. [PMID: 25929570 DOI: 10.2217/nnm.14.194] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 6.6] [Reference Citation Analysis]
8 Tang BD, Xia X, Lv XF, Yu BX, Yuan JN, Mai XY, Shang JY, Zhou JG, Liang SJ, Pang RP. Inhibition of Orai1-mediated Ca2+ entry enhances chemosensitivity of HepG2 hepatocarcinoma cells to 5-fluorouracil. J Cell Mol Med 2017;21:904-15. [PMID: 27878958 DOI: 10.1111/jcmm.13029] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 7.8] [Reference Citation Analysis]
9 Llovet JM. Treatment of hepatocellular carcinoma. Curr Treat Options Gastro 2004;7:431-41. [DOI: 10.1007/s11938-004-0002-8] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
10 Amano H, Tashiro H, Oshita A, Kobayashi T, Tanimoto Y, Kuroda S, Tazawa H, Itamoto T, Asahara T, Ohdan H. Significance of Platelet Count in the Outcomes of Hepatectomized Patients with Hepatocellular Carcinoma Exceeding the Milan Criteria. J Gastrointest Surg 2011;15:1173-81. [DOI: 10.1007/s11605-011-1538-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
11 Jin YJ, Lee JW, Park SW, Lee JI, Lee DH, Kim YS, Cho SG, Jeon YS, Lee KY, Ahn SI. Survival outcome of patients with spontaneously ruptured hepatocellular carcinoma treated surgically or by transarterial embolization. World J Gastroenterol. 2013;19:4537-4544. [PMID: 23901230 DOI: 10.3748/wjg.v19.i28.4537] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
12 Caraiani CN, Marian D, Militaru C, Calin A, Badea R. The role of the diffusion sequence in magnetic resonance imaging for the differential diagnosis between hepatocellular carcinoma and benign liver lesions. Clujul Med. 2016;89:241-249. [PMID: 27152076 DOI: 10.15386/cjmed-567] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
13 Kamino H, Moore R, Negishi M. Role of a novel CAR-induced gene, TUBA8, in hepatocellular carcinoma cell lines. Cancer Genet 2011;204:382-91. [PMID: 21872825 DOI: 10.1016/j.cancergen.2011.05.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
14 Koh S, Shimasaki N, Suwanarusk R, Ho ZZ, Chia A, Banu N, Howland SW, Ong AS, Gehring AJ, Stauss H, Renia L, Sällberg M, Campana D, Bertoletti A. A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus. Mol Ther Nucleic Acids 2013;2:e114. [PMID: 23941866 DOI: 10.1038/mtna.2013.43] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 8.5] [Reference Citation Analysis]
15 Grizzi F, Franceschini B, Hamrick C, Frezza EE, Cobos E, Chiriva-Internati M. Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma. J Transl Med 2007;5:3. [PMID: 17244360 DOI: 10.1186/1479-5876-5-3] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 3.6] [Reference Citation Analysis]
16 Teng CL, Hwang WL, Chen YJ, Chang KH, Cheng SB. Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study. World J Surg Oncol. 2012;10:41. [PMID: 22339891 DOI: 10.1186/1477-7819-10-41] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
17 Li Y, Zhou B, Dai J, Liu R, Han ZG. Aberrant upregulation of LRRC1 contributes to human hepatocellular carcinoma. Mol Biol Rep 2013;40:4543-51. [PMID: 23645086 DOI: 10.1007/s11033-013-2549-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
18 Bouattour M, Payancé A, Wassermann J. Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging. World J Hepatol 2015;7:2245-63. [PMID: 26380650 DOI: 10.4254/wjh.v7.i20.2245] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
19 Liu J, Liu R, Liu Y, Li L, Cao H, Liu J, Cao G. ZSCAN16-AS1 expedites hepatocellular carcinoma progression via modulating the miR-181c-5p/SPAG9 axis to activate the JNK pathway. Cell Cycle 2021;20:1134-46. [PMID: 34097562 DOI: 10.1080/15384101.2021.1919828] [Reference Citation Analysis]
20 Romano M, De Francesco F, Pirozzi G, Gringeri E, Boetto R, Di Domenico M, Zavan B, Ferraro GA, Cillo U. Expression of cancer stem cell biomarkers as a tool for a correct therapeutic approach to hepatocellular carcinoma. Oncoscience 2015;2:443-56. [PMID: 26097877 DOI: 10.18632/oncoscience.163] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
21 Dong L, Xie L, Li M, Dai H, Wang X, Wang P, Zhang Q, Liu W, Hu X, Zhao M. Downregulation of B7-H4 suppresses tumor progression of hepatocellular carcinoma. Sci Rep 2019;9:14854. [PMID: 31619714 DOI: 10.1038/s41598-019-51253-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Clavien PA. Interferon: the magic bullet to prevent hepatocellular carcinoma recurrence after resection? Ann Surg. 2007;245:843-845. [PMID: 17522507 DOI: 10.1097/sla.0b013e31805d0788] [Cited by in Crossref: 31] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
23 Yin XY, Lü MD, Liang LJ, Lai JM, Li DM, Kuang M. Systemic chemo-immunotherapy for advanced-stage hepatocellular carcinoma. World J Gastroenterol 2005;11:2526-9. [PMID: 15832431 DOI: 10.3748/wjg.v11.i16.2526] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
24 Andrisani OM, Studach L, Merle P. Gene signatures in hepatocellular carcinoma (HCC). Semin Cancer Biol 2011;21:4-9. [PMID: 20851183 DOI: 10.1016/j.semcancer.2010.09.002] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
25 Li M, Pathak RR, Lopez-Rivera E, Friedman SL, Aguirre-Ghiso JA, Sikora AG. The In Ovo Chick Chorioallantoic Membrane (CAM) Assay as an Efficient Xenograft Model of Hepatocellular Carcinoma. J Vis Exp 2015. [PMID: 26484588 DOI: 10.3791/52411] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
26 Li J, Yang D, He Y, Wang M, Wen Z, Liu L, Yao J, Matsuda K, Nakamura Y, Yu J. Associations of HLA-DP variants with hepatitis B virus infection in southern and northern Han Chinese populations: a multicenter case-control study. PLoS One. 2011;6:e24221. [PMID: 21904616 DOI: 10.1371/journal.pone.0024221] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 4.1] [Reference Citation Analysis]
27 Ohki T, Sato K, Yamagami M, Ito D, Yamada T, Kawanishi K, Kojima K, Seki M, Toda N, Tagawa K. Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in Japan: a retrospective analysis. Clin Drug Investig 2015;35:751-9. [PMID: 26446004 DOI: 10.1007/s40261-015-0333-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
28 Treiber G, Wex T, Röcken C, Fostitsch P, Malfertheiner P. Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 2006;132:699-708. [PMID: 16835748 DOI: 10.1007/s00432-006-0118-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
29 He B, Zhang H, Shi T. A comprehensive analysis of the dynamic biological networks in HCV induced hepatocarcinogenesis. PLoS One 2011;6:e18516. [PMID: 21526182 DOI: 10.1371/journal.pone.0018516] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
30 Qu LS, Zhou GX. Significance of viral status on occurrence of hepatitis B-related hepatocellular carcinoma. World J Gastroenterol 2014;20:5999-6005. [PMID: 24876722 DOI: 10.3748/wjg.v20.i20.5999] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
31 Yang H, Xiong FX, Lin M, Yang Y, Nie X, Zhou RL. LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol 2010;136:275-81. [PMID: 19690886 DOI: 10.1007/s00432-009-0659-4] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 4.0] [Reference Citation Analysis]
32 Wei W, Chua MS, Grepper S, So SK. Blockade of Wnt-1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells. Mol Cancer 2009;8:76. [PMID: 19778454 DOI: 10.1186/1476-4598-8-76] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 5.3] [Reference Citation Analysis]
33 Pande SB, Doval DC, Pavithran K, Sharma JB, Shirali R, Jena A. Gemcitabine and cisplatin-based combination chemotherapy in advanced hepatocellular carcinoma: An Indian experience. Indian J Med Paediatr Oncol 2012;33:42-7. [PMID: 22754208 DOI: 10.4103/0971-5851.96968] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
34 Gu YK, Luo RG, Huang JH, Si Tu QJ, Li XX, Gao F. Transarterial embolization ablation of hepatocellular carcinoma with a lipiodol-ethanol mixture. World J Gastroenterol 2010;16:5766-72. [PMID: 21128329 DOI: 10.3748/wjg.v16.i45.5766] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
35 Shiina S, Sato K, Tateishi R, Shimizu M, Ohama H, Hatanaka T, Takawa M, Nagamatsu H, Imai Y. Percutaneous Ablation for Hepatocellular Carcinoma: Comparison of Various Ablation Techniques and Surgery. Can J Gastroenterol Hepatol 2018;2018:4756147. [PMID: 29974040 DOI: 10.1155/2018/4756147] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 10.3] [Reference Citation Analysis]
36 Yamakado K, Hirota S. Sub-classification of intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinomas. World J Gastroenterol 2015;21:10604-8. [PMID: 26457020 DOI: 10.3748/wjg.v21.i37.10604] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
37 Satgé D, Sasco AJ, Vekemans MJ, Portal ML, Fléjou JF. Aspects of digestive tract tumors in Down syndrome: a literature review. Dig Dis Sci 2006;51:2053-61. [PMID: 17009117 DOI: 10.1007/s10620-006-9131-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
38 Motola DL, Caravan P, Chung RT, Fuchs BC. Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions. Curr Pathobiol Rep 2014;2:245-56. [PMID: 25396099 DOI: 10.1007/s40139-014-0061-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
39 Zhao J, Vykoukal J, Abdelsalam M, Recio-Boiles A, Huang Q, Qiao Y, Singhana B, Wallace M, Avritscher R, Melancon MP. Stem cell-mediated delivery of SPIO-loaded gold nanoparticles for the theranosis of liver injury and hepatocellular carcinoma. Nanotechnology 2014;25:405101. [PMID: 25211057 DOI: 10.1088/0957-4484/25/40/405101] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
40 Yuan J, Liang H, Li J, Li M, Tang B, Ma H, Xie X, Yin X, Zhang L, Ren Z. Peripheral blood neutrophil count as a prognostic factor for patients with hepatocellular carcinoma treated with sorafenib. Mol Clin Oncol 2017;7:837-42. [PMID: 29181175 DOI: 10.3892/mco.2017.1416] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
41 Lee JM, Jang BK, Lee YJ, Choi WY, Choi SM, Chung WJ, Hwang JS, Kang KJ, Kim YH, Chauhan AK. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis. Clin Mol Hepatol. 2016;22:160-167. [PMID: 27044767 DOI: 10.3350/cmh.2016.22.1.160] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 9.2] [Reference Citation Analysis]
42 Liu J, Fan L, Yu H, Zhang J, He Y, Feng D, Wang F, Li X, Liu Q, Li Y, Guo Z, Gao B, Wei W, Wang H, Sun G. Endoplasmic Reticulum Stress Causes Liver Cancer Cells to Release Exosomal miR-23a-3p and Up-regulate Programmed Death Ligand 1 Expression in Macrophages. Hepatology 2019;70:241-58. [PMID: 30854665 DOI: 10.1002/hep.30607] [Cited by in Crossref: 52] [Cited by in F6Publishing: 82] [Article Influence: 26.0] [Reference Citation Analysis]
43 Cao WZ, Zhou ZQ, Jiang S, Li H, Niu W, Gao P, Li GJ, Chen F. Efficacy and safety of drug-eluting beads for transarterial chemoembolization in patients with advanced hepatocellular carcinoma. Exp Ther Med 2019;18:4625-30. [PMID: 31798699 DOI: 10.3892/etm.2019.8163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
44 Kong LQ, Zhu XD, Xu HX, Zhang JB, Lu L, Wang WQ, Zhang QB, Wu WZ, Wang L, Fan J. The clinical significance of the CD163+ and CD68+ macrophages in patients with hepatocellular carcinoma. PLoS One. 2013;8:e59771. [PMID: 23555776 DOI: 10.1371/journal.pone.0059771] [Cited by in Crossref: 60] [Cited by in F6Publishing: 50] [Article Influence: 7.5] [Reference Citation Analysis]
45 Comar M, Dal Molin G, D'Agaro P, Crocè SL, Tiribelli C, Campello C. HBV, HCV, and TTV detection by in situ polymerase chain reaction could reveal occult infection in hepatocellular carcinoma: comparison with blood markers. J Clin Pathol. 2006;59:526-529. [PMID: 16537674 DOI: 10.1136/jcp.2005.033050] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
46 Zhang JY, Xu D, Liu ZZ, Li Y, Wang LJ, Xing BC. Human U Three Protein 14a Expression is Increased in Hepatocellular Carcinoma and Associated with Poor Prognosis. Chin Med J (Engl) 2017;130:470-6. [PMID: 28218222 DOI: 10.4103/0366-6999.199839] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
47 Zheng Z, Liu J, Yang Z, Wu L, Xie H, Jiang C, Lin B, Chen T, Xing C, Liu Z, Song P, Yin S, Zheng S, Zhou L. MicroRNA-452 promotes stem-like cells of hepatocellular carcinoma by inhibiting Sox7 involving Wnt/β-catenin signaling pathway. Oncotarget 2016;7:28000-12. [PMID: 27058905 DOI: 10.18632/oncotarget.8584] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 12.0] [Reference Citation Analysis]
48 Wu J, Chen P, Xie YG, Gong NM, Sun LL, Sun CF. Comparison of the effectiveness and safety of ultrasound- and CT-guided percutaneous radiofrequency ablation of non-operation hepatocellular carcinoma. Pathol Oncol Res 2015;21:637-42. [PMID: 25466642 DOI: 10.1007/s12253-014-9868-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
49 Qiu DZ, Zhang ZJ, Wu WZ, Yang YK. Bufalin, a component in Chansu, inhibits proliferation and invasion of hepatocellular carcinoma cells. BMC Complement Altern Med. 2013;13:185. [PMID: 23870199 DOI: 10.1186/1472-6882-13-185] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 6.1] [Reference Citation Analysis]
50 Zeng QA, Qiu J, Zou R, Li Y, Li S, Li B, Huang P, Hong J, Zheng Y, Lao X, Yuan Y. Clinical features and outcome of multiple primary malignancies involving hepatocellular carcinoma: a long-term follow-up study. BMC Cancer 2012;12:148. [PMID: 22510321 DOI: 10.1186/1471-2407-12-148] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
51 Gholam PM, Iyer R, Johnson MS. Multidisciplinary Management of Patients with Unresectable Hepatocellular Carcinoma: A Critical Appraisal of Current Evidence. Cancers (Basel) 2019;11:E873. [PMID: 31234476 DOI: 10.3390/cancers11060873] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
52 Yao KF, Ma M, Ding GY, Li ZM, Chen HL, Han B, Chen Q, Jiang XQ, Wang LS. Meta-analysis reveals gender difference in the association of liver cancer incidence and excess BMI. Oncotarget 2017;8:72959-71. [PMID: 29069840 DOI: 10.18632/oncotarget.20127] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
53 Chen YJ, Chien PH, Chen WS, Chien YF, Hsu YY, Wang LY, Chen JY, Lin CW, Huang TC, Yu YL. Hepatitis B Virus-Encoded X Protein Downregulates EGFR Expression via Inducing MicroRNA-7 in Hepatocellular Carcinoma Cells. Evid Based Complement Alternat Med. 2013;2013:682380. [PMID: 23840262 DOI: 10.1155/2013/682380] [Cited by in Crossref: 14] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
54 Kirikoshi H, Yoneda M, Mawatari H, Fujita K, Imajo K, Kato S, Suzuki K, Kobayashi N, Kubota K, Maeda S. Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization? World J Gastroenterol. 2012;18:1933-1939. [PMID: 22563174 DOI: 10.3748/wjg.v18.i16.1933] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
55 Cho J, Lee J, Kim J, Kim ST, Lee S, Kim SY, Ha SY, Park CK, Lim HY. Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma. Transl Oncol 2016;9:466-71. [PMID: 27751352 DOI: 10.1016/j.tranon.2016.08.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
56 Villanueva A, Minguez B, Forner A, Reig M, Llovet JM. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 2010;61:317-28. [PMID: 20059340 DOI: 10.1146/annurev.med.080608.100623] [Cited by in Crossref: 160] [Cited by in F6Publishing: 146] [Article Influence: 14.5] [Reference Citation Analysis]
57 Ji XQ, Ruan XJ, Chen H, Chen G, Li SY, Yu B. Somatostatin analogues in advanced hepatocellular carcinoma: an updated systematic review and meta-analysis of randomized controlled trials. Med Sci Monit. 2011;17:RA169-RA176. [PMID: 21804474 DOI: 10.12659/msm.881892] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
58 Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL, Toffanin S, O'Sullivan M, Lu J, Phillips LA, Lockhart VL. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet. 2009;41:843-848. [PMID: 19483683 DOI: 10.1038/ng.392] [Cited by in Crossref: 576] [Cited by in F6Publishing: 541] [Article Influence: 48.0] [Reference Citation Analysis]
59 Xiao J, Ding Y, Huang J, Li Q, Liu Y, Ni W, Zhang Y, Zhu Y, Chen L, Chen B. The association of HMGB1 gene with the prognosis of HCC. PLoS One. 2014;9:e89097. [PMID: 24586525 DOI: 10.1371/journal.pone.0089097] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
60 Zhou N, Wu J, Wang X, Sun Z, Han Q, Zhao L. Low-level expression of microRNA-375 predicts poor prognosis in hepatocellular carcinoma. Tumour Biol. 2016;37:2145-2152. [PMID: 26349912 DOI: 10.1007/s13277-015-3841-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
61 Ruzzenente A, Capra F, Pachera S, Iacono C, Piccirillo G, Lunardi M, Pistoso S, Valdegamberi A, D’onofrio M, Guglielmi A. Is Liver Resection Justified in Advanced Hepatocellular Carcinoma? Results of an Observational Study in 464 Patients. J Gastrointest Surg 2009;13:1313-20. [DOI: 10.1007/s11605-009-0903-x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 4.4] [Reference Citation Analysis]
62 Franco RA, Fan Y, Jarosek S, Bae S, Galbraith J. Racial and Geographic Disparities in Hepatocellular Carcinoma Outcomes. Am J Prev Med 2018;55:S40-8. [PMID: 30670200 DOI: 10.1016/j.amepre.2018.05.030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 7.5] [Reference Citation Analysis]
63 Zhang Y, Hou J, Feng F, Li D, Jiang Q, Li X, Zhao Q, Li BA. Genetic polymorphisms in human UDP-glucuronosyltransferases 1A7 and the risk of gastrointestinal carcinomas: A systematic review and network meta-analysis. Oncotarget 2017;8:66371-81. [PMID: 29029519 DOI: 10.18632/oncotarget.18675] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
64 Kempinska K, Malik B, Borkin D, Klossowski S, Shukla S, Miao H, Wang J, Cierpicki T, Grembecka J. Pharmacologic Inhibition of the Menin-MLL Interaction Leads to Transcriptional Repression of PEG10 and Blocks Hepatocellular Carcinoma. Mol Cancer Ther 2018;17:26-38. [PMID: 29142068 DOI: 10.1158/1535-7163.MCT-17-0580] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
65 Tokumitsu Y, Shindo Y, Matsui H, Matsukuma S, Nakajima M, Suzuki N, Takeda S, Wada H, Kobayashi S, Eguchi H, Ueno T, Nagano H. Utility of scoring systems combining the product of tumor number and size with liver function for predicting the prognosis of patients with hepatocellular carcinoma after hepatectomy. Oncol Lett 2019;18:3903-13. [PMID: 31516601 DOI: 10.3892/ol.2019.10688] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
66 Huang J, Hernandez-Alejandro R, Croome KP, Yan L, Wu H, Chen Z, Prasoon P, Zeng Y. Radiofrequency ablation versus surgical resection for hepatocellular carcinoma in Childs A cirrhotics-a retrospective study of 1,061 cases. J Gastrointest Surg. 2011;15:311-320. [PMID: 21052859 DOI: 10.1007/s11605-010-1372-y] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 4.7] [Reference Citation Analysis]
67 Feng YH, Tung CL, Su YC, Tsao CJ, Wu TF. Proteomic Profile of Sorafenib Resistance in Hepatocellular Carcinoma; GRP78 Expression Is Associated With Inferior Response to Sorafenib. Cancer Genomics Proteomics 2019;16:569-76. [PMID: 31659110 DOI: 10.21873/cgp.20159] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
68 Zhou S, Ye W, Duan X, Zhang M, Wang J. The noncytotoxic dose of sorafenib sensitizes Bel-7402/5-FU cells to 5-FU by down-regulating 5-FU-induced Nrf2 expression. Dig Dis Sci 2013;58:1615-26. [PMID: 23314856 DOI: 10.1007/s10620-012-2537-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
69 Baker ES, Burnum-Johnson KE, Jacobs JM, Diamond DL, Brown RN, Ibrahim YM, Orton DJ, Piehowski PD, Purdy DE, Moore RJ, Danielson WF 3rd, Monroe ME, Crowell KL, Slysz GW, Gritsenko MA, Sandoval JD, Lamarche BL, Matzke MM, Webb-Robertson BJ, Simons BC, McMahon BJ, Bhattacharya R, Perkins JD, Carithers RL Jr, Strom S, Self SG, Katze MG, Anderson GA, Smith RD. Advancing the high throughput identification of liver fibrosis protein signatures using multiplexed ion mobility spectrometry. Mol Cell Proteomics 2014;13:1119-27. [PMID: 24403597 DOI: 10.1074/mcp.M113.034595] [Cited by in Crossref: 43] [Cited by in F6Publishing: 25] [Article Influence: 6.1] [Reference Citation Analysis]
70 Han XJ, Su HY, Shao HB, Xu K. Prognostic factors of spontaneously ruptured hepatocellular carcinoma. World J Gastroenterol. 2015;21:7488-7494. [PMID: 26139994 DOI: 10.3748/wjg.v21.i24.7488] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
71 Di Maso V, Avellini C, Crocè LS, Rosso N, Quadrifoglio F, Cesaratto L, Codarin E, Bedogni G, Beltrami CA, Tell G. Subcellular localization of APE1/Ref-1 in human hepatocellular carcinoma: possible prognostic significance. Mol Med. 2007;13:89-96. [PMID: 17515960 DOI: 10.2119/2006-00084.di] [Reference Citation Analysis]
72 Chen TA, Wang JL, Hung SW, Chu CL, Cheng YC, Liang SM. Recombinant VP1, an Akt inhibitor, suppresses progression of hepatocellular carcinoma by inducing apoptosis and modulation of CCL2 production. PLoS One. 2011;6:e23317. [PMID: 21826248 DOI: 10.1371/journal.pone.0023317] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
73 Klopstock N, Katzenellenbogen M, Pappo O, Sklair-Levy M, Olam D, Mizrahi L, Potikha T, Galun E, Goldenberg D. HCV tumor promoting effect is dependent on host genetic background. PLoS One. 2009;4:e5025. [PMID: 19340302 DOI: 10.1371/journal.pone.0005025] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
74 Park SJ, Jang JY, Jeong SW, Cho YK, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Park S, Bang HI. Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma. Medicine (Baltimore). 2017;96:e5811. [PMID: 28296720 DOI: 10.1097/md.0000000000005811] [Cited by in Crossref: 43] [Cited by in F6Publishing: 31] [Article Influence: 10.8] [Reference Citation Analysis]
75 Nishikawa H, Kimura T, Kita R, Osaki Y. Treatment for hepatocellular carcinoma in elderly patients: a literature review. J Cancer 2013;4:635-43. [PMID: 24155775 DOI: 10.7150/jca.7279] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 6.1] [Reference Citation Analysis]
76 Yang YM, Lee CG, Koo JH, Kim TH, Lee JM, An J, Kim KM, Kim SG. Gα12 overexpressed in hepatocellular carcinoma reduces microRNA-122 expression via HNF4α inactivation, which causes c-Met induction. Oncotarget 2015;6:19055-69. [PMID: 25965999 DOI: 10.18632/oncotarget.3957] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
77 Tong HV, Song le H, Hoan NX, Cuong BK, Sy BT, Son HA, Quyet D, Binh VQ, Kremsner PG, Bock CT, Velavan TP, Toan NL. Soluble MICB protein levels and platelet counts during hepatitis B virus infection and response to hepatocellular carcinoma treatment. BMC Infect Dis 2015;15:25. [PMID: 25626490 DOI: 10.1186/s12879-015-0754-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
78 You H, Ding W, Dang H, Jiang Y, Rountree CB. c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology. 2011;54:879-889. [PMID: 21618573 DOI: 10.1002/hep.24450] [Cited by in Crossref: 123] [Cited by in F6Publishing: 130] [Article Influence: 12.3] [Reference Citation Analysis]
79 Chow PK, Machin D, Chen Y, Zhang X, Win KM, Hoang HH, Nguyen BD, Jin MY, Lobo R, Findlay M. Randomised double-blind trial of megestrol acetate vs placebo in treatment-naive advanced hepatocellular carcinoma. Br J Cancer. 2011;105:945-952. [PMID: 21863030 DOI: 10.1038/bjc.2011.333] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
80 Idrees M, Rafique S, Rehman I, Akbar H, Yousaf MZ, Butt S, Awan Z, Manzoor S, Akram M, Aftab M, Khubaib B, Riazuddin S. Hepatitis C virus genotype 3a infection and hepatocellular carcinoma: Pakistan experience. World J Gastroenterol 2009;15:5080-5. [PMID: 19860002 DOI: 10.3748/wjg.15.5080] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 41] [Article Influence: 3.6] [Reference Citation Analysis]
81 Serizawa N, Tian J, Fukada H, Baghy K, Scott F, Chen X, Kiss Z, Olson K, Hsu D, Liu FT, Török NJ, Zhao B, Jiang JX. Galectin 3 regulates HCC cell invasion by RhoA and MLCK activation. Lab Invest 2015;95:1145-56. [PMID: 26146960 DOI: 10.1038/labinvest.2015.77] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
82 Man YN, Liu XH, Wu XZ. Chinese medicine herbal treatment based on syndrome differentiation improves the overall survival of patients with unresectable hepatocellular carcinoma. Chin J Integr Med 2015;21:49-57. [PMID: 25533651 DOI: 10.1007/s11655-014-1767-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
83 Sacco R, Bertini M, Petruzzi P, Bertoni M, Bargellini I, Bresci G, Federici G, Gambardella L, Metrangolo S, Parisi G, Romano A, Scaramuzzino A, Tumino E, Silvestri A, Altomare E, Vignali C, Capria A. Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: a cohort study. World J Gastroenterol 2009;15:1843-8. [PMID: 19370781 DOI: 10.3748/wjg.15.1843] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
84 Galuppo R, Ramaiah D, Ponte OM, Gedaly R. Molecular therapies in hepatocellular carcinoma: what can we target? Dig Dis Sci. 2014;59:1688-1697. [PMID: 24573715 DOI: 10.1007/s10620-014-3058-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
85 Duan C, Liu M, Zhang Z, Ma K, Bie P. Radiofrequency ablation versus hepatic resection for the treatment of early-stage hepatocellular carcinoma meeting Milan criteria: a systematic review and meta-analysis. World J Surg Oncol. 2013;11:190. [PMID: 23941614 DOI: 10.1186/1477-7819-11-190] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
86 Chidi AP, Bryce CL, Myaskovsky L, Fine MJ, Geller DA, Landsittel DP, Tsung A. Differences in Physician Referral Drive Disparities in Surgical Intervention for Hepatocellular Carcinoma: A Retrospective Cohort Study. Ann Surg 2016;263:362-8. [PMID: 25563883 DOI: 10.1097/SLA.0000000000001111] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
87 Zhang R, Wang C, Tian Y, Yao Y, Mao J, Wang H, Li Z, Xu Y, Ye M, Wang L. SIRT5 Promotes Hepatocellular Carcinoma Progression by Regulating Mitochondrial Apoptosis. J Cancer 2019;10:3871-82. [PMID: 31333804 DOI: 10.7150/jca.31266] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 8.5] [Reference Citation Analysis]
88 Fang T, Xiao J, Zhang Y, Hu H, Zhu Y, Cheng Y. Combined with interventional therapy, immunotherapy can create a new outlook for tumor treatment. Quant Imaging Med Surg 2021;11:2837-60. [PMID: 34079746 DOI: 10.21037/qims-20-173] [Reference Citation Analysis]
89 Liu L, Dong X, Zhu D, Song L, Zhang H, Leng XG. TAT-LHRH conjugated low molecular weight chitosan as a gene carrier specific for hepatocellular carcinoma cells. Int J Nanomedicine 2014;9:2879-89. [PMID: 24959076 DOI: 10.2147/IJN.S61392] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 2.1] [Reference Citation Analysis]
90 Peng C, Hu W, Weng X, Tong R, Cheng S, Ding C, Xiao H, Lv Z, Xie H, Zhou L, Wu J, Zheng S. Over Expression of Long Non-Coding RNA PANDA Promotes Hepatocellular Carcinoma by Inhibiting Senescence Associated Inflammatory Factor IL8. Sci Rep 2017;7:4186. [PMID: 28646235 DOI: 10.1038/s41598-017-04045-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
91 Yang J, Zhang JX, Wang H, Wang GL, Hu QG, Zheng QC. Hepatocellular carcinoma and macrophage interaction induced tumor immunosuppression via Treg requires TLR4 signaling. World J Gastroenterol. 2012;18:2938-2947. [PMID: 22736917 DOI: /10.3748/wjg.v18.i23.2938] [Reference Citation Analysis]
92 Zhang SG, Li YF, Zhao NN, Lai CC, Cheng SJ, Yan J, Zhang P, Wang Z, Wang XL, Yang PH. Decreased expression of long non-coding RNA LOC728290 in human hepatocellular carcinoma. Oncol Lett 2017;14:4551-6. [PMID: 29085452 DOI: 10.3892/ol.2017.6776] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
93 Ha Y, Lee JB, Shim JH, Kim KM, Lim YS, Yoon HK, Shin YM, Lee HC. Validation and reappraisal of the assessment for retreatment with transarterial chemoembolization score for unresectable non-metastatic hepatocellular carcinoma in a hepatitis b virus-endemic region. Eur Radiol 2016;26:3510-8. [PMID: 26747261 DOI: 10.1007/s00330-015-4185-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
94 Wang GW, Lv C, Shi ZR, Zeng RT, Dong XY, Zhang WD, Liu RH, Shan L, Shen YH. Abieslactone induces cell cycle arrest and apoptosis in human hepatocellular carcinomas through the mitochondrial pathway and the generation of reactive oxygen species. PLoS One 2014;9:e115151. [PMID: 25502685 DOI: 10.1371/journal.pone.0115151] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
95 Li JJ, Zheng JS, Cui SC, Cui XW, Hu CX, Fang D, Ye LC. C-arm Lipiodol CT in transcatheter arterial chemoembolization for small hepatocellular carcinoma. World J Gastroenterol. 2015;21:3035-3040. [PMID: 25780303 DOI: 10.3748/wjg.v21.i10.3035] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
96 Wang WD, Wen Z, Ji W, Ma Y. RACK1 expression contributes to JNK activity, but JNK activity does not enhance RACK1 expression in hepatocellular carcinoma SMMC-7721 cells. Oncol Lett 2015;9:2767-70. [PMID: 26137143 DOI: 10.3892/ol.2015.3129] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
97 Fischer MA, Kartalis N, Grigoriadis A, Loizou L, Stål P, Leidner B, Aspelin P, Brismar TB. Perfusion computed tomography for detection of hepatocellular carcinoma in patients with liver cirrhosis. Eur Radiol 2015;25:3123-32. [PMID: 25903707 DOI: 10.1007/s00330-015-3732-1] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
98 Hung CM, Huang WC, Pan HL, Chien PH, Lin CW, Chen LC, Chien YF, Lin CC, Leow KH, Chen WS, Chen JY, Ho CY, Hou PS, Chen YJ. Hepatitis B virus X upregulates HuR protein level to stabilize HER2 expression in hepatocellular carcinoma cells. Biomed Res Int 2014;2014:827415. [PMID: 24719890 DOI: 10.1155/2014/827415] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
99 Riordan JD, Feddersen CR, Tschida BR, Beckmann PJ, Keng VW, Linden MA, Amin K, Stipp CS, Largaespada DA, Dupuy AJ. Chronic liver injury alters driver mutation profiles in hepatocellular carcinoma in mice. Hepatology. 2018;67:924-939. [PMID: 28961327 DOI: 10.1002/hep.29565] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
100 Lin Y, Wang K, Hu C, Lin L, Qin S, Cai X. Elemene injection induced autophagy protects human hepatoma cancer cells from starvation and undergoing apoptosis. Evid Based Complement Alternat Med 2014;2014:637528. [PMID: 25152762 DOI: 10.1155/2014/637528] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
101 Liu YH, Weng YP, Lin HY, Tang SW, Chen CJ, Liang CJ, Ku CY, Lin JY. Aqueous extract of Polygonum bistorta modulates proteostasis by ROS-induced ER stress in human hepatoma cells. Sci Rep 2017;7:41437. [PMID: 28134285 DOI: 10.1038/srep41437] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
102 Wang R, Zhang D, Sun K, Peng J, Zhu W, Yin S, Tang D, Wu Y. Amygdalin promotes the activity of T cells to suppress the progression of HBV-related hepatocellular carcinoma via the JAK2/STAT3 signaling pathway. BMC Infect Dis 2021;21:56. [PMID: 33435880 DOI: 10.1186/s12879-020-05713-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
103 Zhou HB, Hu JY, Hu HP. Hepatitis B virus infection and intrahepatic cholangiocarcinoma. World J Gastroenterol. 2014;20:5721-5729. [PMID: 24914333 DOI: 10.3748/wjg.v20.i19.5721] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
104 Cho BC, Kim EH, Choi HJ, Kim JH, Roh JK, Chung HC, Ahn JB, Lee JD, Lee JT, Yoo NC, Sohn JH. A pilot study of trans-arterial injection of 166Holmium-Chitosan complex for treatment of small hepatocellular carcinoma. Yonsei Med J 2005;46:799-805. [PMID: 16385656 DOI: 10.3349/ymj.2005.46.6.799] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
105 Sonohara F, Inokawa Y, Hayashi M, Yamada S, Sugimoto H, Fujii T, Kodera Y, Nomoto S. Prognostic Value of Long Non-Coding RNA HULC and MALAT1 Following the Curative Resection of Hepatocellular Carcinoma. Sci Rep 2017;7:16142. [PMID: 29170515 DOI: 10.1038/s41598-017-16260-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
106 Appel-da-Silva MC, Miozzo SA, Dossin IA, Tovo CV, Branco F, de Mattos AA. Incidence of hepatocellular carcinoma in outpatients with cirrhosis in Brazil: A 10-year retrospective cohort study. World J Gastroenterol. 2016;22:10219-10225. [PMID: 28028370 DOI: 10.3748/wjg.v22.i46.10219] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
107 Urano S, Ohara T, Noma K, Katsube R, Ninomiya T, Tomono Y, Tazawa H, Kagawa S, Shirakawa Y, Kimura F. Iron depletion enhances the effect of sorafenib in hepatocarcinoma. Cancer Biol Ther. 2016;17:648-656. [PMID: 27089255 DOI: 10.1080/15384047.2016.1177677] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
108 Kim JM, Kwon CH, Joh JW, Ko JS, Park JB, Lee JH, Kim SJ, Paik SW, Park CK. C-reactive protein may be a prognostic factor in hepatocellular carcinoma with malignant portal vein invasion. World J Surg Oncol. 2013;11:92. [PMID: 23618082 DOI: 10.1186/1477-7819-11-92] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
109 Yamakado K, Miyayama S, Hirota S, Mizunuma K, Nakamura K, Inaba Y, Maeda A, Matsuo K, Nishida N, Aramaki T, Anai H, Koura S, Oikawa S, Watanabe K, Yasumoto T, Furuichi K, Yamaguchi M. Hepatic arterial embolization for unresectable hepatocellular carcinomas: do technical factors affect prognosis? Jpn J Radiol 2012;30:560-6. [PMID: 22644412 DOI: 10.1007/s11604-012-0088-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
110 Huether A, Hopfner M, Sutter AP, Baradari V, Schuppan D, Scherubl H. Signaling pathways involved in the inhibition of epidermal growth factor receptor by erlotinib in hepatocellular cancer. World J Gastroenterol 2006;12:5160-7. [PMID: 16937526 DOI: 10.3748/wjg.v12.i32.5160] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
111 Hwang JP, Hassan MM. Survival and hepatitis status among Asian Americans with hepatocellular carcinoma treated without liver transplantation. BMC Cancer 2009;9:46. [PMID: 19193234 DOI: 10.1186/1471-2407-9-46] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
112 Lloyd DM, Lau KN, Welsh F, Lee KF, Sherlock DJ, Choti MA, Martinie JB, Iannitti DA. International multicentre prospective study on microwave ablation of liver tumours: preliminary results. HPB (Oxford). 2011;13:579-585. [PMID: 21762302 DOI: 10.1111/j.1477-2574.2011.00338.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
113 Ikuta S, Aihara T, Yamanaka N. Efficacy of sequential sorafenib plus hepatic arterial infusion chemotherapy in patients with Barcelona Clinic Liver Cancer stage B and C hepatocellular carcinoma: a retrospective single-institution study. Contemp Oncol (Pozn) 2018;22:165-71. [PMID: 30455588 DOI: 10.5114/wo.2018.78948] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
114 Chen Y, Mo L, Wang X, Chen B, Hua Y, Gong L, Yang F, Li Y, Chen F, Zhu G, Ni W, Zhang C, Cheng Y, Luo Y, Shi J, Qiu M, Wu S, Tan Z, Wang K. TPGS-1000 exhibits potent anticancer activity for hepatocellular carcinoma in vitro and in vivo. Aging (Albany NY) 2020;12:1624-42. [PMID: 31986488 DOI: 10.18632/aging.102704] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
115 Kornek M, Lukacs-Kornek V, Limmer A, Raskopf E, Becker U, Klöckner M, Sauerbruch T, Schmitz V. 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP)-formulated, immune-stimulatory vascular endothelial growth factor a small interfering RNA (siRNA) increases antitumoral efficacy in murine orthotopic hepatocellular carcinoma with liver fibrosis. Mol Med 2008;14:365-73. [PMID: 18392108 DOI: 10.2119/2008-00003.Kornek] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
116 Chen YY, Yen HH, Chou KC, Wu SS. Thalidomide-based multidisciplinary treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis. World J Gastroenterol 2012;18:466-71. [PMID: 22346253 DOI: 10.3748/wjg.v18.i5.466] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
117 Dong W, Yu H, Zhu YY, Xian ZH, Chen J, Wang H, Shi CC, Jin GZ, Dong H, Cong WM. A Novel Pathological Scoring System for Hepatic Cirrhosis with Hepatocellular Carcinoma. Cancer Manag Res 2020;12:5537-47. [PMID: 32753967 DOI: 10.2147/CMAR.S223417] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
118 Jeong SW, Jang JY, Shim KY, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Kim KH, Kim JH. Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis. Gut Liver. 2013;7:696-703. [PMID: 24312711 DOI: 10.5009/gnl.2013.7.6.696] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 4.9] [Reference Citation Analysis]
119 Yuan L, Wang T, Zhang Y, Liu X, Zhang T, Li X, Liu P, Wu K, Shih JW, Yuan Q, Cheng T, Xia N. An HBV-tolerant immunocompetent model that effectively simulates chronic hepatitis B virus infection in mice. Exp Anim 2016;65:373-82. [PMID: 27264142 DOI: 10.1538/expanim.16-0013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
120 Cao X, Xia Y, Yang J, Jiang J, Chen L, Ni R, Li L, Gu Z. Clinical and biological significance of never in mitosis gene A-related kinase 6 (NEK6) expression in hepatic cell cancer. Pathol Oncol Res. 2012;18:201-207. [PMID: 21725899 DOI: 10.1007/s12253-011-9429-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
121 Liu TC, Vachharajani N, Chapman WC, Brunt EM. SALL4 immunoreactivity predicts prognosis in Western hepatocellular carcinoma patients but is a rare event: a study of 236 cases. Am J Surg Pathol 2014;38:966-72. [PMID: 24805857 DOI: 10.1097/PAS.0000000000000218] [Cited by in Crossref: 27] [Cited by in F6Publishing: 10] [Article Influence: 3.9] [Reference Citation Analysis]
122 Bartucci M, Hussein MS, Huselid E, Flaherty K, Patrizii M, Laddha SV, Kui C, Bigos RA, Gilleran JA, El Ansary MMS, Awad MAM, Kimball SD, Augeri DJ, Sabaawy HE. Synthesis and Characterization of Novel BMI1 Inhibitors Targeting Cellular Self-Renewal in Hepatocellular Carcinoma. Target Oncol 2017;12:449-62. [PMID: 28589491 DOI: 10.1007/s11523-017-0501-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
123 Suwa K, Seki T, Aoi K, Yamashina M, Murata M, Yamashiki N, Nishio A, Shimatani M, Naganuma M. Efficacy of microwave ablation versus radiofrequency ablation for hepatocellular carcinoma: a propensity score analysis. Abdom Radiol (NY) 2021;46:3790-7. [PMID: 33675382 DOI: 10.1007/s00261-021-03008-9] [Reference Citation Analysis]
124 Guo J, Ma Z, Ma Q, Wu Z, Fan P, Zhou X, Chen L, Zhou S, Goltzman D, Miao D, Wu E. 1, 25(OH)₂D₃ inhibits hepatocellular carcinoma development through reducing secretion of inflammatory cytokines from immunocytes. Curr Med Chem 2013;20:4131-41. [PMID: 23992309 DOI: 10.2174/09298673113209990248] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
125 Wang Y, Hu Y, Wu G, Yang Y, Tang Y, Zhang W, Wang K, Liu Y, Wang X, Li T. Long noncoding RNA PCAT-14 induces proliferation and invasion by hepatocellular carcinoma cells by inducing methylation of miR-372. Oncotarget 2017;8:34429-41. [PMID: 28415780 DOI: 10.18632/oncotarget.16260] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
126 Yang Q, Zhang W, Liu Q, Liu L, Wu L, Wang J, Yan Z, Luo J. TACE Combined with Implantation of Irradiation Stent Versus TACE Combine with Bare Stent for HCC Complicated by IVCTT. Cardiovasc Intervent Radiol 2016;39:1280-8. [DOI: 10.1007/s00270-016-1372-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
127 Zhang Q, Qiao L, Liao J, Liu Q, Liu P, Liu L. A novel hypoxia gene signature indicates prognosis and immune microenvironments characters in patients with hepatocellular carcinoma. J Cell Mol Med 2021;25:3772-84. [PMID: 33616276 DOI: 10.1111/jcmm.16249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
128 Samonakis DN, Notas G, Christodoulakis N, Kouroumalis EA. Mechanisms of action and resistance of somatostatin analogues for the treatment of hepatocellular carcinoma: a message not well taken. Dig Dis Sci. 2008;53:2359-2365. [PMID: 18273705 DOI: 10.1007/s10620-007-0175-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
129 Itokawa N, Atsukawa M, Tsubota A, Okubo T, Arai T, Nakagawa A, Kondo C, Iwakiri K. Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study. Int J Clin Oncol 2016;21:676-83. [PMID: 26701173 DOI: 10.1007/s10147-015-0942-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
130 Baddour N, Farrag E, Zeid A, Bedewy E, Taher Y. Decreased apoptosis in advanced-stage/high-grade hepatocellular carcinoma complicating chronic hepatitis C is mediated through the downregulation of p21 ras. Chin J Cancer Res 2013;25:281-8. [PMID: 23825904 DOI: 10.3978/j.issn.1000-9604.2013.04.02] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
131 Rammohan A, Sathyanesan J, Ramaswami S, Lakshmanan A, Senthil-Kumar P, Srinivasan UP, Ramasamy R, Ravichandran P. Embolization of liver tumors: Past, present and future. World J Radiol. 2012;4:405-412. [PMID: 23024842 DOI: 10.4329/wjr.v4.i9.405] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
132 Tarantino L, Sordelli I, Calise F, Ripa C, Perrotta M, Sperlongano P. Prognosis of patients with spontaneous rupture of hepatocellular carcinoma in cirrhosis. Updates Surg 2011;63:25-30. [DOI: 10.1007/s13304-010-0041-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
133 Shindoh J, Andreou A, Aloia TA, Zimmitti G, Lauwers GY, Laurent A, Nagorney DM, Belghiti J, Cherqui D, Poon RT, Kokudo N, Vauthey JN. Microvascular invasion does not predict long-term survival in hepatocellular carcinoma up to 2 cm: reappraisal of the staging system for solitary tumors. Ann Surg Oncol. 2013;20:1223-1229. [PMID: 23179993 DOI: 10.1245/s10434-012-2739-y] [Cited by in Crossref: 80] [Cited by in F6Publishing: 72] [Article Influence: 8.9] [Reference Citation Analysis]
134 Goh V, Sarker D, Osmany S, Cook GJ. Functional imaging techniques in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2012;39:1070-1079. [PMID: 22434049 DOI: 10.1007/s00259-012-2096-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
135 Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371:838-851. [PMID: 18328931 DOI: 10.1056/s0140-6736(08)60383-9] [Reference Citation Analysis]
136 Lee YH, Hsia CY, Hsu CY, Huang YH, Lin HC, Huo TI. Total tumor volume is a better marker of tumor burden in hepatocellular carcinoma defined by the Milan criteria. World J Surg 2013;37:1348-55. [PMID: 23467925 DOI: 10.1007/s00268-013-1978-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
137 Wang C, Che L, Hu J, Zhang S, Jiang L, Latte G, Demartis MI, Tao J, Gui B, Pilo MG, Ribback S, Dombrowski F, Evert M, Calvisi DF, Chen X. Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumour formation in mice via AKT2/mTORC1 cascade. Liver Int 2016;36:1176-86. [PMID: 26716908 DOI: 10.1111/liv.13055] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
138 Tranchart H, Di Giuro G, Lainas P, Roudie J, Agostini H, Franco D, Dagher I. Laparoscopic resection for hepatocellular carcinoma: a matched-pair comparative study. Surg Endosc. 2010;24:1170-1176. [PMID: 19915908 DOI: 10.1007/s00464-009-0745-3] [Cited by in Crossref: 174] [Cited by in F6Publishing: 156] [Article Influence: 14.5] [Reference Citation Analysis]
139 Zhou DS, Xu L, Luo YL, He FY, Huang JT, Zhang YJ, Chen MS. Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization. World J Gastroenterol. 2015;21:5582-5590. [PMID: 25987783 DOI: 10.3748/wjg.v21.i18.5582] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
140 Ouaguia L, Mrizak D, Renaud S, Moralès O, Delhem N. Control of the inflammatory response mechanisms mediated by natural and induced regulatory T-cells in HCV-, HTLV-1-, and EBV-associated cancers. Mediators Inflamm 2014;2014:564296. [PMID: 25525301 DOI: 10.1155/2014/564296] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
141 Li R, Yanjiao G, Wubin H, Yue W, Jianhua H, Huachuan Z, Rongjian S, Zhidong L. Secreted GRP78 activates EGFR-SRC-STAT3 signaling and confers the resistance to sorafeinib in HCC cells. Oncotarget 2017;8:19354-64. [PMID: 28423613 DOI: 10.18632/oncotarget.15223] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
142 Morisco F, Stigliano R, Godfrey A, Leandro G, Patch D, Davidson B, Rolles K, Dhillon A, Dhillon AP, Quaglia A. Efficacy of loco-regional ablation therapy of HCC in a population of liver transplanted patients. Dig Dis Sci. 2008;53:1131-1137. [PMID: 17934816 DOI: 10.1007/s10620-007-9986-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
143 Parks AL, McWhirter RM, Evason K, Kelley RK. Cases of spontaneous tumor regression in hepatobiliary cancers: implications for immunotherapy? J Gastrointest Cancer 2015;46:161-5. [PMID: 25662892 DOI: 10.1007/s12029-015-9690-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
144 Uccello M, Malaguarnera G, Pelligra EM, Biondi A, Basile F, Motta M. Lipoprotein(a) as a potential marker of residual liver function in hepatocellular carcinoma. Indian J Med Paediatr Oncol 2011;32:71-5. [PMID: 22174493 DOI: 10.4103/0971-5851.89775] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
145 Yin H, Lin Z, Nie S, Wu J, Tan Z, Zhu J, Dai J, Feng Z, Marrero J, Lubman DM. Mass-selected site-specific core-fucosylation of ceruloplasmin in alcohol-related hepatocellular carcinoma. J Proteome Res. 2014;13:2887-2896. [PMID: 24799124 DOI: 10.1021/pr500043k] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
146 Bartlett A, Heaton N. Hepatocellular carcinoma: defining the place of surgery in an era of organ shortage. World J Gastroenterol. 2008;14:4445-4453. [PMID: 18680222 DOI: 10.3748/wjg.14.4445] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
147 Teng CF, Wu HC, Shyu WC, Jeng LB, Su IJ. Pre-S2 Mutant-Induced Mammalian Target of Rapamycin Signal Pathways as Potential Therapeutic Targets for Hepatitis B Virus-Associated Hepatocellular Carcinoma. Cell Transplant 2017;26:429-38. [PMID: 28195035 DOI: 10.3727/096368916X694382] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
148 Uchino K, Obi S, Tateishi R, Sato S, Kanda M, Sato T, Arano T, Enooku K, Goto E, Masuzaki R. Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma. J Gastroenterol. 2012;47:1152-1159. [PMID: 22438097 DOI: 10.1007/s00535-012-0574-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
149 Alexopoulos LG, Saez-Rodriguez J, Cosgrove BD, Lauffenburger DA, Sorger PK. Networks inferred from biochemical data reveal profound differences in toll-like receptor and inflammatory signaling between normal and transformed hepatocytes. Mol Cell Proteomics. 2010;9:1849-1865. [PMID: 20460255 DOI: 10.1074/mcp.m110.000406] [Cited by in Crossref: 84] [Cited by in F6Publishing: 47] [Article Influence: 7.6] [Reference Citation Analysis]
150 Jung KS, Chun KH, Choi GH, Jeon HM, Shin HS, Park YN, Park JY. Synchronous development of intrahepatic cholangiocarcinoma and hepatocellular carcinoma in different sites of the liver with chronic B-viral hepatitis: two case reports. BMC Res Notes 2013;6:520. [PMID: 24313990 DOI: 10.1186/1756-0500-6-520] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
151 Sørensen M, Frisch K, Bender D, Keiding S. The potential use of 2-[18F]fluoro-2-deoxy-D-galactose as a PET/CT tracer for detection of hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2011;38:1723-1731. [PMID: 21553087 DOI: 10.1007/s00259-011-1831-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
152 Kim G, Han JR, Park SY, Tak WY, Kweon YO, Lee YR, Han YS, Park JG, Kang MK, Lee HW, Lee WK, Kim D, Jang SY, Hur K. Circular noncoding RNA hsa_circ_0005986 as a prognostic biomarker for hepatocellular carcinoma. Sci Rep 2021;11:14930. [PMID: 34294754 DOI: 10.1038/s41598-021-94074-y] [Reference Citation Analysis]
153 El-Zayadi AR, Badran HM, Shawky S, Emara S, El-Bareedy A, Sobhi M. Effect of surveillance for hepatocellular carcinoma on tumor staging and treatment decisions in Egyptian patients. Hepatol Int 2010;4:500-6. [PMID: 20827407 DOI: 10.1007/s12072-010-9170-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
154 Guo X, Xu Y, Wang X, Lin F, Wu H, Duan J, Xiong Y, Han X, Baklaushev VP, Xiong S, Chekhonin VP, Peltzer K, Wang G, Zhang C. Advanced Hepatocellular Carcinoma with Bone Metastases: Prevalence, Associated Factors, and Survival Estimation. Med Sci Monit 2019;25:1105-12. [PMID: 30739123 DOI: 10.12659/MSM.913470] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
155 Fan W, Zhang Y, Wang Y, Yao X, Yang J, Li J. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of survival and metastasis for recurrent hepatocellular carcinoma after transarterial chemoembolization. PLoS One. 2015;10:e0119312. [PMID: 25742141 DOI: 10.1371/journal.pone.0119312] [Cited by in Crossref: 35] [Cited by in F6Publishing: 45] [Article Influence: 5.8] [Reference Citation Analysis]
156 Yoo BK, Santhekadur PK, Gredler R, Chen D, Emdad L, Bhutia S, Pannell L, Fisher PB, Sarkar D. Increased RNA-induced silencing complex (RISC) activity contributes to hepatocellular carcinoma. Hepatology 2011;53:1538-48. [PMID: 21520169 DOI: 10.1002/hep.24216] [Cited by in Crossref: 104] [Cited by in F6Publishing: 102] [Article Influence: 10.4] [Reference Citation Analysis]
157 Kew MC. Hepatocellular carcinoma: epidemiology and risk factors. J Hepatocellular Carcinoma. 2014;1:115-125. [PMID: 27508181 DOI: 10.2147/jhc.s44381] [Cited by in Crossref: 48] [Cited by in F6Publishing: 30] [Article Influence: 6.9] [Reference Citation Analysis]
158 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4:439-474. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Cited by in Crossref: 684] [Cited by in F6Publishing: 670] [Article Influence: 62.2] [Reference Citation Analysis]
159 Akutsu N, Yamamoto H, Sasaki S, Taniguchi H, Arimura Y, Imai K, Shinomura Y. Association of glypican-3 expression with growth signaling molecules in hepatocellular carcinoma. World J Gastroenterol. 2010;16:3521-3528. [PMID: 20653060 DOI: 10.3748/wjg.v16.i28.3521] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
160 Park YK, Kim KM, Lee YJ, Kim KH, Lee SG, Lee D, Shim JH, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Could HBx protein expression affect signal pathway inhibition by gefitinib or selumetinib, a MEK inhibitor, in hepatocellular carcinoma cell lines? J Korean Med Sci 2011;26:214-21. [PMID: 21286012 DOI: 10.3346/jkms.2011.26.2.214] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
161 Wittmann P, Grubinger M, Gröger C, Huber H, Sieghart W, Peck-Radosavljevic M, Mikulits W. Neuropilin-2 induced by transforming growth factor-β augments migration of hepatocellular carcinoma cells. BMC Cancer 2015;15:909. [PMID: 26573807 DOI: 10.1186/s12885-015-1919-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
162 Besaratinia A, Kim SI, Hainaut P, Pfeifer GP. In vitro recapitulating of TP53 mutagenesis in hepatocellular carcinoma associated with dietary aflatoxin B1 exposure. Gastroenterology 2009;137:1127-37, 1137.e1-5. [PMID: 19524575 DOI: 10.1053/j.gastro.2009.06.002] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 4.7] [Reference Citation Analysis]
163 Zhou YM, Wen YH, Kang XY, Qian HH, Yang JM, Yin ZF. Troglitazone, a peroxisome proliferator-activated receptor gamma ligand, induces growth inhibition and apoptosis of HepG2 human liver cancer cells. World J Gastroenterol 2008;14:2168-73. [PMID: 18407589 DOI: 10.3748/wjg.14.2168] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
164 Klein J, Dawson LA, Tran TH, Adeyi O, Purdie T, Sherman M, Brade A. Metabolic syndrome-related hepatocellular carcinoma treated by volumetric modulated arc therapy. Curr Oncol 2014;21:e340-4. [PMID: 24764717 DOI: 10.3747/co.21.1756] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
165 Willatt JM, Francis IR, Novelli PM, Vellody R, Pandya A, Krishnamurthy VN. Interventional therapies for hepatocellular carcinoma. Cancer Imaging 2012;12:79-88. [PMID: 22487698 DOI: 10.1102/1470-7330.2012.0011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
166 Wang Y, Gao B, Tan PY, Handoko YA, Sekar K, Deivasigamani A, Seshachalam VP, OuYang HY, Shi M, Xie C, Goh BKP, Ooi LL, Man Hui K. Genome-wide CRISPR knockout screens identify NCAPG as an essential oncogene for hepatocellular carcinoma tumor growth. FASEB J 2019;33:8759-70. [PMID: 31022357 DOI: 10.1096/fj.201802213RR] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 11.0] [Reference Citation Analysis]
167 Xu Q, Gu J, Lv Y, Yuan J, Yang N, Chen J, Wang C, Hou X, Jia X, Feng L, Yin G. Angiogenesis for tumor vascular normalization of Endostar on hepatoma 22 tumor-bearing mice is involved in the immune response. Oncol Lett 2018;15:3437-46. [PMID: 29467868 DOI: 10.3892/ol.2018.7734] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
168 Li J, Shi L, Zhang X, Sun B, Yang Y, Ge N, Liu H, Yang X, Chen L, Qian H. pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma. Oncotarget. 2016;7:2646-2659. [PMID: 26544731 DOI: 10.18632/oncotarget.6104] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
169 Matsuda Y, Wakai T, Kubota M, Osawa M, Sanpei A, Fujimaki S. Mycotoxins are conventional and novel risk biomarkers for hepatocellular carcinoma. World J Gastroenterol 2013;19:2587-90. [PMID: 23674865 DOI: 10.3748/wjg.v19.i17.2587] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
170 Chen QL, Yan Q, Feng KL, Xie CF, Fang CK, Wang JN, Liu LH, Li Y, Zhong C. Using Integrated Bioinformatics Analysis to Identify Abnormally Methylated Differentially Expressed Genes in Hepatocellular Carcinoma. Int J Gen Med 2021;14:805-23. [PMID: 33732011 DOI: 10.2147/IJGM.S294505] [Reference Citation Analysis]
171 Tian Y, Kuo CF, Chen WL, Ou JH. Enhancement of hepatitis B virus replication by androgen and its receptor in mice. J Virol. 2012;86:1904-1910. [PMID: 22156518 DOI: 10.1128/jvi.06707-11] [Cited by in Crossref: 32] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
172 Xie ZB, Ma L, Wang XB, Bai T, Ye JZ, Zhong JH, Li LQ. Transarterial embolization with or without chemotherapy for advanced hepatocellular carcinoma: a systematic review. Tumour Biol. 2014;35:8451-8459. [PMID: 25038916 DOI: 10.1007/s13277-014-2340-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
173 Bremner KE, Bayoumi AM, Sherman M, Krahn MD. Management of solitary 1 cm to 2 cm liver nodules in patients with compensated cirrhosis: a decision analysis. Can J Gastroenterol 2007;21:491-500. [PMID: 17703248 DOI: 10.1155/2007/182383] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
174 Wang Z, Wu Q, Feng S, Zhao Y, Tao C. Identification of four prognostic LncRNAs for survival prediction of patients with hepatocellular carcinoma. PeerJ. 2017;5:e3575. [PMID: 28729955 DOI: 10.7717/peerj.3575] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
175 Dedeilias P, Nenekidis I, Koukis I, Anagnostakou V, Paparizou N, Zompolos S, Apostolakis E. Acute heart failure caused by a giant hepatocellular metastatic tumor of the right atrium. J Cardiothorac Surg 2011;6:102. [PMID: 21867564 DOI: 10.1186/1749-8090-6-102] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
176 Seleem MI, Gerges SS, Elkhouly A, El-Wakeel B, Hassany M. Laparoscopic Radiofrequency Thermal Ablation of Hepatocellular Carcinoma in Liver Cirrhosis Patients. Gastroenterology Res 2012;5:232-5. [PMID: 27785213 DOI: 10.4021/gr490w] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
177 Nouso K, Ito Y, Kuwaki K, Kobayashi Y, Nakamura S, Ohashi Y, Yamamoto K. Prognostic factors and treatment effects for hepatocellular carcinoma in Child C cirrhosis. Br J Cancer. 2008;98:1161-1165. [PMID: 18349849 DOI: 10.1038/sj.bjc.6604282] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
178 Liu G, Huang X, Cui X, Zhang J, Wei L, Ni R, Lu C. High SKIP expression is correlated with poor prognosis and cell proliferation of hepatocellular carcinoma. Med Oncol 2013;30:537. [PMID: 23696020 DOI: 10.1007/s12032-013-0537-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
179 Tokumitsu Y, Sakamoto K, Tokuhisa Y, Matsui H, Matsukuma S, Maeda Y, Sakata K, Wada H, Eguchi H, Ogihara H, Fujita Y, Hamamoto Y, Iizuka N, Ueno T, Nagano H. A new prognostic model for hepatocellular carcinoma recurrence after curative hepatectomy. Oncol Lett 2018;15:4411-22. [PMID: 29556288 DOI: 10.3892/ol.2018.7821] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
180 Hatanaka T, Arai H, Kakizaki S. Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Hepatol 2018;10:485-95. [PMID: 30079135 DOI: 10.4254/wjh.v10.i7.485] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
181 Zhang Z, Liu T, Yu M, Li K, Li W. The plant alkaloid tetrandrine inhibits metastasis via autophagy-dependent Wnt/β-catenin and metastatic tumor antigen 1 signaling in human liver cancer cells. J Exp Clin Cancer Res 2018;37:7. [PMID: 29334999 DOI: 10.1186/s13046-018-0678-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
182 Kim JY, Sinn DH, Gwak GY, Choi GS, Saleh AM, Joh JW, Cho SK, Shin SW, Carriere KC, Ahn JH, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma. Clin Mol Hepatol 2016;22:250-8. [PMID: 27377909 DOI: 10.3350/cmh.2016.0015] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
183 Asmis T, Balaa F, Scully L, Papadatos D, Marginean C, Fasih N, Shaw-Stiffel T, Goel R. Diagnosis and management of hepatocellular carcinoma: results of a consensus meeting of The Ottawa Hospital Cancer Centre. Curr Oncol 2010;17:6-12. [PMID: 20404972 DOI: 10.3747/co.v17i2.555] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
184 Yu Z, Ou Q, Chen F, Bi J, Li W, Ma J, Wang R, Huang X. Evaluation of the prognostic value of paraoxonase 1 in the recurrence and metastasis of hepatocellular carcinoma and establishment of a liver-specific predictive model of survival. J Transl Med 2018;16:327. [PMID: 30477582 DOI: 10.1186/s12967-018-1707-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
185 Wang JW, Qian Y, Wu CS, Zhao NH, Fang Y, Yuan XD, Gao S, Fan YC, Wang K. Combined use of murine double minute-2 promoter methylation and serum AFP improves diagnostic efficiency in hepatitis B virus-related hepatocellular carcinoma. Int J Med Sci 2020;17:3190-9. [PMID: 33173438 DOI: 10.7150/ijms.47003] [Reference Citation Analysis]
186 Wang J, Xu LB, Liu C, Pang HW, Chen YJ, Ou QJ. Prognostic factors and outcome of 438 Chinese patients with hepatocellular carcinoma underwent partial hepatectomy in a single center. World J Surg 2010;34:2434-41. [PMID: 20523993 DOI: 10.1007/s00268-010-0664-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
187 Aljumah AA, Kuriry H, AlZunaitan M, Al Ghobain M, Al Muaikeel M, Al Olayan A, Azzumeea F, Almutairi B, AlAlwan A, AlGhamdi H. Clinical Presentation, Risk Factors, and Treatment Modalities of Hepatocellular Carcinoma: A Single Tertiary Care Center Experience. Gastroenterol Res Pract 2016;2016:1989045. [PMID: 27525001 DOI: 10.1155/2016/1989045] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
188 Fan C, Zheng W, Fu X, Li X, Wong YS, Chen T. Strategy to enhance the therapeutic effect of doxorubicin in human hepatocellular carcinoma by selenocystine, a synergistic agent that regulates the ROS-mediated signaling. Oncotarget 2014;5:2853-63. [PMID: 24797310 DOI: 10.18632/oncotarget.1854] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 10.3] [Reference Citation Analysis]
189 Saitta C, Raffa G, Alibrandi A, Brancatelli S, Lombardo D, Tripodi G, Raimondo G, Pollicino T. PIVKA-II is a useful tool for diagnostic characterization of ultrasound-detected liver nodules in cirrhotic patients. Medicine (Baltimore) 2017;96:e7266. [PMID: 28658121 DOI: 10.1097/MD.0000000000007266] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
190 Luo X, Wang Y, Shen A, Deng H, Ye M. Relationship between the rs2596542 polymorphism in the MICA gene promoter and HBV/HCV infection-induced hepatocellular carcinoma: a meta-analysis. BMC Med Genet 2019;20:142. [PMID: 31419949 DOI: 10.1186/s12881-019-0871-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
191 Rampone B, Schiavone B, Confuorto G. Current management of hepatocellular cancer. Curr Oncol Rep 2010;12:186-92. [PMID: 20425078 DOI: 10.1007/s11912-010-0094-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
192 Cao M, Prima V, Nelson D, Svetlov S. Composite fatty acid ether amides suppress growth of liver cancer cells in vitro and in an in vivo allograft mouse model. Cell Oncol (Dordr) 2013;36:247-57. [PMID: 23619943 DOI: 10.1007/s13402-013-0132-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
193 Chen X, Ma W, Yao Y, Zhang Q, Li J, Wu X, Mei C, Jiang X, Chen Y, Wang G, Wang K, Liu Y, Guo Y, Liu Z, Yuan Y. Serum deprivation-response protein induces apoptosis in hepatocellular carcinoma through ASK1-JNK/p38 MAPK pathways. Cell Death Dis 2021;12:425. [PMID: 33931585 DOI: 10.1038/s41419-021-03711-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
194 Lu J, Gong W, Cheng H, Wu Z, Li D, Wang X, Liang P, Zhang J. Detection of HBV genotypes of tumor tissues and serum by a fluorescence polarization assay in north-western China’s hepatocellular carcinoma patients. Virol J. 2011;8:362. [PMID: 21781311 DOI: 10.1186/1743-422x-8-362] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
195 Poch FGM, Neizert CA, Geyer B, Gemeinhardt O, Niehues SM, Vahldiek JL, Bressem KK, Lehmann KS. Perivascular vital cells in the ablation center after multibipolar radiofrequency ablation in an in vivo porcine model. Sci Rep 2021;11:13886. [PMID: 34230573 DOI: 10.1038/s41598-021-93406-2] [Reference Citation Analysis]
196 Andersson KL, Salomon JA, Goldie SJ, Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2008;6:1418-1424. [PMID: 18848905 DOI: 10.1016/j.cgh.2008.08.005] [Cited by in Crossref: 139] [Cited by in F6Publishing: 114] [Article Influence: 10.7] [Reference Citation Analysis]
197 Campos-Correia D, Cruz J, Matos AP, Figueiredo F, Ramalho M. Magnetic resonance imaging ancillary features used in Liver Imaging Reporting and Data System: An illustrative review. World J Radiol 2018;10:9-23. [PMID: 29507710 DOI: 10.4329/wjr.v10.i2.9] [Cited by in CrossRef: 1] [Article Influence: 0.3] [Reference Citation Analysis]
198 Zekri AR, Alam El-Din HM, Bahnassy AA, Zayed NA, Mohamed WS, El-Masry SH, Gouda SK, Esmat G. Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II, interleukin-2 receptor and interleukin-8 as early predictors of hepatocellular carcinoma in Egyptian patients with hepatitis C virus genotype-4. Comp Hepatol. 2010;9:1. [PMID: 20051112 DOI: 10.1186/1476-5926-9-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
199 Shirata C, Hasegawa K, Kokudo T, Yamashita S, Yamamoto S, Arita J, Akamatsu N, Kaneko J, Sakamoto Y, Kokudo N. Liver Resection for Hepatocellular Carcinoma in Patients with Renal Dysfunction. World J Surg. 2018;42:4054-4062. [PMID: 29947980 DOI: 10.1007/s00268-018-4698-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
200 Zhang PF, Li KS, Shen YH, Gao PT, Dong ZR, Cai JB, Zhang C, Huang XY, Tian MX, Hu ZQ, Gao DM, Fan J, Ke AW, Shi GM. Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling. Cell Death Dis 2016;7:e2201. [PMID: 27100895 DOI: 10.1038/cddis.2015.324] [Cited by in Crossref: 105] [Cited by in F6Publishing: 101] [Article Influence: 21.0] [Reference Citation Analysis]
201 Chen L, Chan TH, Guan XY. Chromosome 1q21 amplification and oncogenes in hepatocellular carcinoma. Acta Pharmacol Sin. 2010;31:1165-1171. [PMID: 20676120 DOI: 10.1038/aps.2010.94] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
202 Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C, Zheng L. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med. 2009;206:1327-1337. [PMID: 19451266 DOI: 10.1084/jem.20082173] [Cited by in Crossref: 513] [Cited by in F6Publishing: 477] [Article Influence: 42.8] [Reference Citation Analysis]
203 Xiao CL, Tao ZH, Guo L, Li WW, Wan JL, Sun HC, Wang L, Tang ZY, Fan J, Wu WZ. Isomalto oligosaccharide sulfate inhibits tumor growth and metastasis of hepatocellular carcinoma in nude mice. BMC Cancer 2011;11:150. [PMID: 21513518 DOI: 10.1186/1471-2407-11-150] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
204 Gish RG, Gordon SC, Nelson D, Rustgi V, Rios I. A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma. Hepatol Int 2009;3:480-9. [PMID: 19669251 DOI: 10.1007/s12072-009-9132-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
205 Negussie AH, Dreher MR, Johnson CG, Tang Y, Lewis AL, Storm G, Sharma KV, Wood BJ. Synthesis and characterization of image-able polyvinyl alcohol microspheres for image-guided chemoembolization. J Mater Sci Mater Med 2015;26:198. [PMID: 26105830 DOI: 10.1007/s10856-015-5530-3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
206 Chen S, Pu J, Bai J, Yin Y, Wu K, Wang J, Shuai X, Gao J, Tao K, Wang G, Li H. EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis. J Exp Clin Cancer Res 2018;37:3. [PMID: 29316949 DOI: 10.1186/s13046-017-0670-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
207 Sawhney S, Montano-Loza AJ, Salat P, McCarthy M, Kneteman N, Meza-Junco J, Owen R. Transarterial chemoembolization in patients with hepatocellular carcinoma: predictors of survival. Can J Gastroenterol 2011;25:426-32. [PMID: 21912767 DOI: 10.1155/2011/864234] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
208 Schmilovitz-Weiss H, Tobar A, Halpern M, Levy I, Shabtai E, Ben-Ari Z. Tissue expression of squamous cellular carcinoma antigen and Ki67 in hepatocellular carcinoma-correlation with prognosis: a historical prospective study. Diagn Pathol. 2011;6:121. [PMID: 22151825 DOI: 10.1186/1746-1596-6-121] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
209 Thuy le TT, Morita T, Yoshida K, Wakasa K, Iizuka M, Ogawa T, Mori M, Sekiya Y, Momen S, Motoyama H, Ikeda K, Yoshizato K, Kawada N. Promotion of liver and lung tumorigenesis in DEN-treated cytoglobin-deficient mice. Am J Pathol 2011;179:1050-60. [PMID: 21684245 DOI: 10.1016/j.ajpath.2011.05.006] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 5.8] [Reference Citation Analysis]
210 Xu J, Zheng L, Chen J, Sun Y, Lin H, Jin RA, Tang M, Liang X, Cai X. Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals. Cell Death Dis 2017;8:e3095. [PMID: 29022906 DOI: 10.1038/cddis.2017.411] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
211 Yang Y, Lu Y, Wang C, Bai W, Qu J, Chen Y, Chang X, An L, Zhou L, Zeng Z. Cryotherapy is associated with improved clinical outcomes of Sorafenib therapy for advanced hepatocellular carcinoma. Cell Biochem Biophys. 2012;63:159-169. [PMID: 22477032 DOI: 10.1007/s12013-012-9353-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
212 Chen YY, Zhang XN, Xu CZ, Zhou DH, Chen J, Liu ZX, Sun Y, Huang W, Qu LS. MCCC2 promotes HCC development by supporting leucine oncogenic function. Cancer Cell Int 2021;21:22. [PMID: 33407468 DOI: 10.1186/s12935-020-01722-w] [Reference Citation Analysis]
213 Andersen KJ, Knudsen AR, Kannerup AS, Sasanuma H, Nyengaard JR, Hamilton-Dutoit S, Ladekarl M, Mortensen FV. Sorafenib inhibits liver regeneration in rats. HPB (Oxford) 2013;15:944-50. [PMID: 23461776 DOI: 10.1111/hpb.12068] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
214 Prajapati HJ, Kim HS. Treatment algorithm based on the multivariate survival analyses in patients with advanced hepatocellular carcinoma treated with trans-arterial chemoembolization. PLoS One 2017;12:e0170750. [PMID: 28170405 DOI: 10.1371/journal.pone.0170750] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
215 Hoffmann K, Xiao Z, Franz C, Mohr E, Serba S, Büchler MW, Schemmer P. Involvement of the epidermal growth factor receptor in the modulation of multidrug resistance in human hepatocellular carcinoma cells in vitro. Cancer Cell Int. 2011;11:40. [PMID: 22088142 DOI: 10.1186/1475-2867-11-40] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
216 Liu CJ, Chang J, Lee PH, Lin DY, Wu CC, Jeng LB, Lin YJ, Mok KT, Lee WC, Yeh HZ. Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence. World J Gastroenterol. 2014;20:11384-11393. [PMID: 25170226 DOI: 10.3748/wjg.v20.i32.11384] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 35] [Article Influence: 6.3] [Reference Citation Analysis]
217 Chen J, Lu S, Zhang Y, Xu L, Chen J, Wang J, Chen M, Zhang R, Zhou Z. Sorafenib Monotherapy Versus Sorafenib Combined with Regional Therapies for Hepatocellular Carcinoma Patients with Pulmonary Oligometastases: A Propensity Score-matched Analysis. J Cancer. 2018;9:1745-1753. [PMID: 29805700 DOI: 10.7150/jca.24568] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
218 Chen HY, Han ZB, Fan JW, Xia J, Wu JY, Qiu GQ, Tang HM, Peng ZH. miR-203 expression predicts outcome after liver transplantation for hepatocellular carcinoma in cirrhotic liver. Med Oncol. 2012;29:1859-1865. [PMID: 21786180 DOI: 10.1007/s12032-011-0031-9] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.7] [Reference Citation Analysis]
219 Hanada M, Baba A, Tsutsumishita Y, Noguchi T, Yamaoka T, Chiba N, Nishikaku F. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis. Cancer Chemother Pharmacol. 2009;64:473-483. [PMID: 19104812 DOI: 10.1007/s00280-008-0895-3] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
220 Levi Sandri GB, Colasanti M, Santoro R, Ettorre GM. Laparoscopic right hepatectomy for hepatocellular carcinoma in cirrhotic patient. Hepatobiliary Surg Nutr 2015;4:436-8. [PMID: 26734630 DOI: 10.3978/j.issn.2304-3881.2015.07.01] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
221 Izumi N, Asahina Y, Kurosaki M, Yamada G, Kawai T, Kajiwara E, Okamura Y, Takeuchi T, Yokosuka O, Kariyama K, Toyoda J, Inao M, Tanaka E, Moriwaki H, Adachi H, Katsushima S, Kudo M, Takaguchi K, Hiasa Y, Chayama K, Yatsuhashi H, Oketani M, Kumada H. Inhibition of hepatocellular carcinoma by PegIFNα-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study. J Gastroenterol 2013;48:382-90. [PMID: 22875473 DOI: 10.1007/s00535-012-0641-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
222 You MW, Kim SY, Kim KW, Lee SJ, Shin YM, Kim JH, Lee MG. Recent advances in the imaging of hepatocellular carcinoma. Clin Mol Hepatol. 2015;21:95-103. [PMID: 25834808 DOI: 10.3350/cmh.2015.21.1.95] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
223 Zhong JH, You XM, Gong WF, Ma L, Zhang Y, Mo QG, Wu LC, Xiao J, Li LQ. Epidermal growth factor gene polymorphism and risk of hepatocellular carcinoma: a meta-analysis. PLoS One 2012;7:e32159. [PMID: 22403631 DOI: 10.1371/journal.pone.0032159] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
224 Qiu J, Huang P, Liu Q, Hong J, Li B, Lu C, Wang L, Wang J, Yuan Y. Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. J Transl Med. 2011;9:166. [PMID: 21955323 DOI: 10.1186/1479-5876-9-166] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 5.7] [Reference Citation Analysis]
225 Lee IJ, Seong J. The optimal selection of radiotherapy treatment for hepatocellular carcinoma. Gut Liver 2012;6:139-48. [PMID: 22570744 DOI: 10.5009/gnl.2012.6.2.139] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
226 Kim DH, Choy T, Huang S, Green RM, Omary RA, Larson AC. Microfluidic fabrication of 6-methoxyethylamino numonafide-eluting magnetic microspheres. Acta Biomater 2014;10:742-50. [PMID: 24161384 DOI: 10.1016/j.actbio.2013.10.018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
227 Huang ZJ, Zhu JJ, Yang XY, Biskup E. NEDD4 promotes cell growth and migration via PTEN/PI3K/AKT signaling in hepatocellular carcinoma. Oncol Lett 2017;14:2649-56. [PMID: 28928809 DOI: 10.3892/ol.2017.6532] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
228 Matsuura Y, Wada H, Eguchi H, Gotoh K, Kobayashi S, Kinoshita M, Kubo M, Hayashi K, Iwagami Y, Yamada D, Asaoka T, Noda T, Kawamoto K, Takeda Y, Tanemura M, Umeshita K, Doki Y, Mori M. Exosomal miR-155 Derived from Hepatocellular Carcinoma Cells Under Hypoxia Promotes Angiogenesis in Endothelial Cells. Dig Dis Sci 2019;64:792-802. [PMID: 30465177 DOI: 10.1007/s10620-018-5380-1] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
229 Qu LS, Liu JX, Liu TT, Shen XZ, Chen TY, Ni ZP, Lu CH. Association of hepatitis B virus pre-S deletions with the development of hepatocellular carcinoma in Qidong, China. PLoS One. 2014;9:e98257. [PMID: 24849936 DOI: 10.1371/journal.pone.0098257] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
230 Tian Y, Lyu H, He Y, Kanduri HK. Evaluating the Ability of the New Subclassification to Prognosticate Outcomes Following Hepatectomy for Patients with HBV-Related HCC. J Gastrointest Cancer 2019;50:400-7. [PMID: 29512001 DOI: 10.1007/s12029-018-0085-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
231 Han LY, Fan YC, Mu NN, Gao S, Li F, Ji XF, Dou CY, Wang K. Aberrant DNA methylation of G-protein-coupled bile acid receptor Gpbar1 (TGR5) is a potential biomarker for hepatitis B Virus associated hepatocellular carcinoma. Int J Med Sci 2014;11:164-71. [PMID: 24465162 DOI: 10.7150/ijms.6745] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
232 Younossi ZM, Henry L. Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. JHEP Rep 2021;3:100305. [PMID: 34189448 DOI: 10.1016/j.jhepr.2021.100305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
233 Shi J, Zhu L, Liu S, Xie WF. A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J Cancer. 2005;92:607-612. [PMID: 15685242 DOI: 10.1038/sj.bjc.6602333] [Cited by in Crossref: 118] [Cited by in F6Publishing: 120] [Article Influence: 7.4] [Reference Citation Analysis]
234 Xu H, Mao Y. A brief comment on liver resection for hepatocellular carcinoma. Gastroenterol Rep (Oxf) 2013;1:184-5. [PMID: 24759963 DOI: 10.1093/gastro/got019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
235 Ye SL, Chen X, Yang J, Bie P, Zhang S, Liu F, Liu L, Zhou J, Dou K, Hao C, Shao G, Xia Q, Chen Y, Yang J, Deng X, Liu Y, Yuan Y, Fu Z, Nakajima K, Yip CS, Lu Z. Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study. Oncotarget 2016;7:6639-48. [PMID: 26735891 DOI: 10.18632/oncotarget.6781] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
236 Zhou S, Han Q, Wang R, Li X, Wang Q, Wang H, Wang J, Ma Y. PRDX2 protects hepatocellular carcinoma SMMC-7721 cells from oxidative stress. Oncol Lett 2016;12:2217-21. [PMID: 27602166 DOI: 10.3892/ol.2016.4899] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
237 Braunwarth E, Stättner S, Fodor M, Cardini B, Resch T, Oberhuber R, Putzer D, Bale R, Maglione M, Margreiter C, Schneeberger S, Öfner D, Primavesi F. Surgical techniques and strategies for the treatment of primary liver tumours: hepatocellular and cholangiocellular carcinoma. Eur Surg 2018;50:100-12. [PMID: 29875798 DOI: 10.1007/s10353-018-0537-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
238 Hagihara A, Ikeda M, Ueno H, Morizane C, Kondo S, Nakachi K, Mitsunaga S, Shimizu S, Kojima Y, Suzuki E, Katayama K, Imanaka K, Tamai C, Inaba Y, Sato Y, Kato M, Okusaka T. Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma. Cancer Sci 2014;105:354-8. [PMID: 24438504 DOI: 10.1111/cas.12353] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
239 Zhou YM, Shao WY, Zhao YF, Xu DH, Li B. Meta-analysis of laparoscopic versus open resection for hepatocellular carcinoma. Dig Dis Sci. 2011;56:1937-1943. [PMID: 21259071 DOI: 10.1007/s10620-011-1572-7] [Cited by in Crossref: 74] [Cited by in F6Publishing: 72] [Article Influence: 7.4] [Reference Citation Analysis]
240 Jung HI, Ahn T, Bae SH, Chung JC, Kim H, Chin S, Jeong D, Cho HD, Lee MS, Kim HC, Kim CH, Baek MJ. Astrocyte elevated gene-1 overexpression in hepatocellular carcinoma: an independent prognostic factor. Ann Surg Treat Res 2015;88:77-85. [PMID: 25692118 DOI: 10.4174/astr.2015.88.2.77] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
241 Ling TC, Kang JI, Bush DA, Slater JD, Yang GY. Proton therapy for hepatocellular carcinoma. Chin J Cancer Res 2012;24:361-7. [PMID: 23359779 DOI: 10.3978/j.issn.1000-9604.2012.10.09] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
242 Aghoram R, Cai P, Dickinson JA. Alpha-foetoprotein and/or liver ultrasonography for screening of hepatocellular carcinoma in patients with chronic hepatitis B. Cochrane Database Syst Rev 2012;:CD002799. [PMID: 22972059 DOI: 10.1002/14651858.CD002799.pub2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
243 Coleman SJ, Grose RP, Kocher HM. Fibroblast growth factor family as a potential target in the treatment of hepatocellular carcinoma. J Hepatocell Carcinoma 2014;1:43-54. [PMID: 27508175 DOI: 10.2147/JHC.S48958] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
244 Di Maso V, Avellini C, Crocè LS, Rosso N, Quadrifoglio F, Cesaratto L, Codarin E, Bedogni G, Beltrami CA, Tell G, Tiribelli C. Subcellular localization of APE1/Ref-1 in human hepatocellular carcinoma: possible prognostic significance. Mol Med 2007;13:89-96. [PMID: 17515960 DOI: 10.2119/2006-00084.dimaso] [Cited by in Crossref: 66] [Cited by in F6Publishing: 39] [Article Influence: 4.7] [Reference Citation Analysis]
245 Chen YX, Zeng ZC, Sun J, Zeng HY, Huang Y, Zhang ZY. Mesenchymal stem cell-conditioned medium prevents radiation-induced liver injury by inhibiting inflammation and protecting sinusoidal endothelial cells. J Radiat Res 2015;56:700-8. [PMID: 26070321 DOI: 10.1093/jrr/rrv026] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
246 Mikoshiba N, Tateishi R, Tanaka M, Sakai T, Blazeby JM, Kokudo N, Koike K, Kazuma K. Validation of the Japanese version of the EORTC hepatocellular carcinoma-specific quality of life questionnaire module (QLQ-HCC18). Health Qual Life Outcomes 2012;10:58. [PMID: 22651810 DOI: 10.1186/1477-7525-10-58] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
247 Horváth Z, Kovalszky I, Fullár A, Kiss K, Schaff Z, Iozzo RV, Baghy K. Decorin deficiency promotes hepatic carcinogenesis. Matrix Biol 2014;35:194-205. [PMID: 24361483 DOI: 10.1016/j.matbio.2013.11.004] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 6.3] [Reference Citation Analysis]
248 Lin YT, Jeng LB, Chan WL, Su IJ, Teng CF. Hepatitis B Virus Pre-S Gene Deletions and Pre-S Deleted Proteins: Clinical and Molecular Implications in Hepatocellular Carcinoma. Viruses 2021;13:862. [PMID: 34066744 DOI: 10.3390/v13050862] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
249 Honda M, Yamashita T, Yamashita T, Arai K, Sakai Y, Sakai A, Nakamura M, Mizukoshi E, Kaneko S. Peretinoin, an acyclic retinoid, improves the hepatic gene signature of chronic hepatitis C following curative therapy of hepatocellular carcinoma. BMC Cancer. 2013;13:191. [PMID: 23587162 DOI: 10.1186/1471-2407-13-191] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
250 Kudo M, Ikeda M, Takayama T, Numata K, Izumi N, Furuse J, Okusaka T, Kadoya M, Yamashita S, Ito Y, Kokudo N. Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON. J Gastroenterol 2016;51:1150-60. [PMID: 27106231 DOI: 10.1007/s00535-016-1204-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
251 Guzman G, Chennuri R, Chan A, Rea B, Quintana A, Patel R, Xu PZ, Xie H, Hay N. Evidence for heightened hexokinase II immunoexpression in hepatocyte dysplasia and hepatocellular carcinoma. Dig Dis Sci 2015;60:420-6. [PMID: 25381201 DOI: 10.1007/s10620-014-3364-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
252 Varshosaz J, Farzan M. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma. World J Gastroenterol 2015;21:12022-41. [PMID: 26576089 DOI: 10.3748/wjg.v21.i42.12022] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 39] [Article Influence: 8.8] [Reference Citation Analysis]
253 Petersen J, Henninger B, Glodny B, Jaschke W. [Transarterial chemoembolisation in hepatocellular carcinoma]. Wien Med Wochenschr 2013;163:123-7. [PMID: 23413009 DOI: 10.1007/s10354-013-0180-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
254 Kudou M, Shiozaki A, Kosuga T, Ichikawa D, Konishi H, Morimura R, Komatsu S, Ikoma H, Fujiwara H, Okamoto K, Hosogi S, Nakahari T, Marunaka Y, Otsuji E. Inhibition of Regulatory Volume Decrease Enhances the Cytocidal Effect of Hypotonic Shock in Hepatocellular Carcinoma. J Cancer 2016;7:1524-33. [PMID: 27471568 DOI: 10.7150/jca.15181] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
255 Ma KW, Chok KSH, Fung JYY, Lo CM. Liver Transplantation for Hepatitis B Virus-related Hepatocellular Carcinoma in Hong Kong. J Clin Transl Hepatol 2018;6:283-8. [PMID: 30271740 DOI: 10.14218/JCTH.2017.00058] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
256 Miyamoto N, Hiramatsu K, Tsuchiya K, Sato Y, Terae S, Shirato H. Sonazoid-enhanced sonography for guiding radiofrequency ablation for hepatocellular carcinoma: better tumor visualization by Kupffer-phase imaging and vascular-phase imaging after reinjection. Jpn J Radiol 2009;27:185-93. [PMID: 19499310 DOI: 10.1007/s11604-009-0317-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
257 Velázquez KT, Enos RT, Carson MS, Cranford TL, Bader JE, Chatzistamou I, Singh UP, Nagarkatti PS, Nagarkatti M, Davis JM, Carson JA, Murphy EA. Weight loss following diet-induced obesity does not alter colon tumorigenesis in the AOM mouse model. Am J Physiol Gastrointest Liver Physiol 2016;311:G699-712. [PMID: 27609769 DOI: 10.1152/ajpgi.00207.2016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
258 Tai CJ, Wang WC, Wang CK, Wu CH, Yang MD, Chang YJ, Jian JY, Tai CJ. Fermented wheat germ extract induced cell death and enhanced cytotoxicity of Cisplatin and 5-Fluorouracil on human hepatocellular carcinoma cells. Evid Based Complement Alternat Med 2013;2013:121725. [PMID: 24454483 DOI: 10.1155/2013/121725] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
259 Ashtari S, Pourhoseingholi MA, Sharifian A, Zali MR. Hepatocellular carcinoma in Asia: Prevention strategy and planning. World J Hepatol. 2015;7:1708-1717. [PMID: 26140091 DOI: 10.4254/wjh.v7.i12.1708] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 8.7] [Reference Citation Analysis]
260 Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485-91. [PMID: 19224838 DOI: 10.1200/JCO.2008.20.7753] [Cited by in Crossref: 1121] [Cited by in F6Publishing: 593] [Article Influence: 93.4] [Reference Citation Analysis]
261 Zhang Z, Zhou Y, Yang J, Hu K, Huang Y. The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis. BMC Cancer 2019;19:511. [PMID: 31142283 DOI: 10.1186/s12885-019-5735-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 13.0] [Reference Citation Analysis]
262 Deng GL, Zeng S, Shen H. Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges. World J Hepatol 2015;7:787-98. [PMID: 25914779 DOI: 10.4254/wjh.v7.i5.787] [Cited by in Crossref: 99] [Cited by in F6Publishing: 88] [Article Influence: 16.5] [Reference Citation Analysis]
263 Teng CF, Wu HC, Su IJ, Jeng LB. Hepatitis B Virus Pre-S Mutants as Biomarkers and Targets for the Development and Recurrence of Hepatocellular Carcinoma. Viruses 2020;12:E945. [PMID: 32859114 DOI: 10.3390/v12090945] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
264 Teng CF, Li TC, Huang HY, Chan WL, Wu HC, Shyu WC, Su IJ, Jeng LB. Hepatitis B virus pre-S2 deletion (nucleotide 1 to 54) in plasma predicts recurrence of hepatocellular carcinoma after curative surgical resection. PLoS One 2020;15:e0242748. [PMID: 33237972 DOI: 10.1371/journal.pone.0242748] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
265 Robertson CL, Srivastava J, Rajasekaran D, Gredler R, Akiel MA, Jariwala N, Siddiq A, Emdad L, Fisher PB, Sarkar D. The role of AEG-1 in the development of liver cancer. Hepat Oncol 2015;2:303-12. [PMID: 26798451 DOI: 10.2217/hep.15.10] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
266 Yang H, Zhai G, Ji X, Xiong F, Su J, McNutt MA. LAPTM4B allele *2 is a marker of poor prognosis following hepatic tumor resection for hepatocellular carcinoma. PLoS One 2012;7:e34984. [PMID: 22509374 DOI: 10.1371/journal.pone.0034984] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
267 Rui R, Lou J, Zou L, Zhong R, Wang J, Xia D, Wang Q, Li H, Wu J, Lu X, Li C, Liu L, Xia J, Xu H. Excess body mass index and risk of liver cancer: a nonlinear dose-response meta-analysis of prospective studies. PLoS One. 2012;7:e44522. [PMID: 23028553 DOI: 10.1371/journal.pone.0044522] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
268 Lin MT, Wang CC, Cheng YF, Eng HL, Yen YH, Tsai MC, Tseng PL, Chang KC, Wu CK, Hu TH. Comprehensive Comparison of Multiple-Detector Computed Tomography and Dynamic Magnetic Resonance Imaging in the Diagnosis of Hepatocellular Carcinoma with Varying Degrees of Fibrosis. PLoS One 2016;11:e0166157. [PMID: 27829060 DOI: 10.1371/journal.pone.0166157] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
269 Edeline J, Raoul JL, Vauleon E, Guillygomac'h A, Boudjema K, Boucher E. Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: a retrospective study. World J Gastroenterol 2009;15:713-6. [PMID: 19222095 DOI: 10.3748/wjg.15.713] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
270 Zhou Y, Zhao Y, Li B, Xu D, Yin Z, Xie F, Yang J. Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC Gastroenterol. 2010;10:78. [PMID: 20618937 DOI: 10.1186/1471-230x-10-78] [Cited by in Crossref: 116] [Cited by in F6Publishing: 58] [Article Influence: 10.5] [Reference Citation Analysis]
271 Wu X, Li C, Xing G, Qi X, Ren J. Resveratrol Downregulates Cyp2e1 and Attenuates Chemically Induced Hepatocarcinogenesis in SD Rats. J Toxicol Pathol 2013;26:385-92. [PMID: 24526811 DOI: 10.1293/tox.2013-0020] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
272 Forner A, Rodríguez-Lopez C, Reig M. Natural history and staging for hepatocellular carcinoma. Clin Liver Dis (Hoboken) 2012;1:183-5. [PMID: 31186883 DOI: 10.1002/cld.129] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
273 Cappelli A, Sangro P, Mosconi C, Deppe I, Terzi E, Bilbao JI, Rodriguez-Fraile M, De Benedittis C, Ricke J, Golfieri R, Sangro B. Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage. Eur J Nucl Med Mol Imaging 2019;46:661-8. [PMID: 30209522 DOI: 10.1007/s00259-018-4152-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
274 Csepregi A, Röcken C, Hoffmann J, Gu P, Saliger S, Müller O, Schneider-Stock R, Kutzner N, Roessner A, Malfertheiner P. APC promoter methylation and protein expression in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2008;134:579-589. [PMID: 17973119 DOI: 10.1007/s00432-007-0321-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
275 Huang Y, Zeng J, Liu T, Lin X, Guo P, Zeng J, Zhou W, Liu J. Prognostic Significance of Elevated Preoperative Serum CA125 Levels After Curative Hepatectomy for Hepatocellular Carcinoma. Onco Targets Ther 2020;13:4559-67. [PMID: 32547086 DOI: 10.2147/OTT.S236475] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
276 Yang X, Qiu Z, Ran R, Cui L, Luo X, Wu M, Tan WF, Jiang X. Prognostic importance of bile duct invasion in surgical resection with curative intent for hepatocellular carcinoma using PSM analysis. Oncol Lett. 2018;16:3593-3602. [PMID: 30127966 DOI: 10.3892/ol.2018.9108] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
277 Steinway SN, Dang H, You H, Rountree CB, Ding W. The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma. PLoS One. 2015;10:e0128159. [PMID: 26000702 DOI: 10.1371/journal.pone.0128159] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
278 Kinoshita A, Onoda H, Fushiya N, Koike K, Nishino H, Tajiri H. Staging systems for hepatocellular carcinoma: Current status and future perspectives. World J Hepatol. 2015;7:406-424. [PMID: 25848467 DOI: 10.4254/wjh.v7.i3.406] [Cited by in Crossref: 65] [Cited by in F6Publishing: 56] [Article Influence: 10.8] [Reference Citation Analysis]
279 Nassir F, Ibdah JA. Role of mitochondria in alcoholic liver disease. World J Gastroenterol. 2014;20:2136-2142. [PMID: 24605012 DOI: 10.3748/wjg.v20.i9.2136] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 52] [Article Influence: 9.3] [Reference Citation Analysis]
280 Yang H, Woo HY, Lee SK, Han JW, Jang B, Nam HC, Lee HL, Lee SW, Song DS, Song MJ, Oh JS, Chun HJ, Jang JW, Lozada A, Bae SH, Choi JY, Yoon SK. A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function. Clin Mol Hepatol. 2017;23:128-137. [PMID: 28494528 DOI: 10.3350/cmh.2016.0071] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
281 Schulze-Bergkamen H, Fleischer B, Schuchmann M, Weber A, Weinmann A, Krammer PH, Galle PR. Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction. BMC Cancer 2006;6:232. [PMID: 17014711 DOI: 10.1186/1471-2407-6-232] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 4.7] [Reference Citation Analysis]
282 Hao QQ, Chen GY, Zhang JH, Sheng JH, Gao Y. Diagnostic value of long noncoding RNAs for hepatocellular carcinoma: A PRISMA-compliant meta-analysis. Medicine (Baltimore). 2017;96:e7496. [PMID: 28700498 DOI: 10.1097/md.0000000000007496] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
283 Tang KF, Chen M, Xie J, Song GB, Shi YS, Liu Q, Mei ZC, Steinle A, Ren H. Inhibition of hepatitis B virus replication by small interference RNA induces expression of MICA in HepG2.2.15 cells. Med Microbiol Immunol. 2009;198:27-32. [PMID: 18685862 DOI: 10.1007/s00430-008-0101-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
284 Hai H, Tamori A, Kawada N. Role of hepatitis B virus DNA integration in human hepatocarcinogenesis. World J Gastroenterol. 2014;20:6236-6243. [PMID: 24876744 DOI: 10.3748/wjg.v20.i20.6236] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 48] [Article Influence: 9.2] [Reference Citation Analysis]
285 Facciuto ME, Rochon C, Pandey M, Rodriguez-Davalos M, Samaniego S, Wolf DC, Kim-Schluger L, Rozenblit G, Sheiner PA. Surgical dilemma: liver resection or liver transplantation for hepatocellular carcinoma and cirrhosis. Intention-to-treat analysis in patients within and outwith Milan criteria. HPB (Oxford) 2009;11:398-404. [PMID: 19768144 DOI: 10.1111/j.1477-2574.2009.00073.x] [Reference Citation Analysis]
286 Bubici C, Papa S. JNK signalling in cancer: in need of new, smarter therapeutic targets. Br J Pharmacol 2014;171:24-37. [PMID: 24117156 DOI: 10.1111/bph.12432] [Cited by in Crossref: 212] [Cited by in F6Publishing: 175] [Article Influence: 30.3] [Reference Citation Analysis]
287 Cai MY, Wang FW, Li CP, Yan LX, Chen JW, Luo RZ, Yun JP, Zeng YX, Xie D. Prognostic factors affecting postoperative survival of patients with solitary small hepatocellular carcinoma. Chin J Cancer 2016;35:80. [PMID: 27527497 DOI: 10.1186/s40880-016-0143-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
288 Frydrychowicz A, Lubner MG, Brown JJ, Merkle EM, Nagle SK, Rofsky NM, Reeder SB. Hepatobiliary MR imaging with gadolinium-based contrast agents. J Magn Reson Imaging. 2012;35:492-511. [PMID: 22334493 DOI: 10.1002/jmri.22833] [Cited by in Crossref: 98] [Cited by in F6Publishing: 69] [Article Influence: 10.9] [Reference Citation Analysis]
289 Sukowati CHC, Anfuso B, Fiore E, Ie SI, Raseni A, Vascotto F, Avellini C, Mazzolini G, Tiribelli C. Hyaluronic acid inhibition by 4-methylumbelliferone reduces the expression of cancer stem cells markers during hepatocarcinogenesis. Sci Rep. 2019;9:4026. [PMID: 30858465 DOI: 10.1038/s41598-019-40436-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
290 Kobayashi K, Uldry E, Kokudo T, Cristaudi A, Kawaguchi Y, Shirata C, Yamaguchi T, Dormond O, Duran R, Hasegawa K, Demartines N, Halkic N. Correlation Between Portal Pressure and Indocyanine Green Retention Rate is Unaffected by the Cause of Cirrhosis: A Prospective Study. World J Surg 2021;45:2546-55. [PMID: 33891139 DOI: 10.1007/s00268-021-06111-6] [Reference Citation Analysis]
291 Komatsu S, Brustia R, Goumard C, Perdigao F, Soubrane O, Scatton O. Laparoscopic versus open major hepatectomy for hepatocellular carcinoma: a matched pair analysis. Surg Endosc. 2016;30:1965-1974. [PMID: 26194255 DOI: 10.1007/s00464-015-4422-4] [Cited by in Crossref: 77] [Cited by in F6Publishing: 73] [Article Influence: 12.8] [Reference Citation Analysis]
292 Song Y, Jang J, Shin TH, Bae SM, Kim JS, Kim KM, Myung SJ, Choi EK, Seo HR. Sulfasalazine attenuates evading anticancer response of CD133-positive hepatocellular carcinoma cells. J Exp Clin Cancer Res 2017;36:38. [PMID: 28253902 DOI: 10.1186/s13046-017-0511-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
293 Luo X, Feng GS. VEGFA genomic amplification tailors treatment of HCCs with sorafenib. Cancer Discov 2014;4:640-1. [PMID: 24891362 DOI: 10.1158/2159-8290.CD-14-0406] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
294 Chen HW, Qiao HY, Li HC, Li ZF, Zhang HJ, Pei L, Liu HW, Jin L, Wang D, Li JL. Prognostic significance of Nemo-like kinase expression in patients with hepatocellular carcinoma. Tumour Biol 2015;36:8447-53. [PMID: 26022162 DOI: 10.1007/s13277-015-3609-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
295 Rawla P, Thandra KC, Vellipuram A, Ali CDM. Efficacy and safety of megestrol in the management of hepatocellular carcinoma: a systematic review of the literature. Contemp Oncol (Pozn) 2018;22:209-14. [PMID: 30783383 DOI: 10.5114/wo.2018.82641] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
296 Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y, Villanueva A, Minguez B, Tsai HW, Ward SC, Thung S, Friedman SL, Llovet JM. Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol. 2012;56:1343-1350. [PMID: 22322234 DOI: 10.1016/j.jhep.2012.01.009] [Cited by in Crossref: 131] [Cited by in F6Publishing: 119] [Article Influence: 14.6] [Reference Citation Analysis]
297 Papatheofani V, Levidou G, Sarantis P, Koustas E, Karamouzis MV, Pergaris A, Kouraklis G, Theocharis S. HuR Protein in Hepatocellular Carcinoma: Implications in Development, Prognosis and Treatment. Biomedicines 2021;9:119. [PMID: 33513829 DOI: 10.3390/biomedicines9020119] [Reference Citation Analysis]
298 Su ZX, Zhao J, Rong ZH, Geng WM, Wu YG, Qin CK. Upregulation of microRNA-25 associates with prognosis in hepatocellular carcinoma. Diagn Pathol 2014;9:47. [PMID: 24593846 DOI: 10.1186/1746-1596-9-47] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 5.6] [Reference Citation Analysis]
299 Zheng YB, Meng QW, Zhao W, Liu B, Huang JW, He X, Li Y, Hu BS, Lu LG. Prognostic value of serum vascular endothelial growth factor receptor 2 response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Med Oncol. 2014;31:843. [PMID: 24442426 DOI: 10.1007/s12032-014-0843-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
300 Xu Y, Shen Q, Wang N, Wu PP, Huang B, Kuang M, Qian GJ. Microwave ablation is as effective as radiofrequency ablation for very-early-stage hepatocellular carcinoma. Chin J Cancer 2017;36:14. [PMID: 28103953 DOI: 10.1186/s40880-017-0183-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
301 Ahn SM, Haq F, Park I, Nault JC, Zucman-Rossi J, Yu E. The clinical implications of G1-G6 transcriptomic signature and 5-gene score in Korean patients with hepatocellular carcinoma. BMC Cancer 2018;18:571. [PMID: 29776391 DOI: 10.1186/s12885-018-4192-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
302 Zangos S, Eichler K, Balzer JO, Straub R, Hammerstingl R, Herzog C, Lehnert T, Heller M, Thalhammer A, Mack MG, Vogl TJ. Large-sized hepatocellular carcinoma (HCC): a neoadjuvant treatment protocol with repetitive transarterial chemoembolization (TACE) before percutaneous MR-guided laser-induced thermotherapy (LITT). Eur Radiol 2007;17:553-63. [PMID: 16896704 DOI: 10.1007/s00330-006-0343-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
303 Xiangfei M, Yinzhe X, Yingwei P, Shichun L, Weidong D. Open versus laparoscopic hepatic resection for hepatocellular carcinoma: a systematic review and meta-analysis. Surg Endosc 2019;33:2396-418. [DOI: 10.1007/s00464-019-06781-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
304 Chen JC, Chuang HY, Hsu FT, Chen YC, Chien YC, Hwang JJ. Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model. Oncotarget 2016;7:85450-63. [PMID: 27863427 DOI: 10.18632/oncotarget.13398] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
305 Oh BS, Jang JW, Kwon JH, You CR, Chung KW, Kay CS, Jung HS, Lee S. Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma. BMC Cancer. 2013;13:78. [PMID: 23409924 DOI: 10.1186/1471-2407-13-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
306 Ramalho M, Matos AP, AlObaidy M, Velloni F, Altun E, Semelka RC. Magnetic resonance imaging of the cirrhotic liver: diagnosis of hepatocellular carcinoma and evaluation of response to treatment - Part 1. Radiol Bras. 2017;50:38-47. [PMID: 28298731 DOI: 10.1590/0100-3984.2015.0132] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
307 Wang Q, Cheng F, Ma TT, Xiong HY, Li ZW, Xie CL, Liu CY, Tu ZG. Interleukin-12 inhibits the hepatocellular carcinoma growth by inducing macrophage polarization to the M1-like phenotype through downregulation of Stat-3. Mol Cell Biochem. 2016;415:157-168. [PMID: 27003285 DOI: 10.1007/s11010-016-2687-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
308 Stefaniuk P, Cianciara J, Wiercinska-Drapalo A. Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol. 2010;16:418-424. [PMID: 20101765 DOI: 10.3748/wjg.v16.i4.418] [Cited by in CrossRef: 111] [Cited by in F6Publishing: 102] [Article Influence: 10.1] [Reference Citation Analysis]
309 Shi C, Hao B, Yang Y, Muhammad I, Zhang Y, Chang Y, Li Y, Li C, Li R, Liu F. JNK Signaling Pathway Mediates Acetaminophen-Induced Hepatotoxicity Accompanied by Changes of Glutathione S-Transferase A1 Content and Expression. Front Pharmacol 2019;10:1092. [PMID: 31620005 DOI: 10.3389/fphar.2019.01092] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
310 Kanda M, Sugimoto H, Kodera Y. Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. World J Gastroenterol. 2015;21:10584-10597. [PMID: 26457018 DOI: 10.3748/wjg.v21.i37.10584] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 41] [Article Influence: 7.4] [Reference Citation Analysis]
311 Utsunomiya T, Shimada M, Imura S, Morine Y, Ikemoto T, Mori M. Molecular signatures of noncancerous liver tissue can predict the risk for late recurrence of hepatocellular carcinoma. J Gastroenterol. 2010;45:146-152. [PMID: 19997856 DOI: 10.1007/s00535-009-0164-1] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 4.8] [Reference Citation Analysis]
312 Hamid AS, Tesfamariam IG, Zhang Y, Zhang ZG. Aflatoxin B1-induced hepatocellular carcinoma in developing countries: Geographical distribution, mechanism of action and prevention. Oncol Lett 2013;5:1087-92. [PMID: 23599745 DOI: 10.3892/ol.2013.1169] [Cited by in Crossref: 149] [Cited by in F6Publishing: 115] [Article Influence: 18.6] [Reference Citation Analysis]
313 Hwang GL, van den Bosch MA, Kim YI, Katzenberg R, Willmann JK, Paulmurugan R, Gambhir SS, Hofmann L. Development of a High-Throughput Molecular Imaging-Based Orthotopic Hepatocellular Carcinoma Model. Cureus 2015;7:e281. [PMID: 26180705 DOI: 10.7759/cureus.281] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
314 Chen S, Yu W, Zhang K, Liu W. Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma. BMC Cancer 2018;18:1131. [PMID: 30453925 DOI: 10.1186/s12885-018-5081-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
315 Merle P, Trepo C. Molecular mechanisms underlying hepatocellular carcinoma. Viruses. 2009;1:852-872. [PMID: 21994573 DOI: 10.3390/v1030852] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
316 Chang CW, Wang TE, Chen LT, Chang WH, Leu YS, Fan YK, Chan YJ. Unusual presentation of metastatic hepatocellular carcinoma in the nasal septum: a case report and review of the literature. Med Oncol 2008;25:264-8. [PMID: 18040899 DOI: 10.1007/s12032-007-9028-9] [Cited by in Crossref: 7] [Article Influence: 0.5] [Reference Citation Analysis]
317 Golfieri R, Bezzi M, Verset G, Fucilli F, Mosconi C, Cappelli A, Paccapelo A, Lucatelli P, Magand N, Rode A, De Baere T. Retrospective European Multicentric Evaluation of Selective Transarterial Chemoembolisation with and without Balloon-Occlusion in Patients with Hepatocellular Carcinoma: A Propensity Score Matched Analysis. Cardiovasc Intervent Radiol 2021;44:1048-59. [PMID: 33709273 DOI: 10.1007/s00270-021-02805-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
318 Yu X, Wu Q, Wang L, Zhao Y, Zhang Q, Meng Q, Pawan, Wang S. Silencing of ST6GalNAc I suppresses the proliferation, migration and invasion of hepatocarcinoma cells through PI3K/AKT/NF-κB pathway. Tumour Biol 2016;37:12213-21. [PMID: 27235117 DOI: 10.1007/s13277-016-5086-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
319 Zhou Y, Xu D, Wu L, Li B. Meta-analysis of anatomic resection versus nonanatomic resection for hepatocellular carcinoma. Langenbecks Arch Surg. 2011;396:1109-1117. [PMID: 21476060 DOI: 10.1007/s00423-011-0784-9.] [Reference Citation Analysis]
320 Chen HY, Ma XM, Bai YR. Radiographic characteristics of bone metastases from hepatocellular carcinoma. Contemp Oncol (Pozn) 2012;16:424-31. [PMID: 23788922 DOI: 10.5114/wo.2012.31773] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
321 Elkhenany H, Shekshek A, Abdel-Daim M, El-Badri N. Stem Cell Therapy for Hepatocellular Carcinoma: Future Perspectives. Adv Exp Med Biol 2020;1237:97-119. [PMID: 31728916 DOI: 10.1007/5584_2019_441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
322 Liu B, Liu T, Su M, Ma YQ, Zhang BF, Wang YF, Hu BY, Chen YL. Improving the Surgical Effect for Primary Liver Cancer with Intraoperative Fluorescence Navigation Compared with Intraoperative Ultrasound. Med Sci Monit 2019;25:3406-16. [PMID: 31067211 DOI: 10.12659/MSM.916423] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
323 Chiu CC, Lee KT, Lee HH, Wang JJ, Sun DP, Huang CC, Shi HY. Comparison of Models for Predicting Quality of Life After Surgical Resection of Hepatocellular Carcinoma: a Prospective Study. J Gastrointest Surg. 2018;22:1724-1731. [PMID: 29916106 DOI: 10.1007/s11605-018-3833-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
324 Liu H, Liu W, Liu Z, Liu Y, Zhang W, Xu L, Xu J. Prognostic value of purinergic P2X7 receptor expression in patients with hepatocellular carcinoma after curative resection. Tumour Biol 2015;36:5039-49. [PMID: 25722111 DOI: 10.1007/s13277-015-3155-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
325 Murata S, Mine T, Sugihara F, Yasui D, Yamaguchi H, Ueda T, Onozawa S, Kumita S. Interventional treatment for unresectable hepatocellular carcinoma. World J Gastroenterol. 2014;20:13453-13465. [PMID: 25309076 DOI: 10.3748/wjg.v20.i37.13453] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
326 Hwang J, Kim SH, Lee MW, Lee JY. Small (≤ 2 cm) hepatocellular carcinoma in patients with chronic liver disease: comparison of gadoxetic acid-enhanced 3.0 T MRI and multiphasic 64-multirow detector CT. Br J Radiol 2012;85:e314-22. [PMID: 22167508 DOI: 10.1259/bjr/27727228] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 4.7] [Reference Citation Analysis]
327 Shi Y, Sun X, He X. Overexpression of Aristaless-Like Homeobox-4 Inhibits Proliferation, Invasion, and EMT in Hepatocellular Carcinoma Cells. Oncol Res 2017;25:11-8. [PMID: 28081728 DOI: 10.3727/096504016X14685034103833] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
328 Nawawi O, Hazman M, Abdullah B, Vijayananthan A, Manikam J, Mahadeva S, Goh K. Transarterial embolisation of hepatocellular carcinoma with doxorubicin-eluting beads: single centre early experience. Biomed Imaging Interv J 2010;6:e7. [PMID: 21611067 DOI: 10.2349/biij.6.1.e7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
329 Watanabe M. A novel in situ permeation system and its utility in cancer tissue ablation. Int J Oncol 2015;47:875-83. [PMID: 26134633 DOI: 10.3892/ijo.2015.3068] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
330 Mancuso A. Hepatocellular carcinoma in thalassemia: A critical review. World J Hepatol 2010;2:171-4. [PMID: 21160991 DOI: 10.4254/wjh.v2.i5.171] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
331 Peisen F, Maurer M, Grosse U, Nikolaou K, Syha R, Ketelsen D, Artzner C, Bitzer M, Horger M, Grözinger G. Predictive performance of the mHAP-II score in a real-life western cohort with hepatocellular carcinoma following trans-arterial chemoembolisation with drug-eluting beads (DEB-TACE). Eur Radiol 2020;30:3782-92. [PMID: 32125515 DOI: 10.1007/s00330-020-06734-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
332 Belghiti J, Fuks D. Liver resection and transplantation in hepatocellular carcinoma. Liver Cancer. 2012;1:71-82. [PMID: 24159575 DOI: 10.1159/000342403] [Cited by in Crossref: 54] [Cited by in F6Publishing: 60] [Article Influence: 7.7] [Reference Citation Analysis]
333 Adhoute X, Penaranda G, Castellani P, Perrier H, Bourliere M. Recommendations for the use of chemoembolization in patients with hepatocellular carcinoma: Usefulness of scoring system? World J Hepatol. 2015;7:521-531. [PMID: 25848475 DOI: 10.4254/wjh.v7.i3.521] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
334 Wang CP, Wang H, Qu JH, Lu YY, Bai WL, Dong Z, Gao XD, Rong GH, Zeng Z, Yang YP. Tumour seeding after percutaneous cryoablation for hepatocellular carcinoma. World J Gastroenterol. 2012;18:6587-6596. [PMID: 23236233 DOI: 10.3748/wjg.v18.i45.6587] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
335 Wan J, Wen D, Dong L, Tang J, Liu D, Liu Y, Tao Z, Gao D, Sun H, Cao Y, Fan J, Wu W. Establishment of monoclonal HCC cell lines with organ site-specific tropisms. BMC Cancer 2015;15:678. [PMID: 26459277 DOI: 10.1186/s12885-015-1692-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
336 Zhang D, Cao L, Li Y, Lu H, Yang X, Xue P. Expression of glioma-associated oncogene 2 (Gli 2) is correlated with poor prognosis in patients with hepatocellular carcinoma undergoing hepatectomy. World J Surg Oncol 2013;11:25. [PMID: 23356443 DOI: 10.1186/1477-7819-11-25] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
337 Hanaoka H, Nagaya T, Sato K, Nakamura Y, Watanabe R, Harada T, Gao W, Feng M, Phung Y, Kim I, Paik CH, Choyke PL, Ho M, Kobayashi H. Glypican-3 targeted human heavy chain antibody as a drug carrier for hepatocellular carcinoma therapy. Mol Pharm 2015;12:2151-7. [PMID: 25955255 DOI: 10.1021/acs.molpharmaceut.5b00132] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 7.2] [Reference Citation Analysis]
338 Lambert B, Van de Wiele C. Treatment of hepatocellular carcinoma by means of radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2005;32:980-989. [PMID: 16032439 DOI: 10.1007/s00259-005-1859-z] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
339 Chung C, Al Ali J, Owen DA, Weiss AA, Yoshida EM, Tai IT. A rare case of isolated duodenal metastases from hepatocellular carcinoma associated with p53 and ki-67 expression: a case report. Cases J 2009;2:9344. [PMID: 20062599 DOI: 10.1186/1757-1626-2-9344] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
340 McCarthy CM, McCarthy M, O'Donoghue K. Recurrent hepatocellular carcinoma in pregnancy: A case report and literature review. Obstet Med 2019;12:202-4. [PMID: 31853263 DOI: 10.1177/1753495X18784074] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
341 Ozaki I, Hamajima H, Matsuhashi S, Mizuta T. Regulation of TGF-β1-induced pro-apoptotic signaling by growth factor receptors and extracellular matrix receptor integrins in the liver. Front Physiol. 2011;2:78. [PMID: 22028694 DOI: 10.3389/fphys.2011.00078] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
342 Au JS, Frenette CT. Management of Hepatocellular Carcinoma: Current Status and Future Directions. Gut Liver. 2015;9:437-448. [PMID: 26087860 DOI: 10.5009/gnl15022] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
343 Ramachandran J. Surveillance for hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4:S50-S56. [PMID: 25755611 DOI: 10.1016/j.jceh.2014.03.050] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
344 Shin JW, Chung YH. Molecular targeted therapy for hepatocellular carcinoma: current and future. World J Gastroenterol 2013;19:6144-55. [PMID: 24115810 DOI: 10.3748/wjg.v19.i37.6144] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 49] [Article Influence: 7.0] [Reference Citation Analysis]
345 Lai JP, Sandhu DS, Moser CD, Cazanave SC, Oseini AM, Shire AM, Shridhar V, Sanderson SO, Roberts LR. Additive effect of apicidin and doxorubicin in sulfatase 1 expressing hepatocellular carcinoma in vitro and in vivo. J Hepatol. 2009;50:1112-1121. [PMID: 19376607 DOI: 10.1016/j.jhep.2008.12.031] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
346 Hsieh PM, Hung KC, Chen YS. Tumor lysis syndrome after transarterial chemoembolization of hepatocellular carcinoma: case reports and literature review. World J Gastroenterol 2009;15:4726-8. [PMID: 19787837 DOI: 10.3748/wjg.15.4726] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
347 Mas VR, Maluf DG, Archer KJ, Yanek K, Kong X, Kulik L, Freise CE, Olthoff KM, Ghobrial RM, McIver P. Genes involved in viral carcinogenesis and tumor initiation in hepatitis C virus-induced hepatocellular carcinoma. Mol Med. 2009;15:85-94. [PMID: 19098997 DOI: 10.2119/molmed.2008.00110] [Cited by in Crossref: 159] [Cited by in F6Publishing: 153] [Article Influence: 12.2] [Reference Citation Analysis]
348 Zhang PF, Wei CY, Huang XY, Peng R, Yang X, Lu JC, Zhang C, Gao C, Cai JB, Gao PT, Gao DM, Shi GM, Ke AW, Fan J. Circular RNA circTRIM33-12 acts as the sponge of MicroRNA-191 to suppress hepatocellular carcinoma progression. Mol Cancer 2019;18:105. [PMID: 31153371 DOI: 10.1186/s12943-019-1031-1] [Cited by in Crossref: 80] [Cited by in F6Publishing: 70] [Article Influence: 40.0] [Reference Citation Analysis]
349 Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, Kudo M, Johnson P, Wagner S, Orsini LS, Sherman M. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35:2155-2166. [PMID: 25752327 DOI: 10.1111/liv.12818] [Cited by in Crossref: 369] [Cited by in F6Publishing: 342] [Article Influence: 61.5] [Reference Citation Analysis]
350 Oh JH, Sinn DH, Choi GS, Kim JM, Joh JW, Kang TW, Hyun D, Kang W, Gwak GY, Paik YH, Lee JH, Koh KC, Paik SW, Choi MS. Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy for multiple small hepatocellular carcinoma within the Milan criteria. Ann Surg Treat Res 2020;99:238-46. [PMID: 33029483 DOI: 10.4174/astr.2020.99.4.238] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
351 Kumar A, Acharya SK, Singh SP, Saraswat VA, Arora A, Duseja A, Goenka MK, Jain D, Kar P, Kumar M, Kumaran V, Mohandas KM, Panda D, Paul SB, Ramachandran J, Ramesh H, Rao PN, Shah SR, Sharma H, Thandassery RB; (The INASL Task-Force on Hepatocellular Carcinoma). The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations. J Clin Exp Hepatol 2014;4:S3-S26. [PMID: 25755608 DOI: 10.1016/j.jceh.2014.04.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
352 Chen CC, Kim KH, Lau LF. The matricellular protein CCN1 suppresses hepatocarcinogenesis by inhibiting compensatory proliferation. Oncogene 2016;35:1314-23. [PMID: 26028023 DOI: 10.1038/onc.2015.190] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
353 Wu L, Peng CW, Hou JX, Zhang YH, Chen C, Chen LD, Li Y. Coronin-1C is a novel biomarker for hepatocellular carcinoma invasive progression identified by proteomics analysis and clinical validation. J Exp Clin Cancer Res 2010;29:17. [PMID: 20181269 DOI: 10.1186/1756-9966-29-17] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
354 Gong J, Cho M, Fakih M. Chemotherapy in patients with hepatobiliary cancers and abnormal hepatic function. J Gastrointest Oncol 2017;8:314-23. [PMID: 28480070 DOI: 10.21037/jgo.2016.09.17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
355 Sanduzzi Zamparelli M, Rocco A, Compare D, Nardone G. The gut microbiota: A new potential driving force in liver cirrhosis and hepatocellular carcinoma. United European Gastroenterol J. 2017;5:944-953. [PMID: 29163959 DOI: 10.1177/2050640617705576] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
356 Fang Y, Chai Z, Wang D, Kuang T, Wu W, Lou W. DNA-PKcs deficiency sensitizes the human hepatoma HepG2 cells to cisplatin and 5-fluorouracil through suppression of the PI3K/Akt/NF-κB pathway. Mol Cell Biochem 2015;399:269-78. [PMID: 25348361 DOI: 10.1007/s11010-014-2253-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
357 Liu K, Wu X, Zang X, Huang Z, Lin Z, Tan W, Wu X, Hu W, Li B, Zhang L. TRAF4 Regulates Migration, Invasion, and Epithelial-Mesenchymal Transition via PI3K/AKT Signaling in Hepatocellular Carcinoma. Oncol Res 2017;25:1329-40. [PMID: 28256185 DOI: 10.3727/096504017X14876227286564] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 5.8] [Reference Citation Analysis]
358 Kwon JH, Bae SH, Kim JY, Choi BO, Jang HS, Jang JW, Choi JY, Yoon SK, Chung KW. Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer. 2010;10:475. [PMID: 20813065 DOI: 10.1186/1471-2407-10-475] [Cited by in Crossref: 164] [Cited by in F6Publishing: 149] [Article Influence: 14.9] [Reference Citation Analysis]
359 Yamaguchi T, Seki T, Miyasaka C, Inokuchi R, Kawamura R, Sakaguchi Y, Murata M, Matsuzaki K, Nakano Y, Uemura Y, Okazaki K. Interstitial pneumonia induced by sorafenib in a patient with hepatocellular carcinoma: An autopsy case report. Oncol Lett 2015;9:1633-6. [PMID: 25789013 DOI: 10.3892/ol.2015.2934] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
360 Sheng Z, Wang X, Xu G, Shan G, Chen L. Analyses of a Panel of Transcripts Identified From a Small Sample Size and Construction of RNA Networks in Hepatocellular Carcinoma. Front Genet 2019;10:431. [PMID: 31156698 DOI: 10.3389/fgene.2019.00431] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
361 Nakazawa T, Hidaka H, Shibuya A, Koizumi W. Rapid regression of advanced hepatocellular carcinoma associated with elevation of des-gamma-carboxy prothrombin after short-term treatment with sorafenib - a report of two cases. Case Rep Oncol. 2010;3:298-303. [PMID: 21347197 DOI: 10.1159/000319831] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
362 Karabulut S, Tas F, Akyüz F, Ormeci AC, Serilmez M, Soydinç HO, Vatansever S, Yasasever V. Clinical significance of serum hepatocyte growth factor (HGF) levels in hepatocellular carcinoma. Tumour Biol 2014;35:2327-33. [PMID: 24142532 DOI: 10.1007/s13277-013-1308-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
363 Zhang YW, Ao J, Liu Y, Qiao MX, Yang XL, Tang SX, Li C, Xu K. Pharmacokinetics of gelatin sponge microparticles in a rabbit VX2 liver tumor model of hepatic arterial chemoembolization. Tumour Biol 2014;35:10905-10. [PMID: 25085588 DOI: 10.1007/s13277-014-2408-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
364 Jiang H, Wang H, Tan Z, Hu S, Wang H, Shi B, Yang L, Li P, Gu J, Wang H, Li Z. Growth suppression of human hepatocellular carcinoma xenografts by a monoclonal antibody CH12 directed to epidermal growth factor receptor variant III. J Biol Chem 2011;286:5913-20. [PMID: 21163950 DOI: 10.1074/jbc.M110.192252] [Cited by in Crossref: 34] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
365 Hochnadel I, Kossatz-Boehlert U, Jedicke N, Lenzen H, Manns MP, Yevsa T. Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic cancers. Hum Vaccin Immunother. 2017;13:2931-2952. [PMID: 29112462 DOI: 10.1080/21645515.2017.1359362] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
366 Kim BK, Park JY, Choi HJ, Kim DY, Ahn SH, Kim JK, Lee DY, Lee KH, Han KH. Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. J Cancer Res Clin Oncol. 2011;137:659-667. [PMID: 20552225 DOI: 10.1007/s00432-010-0917-5] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 3.5] [Reference Citation Analysis]
367 Wang M, Han J, Xing H, Zhang H, Li Z, Liang L, Li C, Dai S, Wu M, Shen F, Yang T. Dysregulated fatty acid metabolism in hepatocellular carcinoma. Hepat Oncol 2016;3:241-51. [PMID: 30191046 DOI: 10.2217/hep-2016-0012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
368 Mahgoub A, Steer CJ. MicroRNAs in the Evaluation and Potential Treatment of Liver Diseases. J Clin Med 2016;5:E52. [PMID: 27171116 DOI: 10.3390/jcm5050052] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
369 Tacher V, Radaelli A, Lin M, Geschwind JF. How I do it: Cone-beam CT during transarterial chemoembolization for liver cancer. Radiology 2015;274:320-34. [PMID: 25625741 DOI: 10.1148/radiol.14131925] [Cited by in Crossref: 88] [Cited by in F6Publishing: 61] [Article Influence: 14.7] [Reference Citation Analysis]
370 Oh BS, Jang JW, Kwon JH, You CR, Chung KW, Kay CS, Jung HS, Lee S. Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma. BMC Cancer. 2013;13:78. [PMID: 23409924 DOI: 10.1186/1471-2407-13-78] [Cited by in Crossref: 61] [Cited by in F6Publishing: 68] [Article Influence: 7.6] [Reference Citation Analysis]
371 Csepregi A, Röcken C, Hoffmann J, Gu P, Saliger S, Müller O, Schneider-Stock R, Kutzner N, Roessner A, Malfertheiner P. APC promoter methylation and protein expression in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2008;134:579-589. [PMID: 17973119 DOI: 10.1111/j.1582-4934.2010.01124.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 3.0] [Reference Citation Analysis]
372 Lubienski A, Simon M, Lubienski K, Gellissen J, Hoffmann R, Jakobs T, Helmberger T. Update Chemoperfusion und -embolisation. Radiologe 2007;47:1097-108. [DOI: 10.1007/s00117-007-1587-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
373 Ling W, Wang M, Ma X, Qiu T, Li J, Lu Q, Luo Y. The preliminary application of liver imaging reporting and data system (LI-RADS) with contrast-enhanced ultrasound (CEUS) on small hepatic nodules (≤ 2cm). J Cancer 2018;9:2946-52. [PMID: 30123363 DOI: 10.7150/jca.25539] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
374 Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L, Minguez B, Savic R, Ward SC, Thung S, Chiang DY. MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology. 2011;140:1618-1628.e16. [PMID: 21324318 DOI: 10.1053/j.gastro.2011.02.009] [Cited by in Crossref: 153] [Cited by in F6Publishing: 148] [Article Influence: 15.3] [Reference Citation Analysis]
375 Luo HC, Zhang HB, Xin XJ, Huang WX. Haplotype-based case-control study of DNA repair gene XRCC3 and hepatocellular carcinoma risk in a Chinese population. Tumour Biol 2014;35:3415-9. [PMID: 24307625 DOI: 10.1007/s13277-013-1451-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
376 Liang HH, Wei PL, Hung CS, Wu CT, Wang W, Huang MT, Chang YJ. MicroRNA-200a/b influenced the therapeutic effects of curcumin in hepatocellular carcinoma (HCC) cells. Tumour Biol 2013;34:3209-18. [PMID: 23760980 DOI: 10.1007/s13277-013-0891-z] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 4.5] [Reference Citation Analysis]
377 Abeni E, Salvi A, Marchina E, Traversa M, Arici B, De Petro G. Sorafenib induces variations of the DNA methylome in HA22T/VGH human hepatocellular carcinoma-derived cells. Int J Oncol 2017;51:128-44. [PMID: 28560380 DOI: 10.3892/ijo.2017.4019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
378 Yamakado K, Miyayama S, Hirota S, Mizunuma K, Nakamura K, Inaba Y, Yamamoto S, Matsuo K, Nishida N, Aramaki T, Anai H, Kora S, Oikawa S, Watanabe K, Yasumoto T, Furuichi K, Yamaguchi M. Prognosis of patients with intermediate-stage hepatocellular carcinomas based on the Child-Pugh score: subclassifying the intermediate stage (Barcelona Clinic Liver Cancer stage B). Jpn J Radiol 2014;32:644-9. [DOI: 10.1007/s11604-014-0358-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
379 Rinninella E, Cerrito L, Spinelli I, Cintoni M, Mele MC, Pompili M, Gasbarrini A. Chemotherapy for Hepatocellular Carcinoma: Current Evidence and Future Perspectives. J Clin Transl Hepatol 2017;5:235-48. [PMID: 28936405 DOI: 10.14218/JCTH.2017.00002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
380 Kudo M, Tateishi R, Yamashita T, Ikeda M, Furuse J, Ikeda K, Kokudo N, Izumi N, Matsui O. Current status of hepatocellular carcinoma treatment in Japan: case study and discussion-voting system. Clin Drug Investig. 2012;32 Suppl 2:37-51. [PMID: 22873626 DOI: 10.2165/1163024-s0-000000000-00000] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
381 Teng CF, Tsai HW, Li TC, Wang T, Wang J, Shyu WC, Wu HC, Su IJ, Jeng LB. Detection of hepatitis B virus pre-S mutants in plasma by a next-generation sequencing-based platform determines their patterns in liver tissues. PLoS One 2020;15:e0234773. [PMID: 32559248 DOI: 10.1371/journal.pone.0234773] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
382 Huang CP, Chen CC, Shyr CR. Xenogeneic cell therapy provides a novel potential therapeutic option for cancers by restoring tissue function, repairing cancer wound and reviving anti-tumor immune responses. Cancer Cell Int 2018;18:9. [PMID: 29371832 DOI: 10.1186/s12935-018-0501-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
383 Dong W, Zhang T, Wang ZG, Liu H. Clinical outcome of small hepatocellular carcinoma after different treatments: a meta-analysis. World J Gastroenterol. 2014;20:10174-10182. [PMID: 25110446 DOI: 10.3748/wjg.v20.i29.10174] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
384 Chen JS, Li HS, Huang JQ, Zhang LJ, Chen XL, Wang Q, Lei J, Feng JT, Liu Q, Huang XH. Down-regulation of Gli-1 inhibits hepatocellular carcinoma cell migration and invasion. Mol Cell Biochem. 2014;393:283-291. [PMID: 24792036 DOI: 10.1007/s11010-014-2071-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
385 Li S, Feng X, Cao G, Wang Q, Wang L. Prognostic significance of inflammatory indices in hepatocellular carcinoma treated with transarterial chemoembolization: A systematic review and meta-analysis. PLoS One 2020;15:e0230879. [PMID: 32214401 DOI: 10.1371/journal.pone.0230879] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
386 Niu J, Lin Y, Liu P, Yu Y, Su C, Wang X. Microarray analysis on the lncRNA expression profile in male hepatocelluar carcinoma patients with chronic hepatitis B virus infection. Oncotarget 2016;7:76169-80. [PMID: 27769059 DOI: 10.18632/oncotarget.12732] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
387 Reiter FP, Denk G, Ziesch A, Ofner A, Wimmer R, Hohenester S, Schiergens TS, Spampatti M, Ye L, Itzel T, Munker S, Teufel A, Gerbes AL, Mayerle J, De Toni EN. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells. Cell Oncol (Dordr) 2019;42:705-15. [PMID: 31250364 DOI: 10.1007/s13402-019-00458-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
388 Li J, Zhou Y, Liu Y, Dai B, Zhang YH, Zhang PF, Shi XL. Sorafenib inhibits caspase-1 expression through suppressing TLR4/stat3/SUMO1 pathway in hepatocellular carcinoma. Cancer Biol Ther. 2018;1-8. [PMID: 30277836 DOI: 10.1080/15384047.2018.1480280] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
389 Sasikala M, Surya P, Radhika G, Kumar PP, Rao MS, Mukherjee RM, Rao PN, Reddy DN. Identification of circulating CD90 CD73 cells in cirrhosis of liver. World J Stem Cells 2011;3:63-9. [PMID: 21860671 DOI: 10.4252/wjsc.v3.i7.63] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
390 Moawad AW, Szklaruk J, Lall C, Blair KJ, Kaseb AO, Kamath A, Rohren SA, Elsayes KM. Angiogenesis in Hepatocellular Carcinoma; Pathophysiology, Targeted Therapy, and Role of Imaging. J Hepatocell Carcinoma 2020;7:77-89. [PMID: 32426302 DOI: 10.2147/JHC.S224471] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
391 Jihye C, Jinsil S. Application of Radiotherapeutic Strategies in the BCLC-Defined Stages of Hepatocellular Carcinoma. Liver Cancer 2012;1:216-25. [PMID: 24159586 DOI: 10.1159/000343836] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
392 Liu Z, Gao F, Yang G, Singh S, Lu M, Zhang T, Zhong Z, Zhang F, Tang R. Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: an up-to-date meta-analysis. Tumour Biol. 2014;35:7407-7413. [PMID: 24777334 DOI: 10.1007/s13277-014-1976-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 4.4] [Reference Citation Analysis]
393 Wang F, Zhou H, Yang Y, Xia X, Sun Q, Luo J, Cheng B. Hepatitis B virus X protein promotes the growth of hepatocellular carcinoma by modulation of the Notch signaling pathway. Oncol Rep. 2012;27:1170-1176. [PMID: 22218807 DOI: 10.3892/or.2012.1620] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
394 Somma F, Stoia V, Serra N, D'Angelo R, Gatta G, Fiore F. Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: The impact of portal vein thrombosis on survival. PLoS One 2019;14:e0216935. [PMID: 31141552 DOI: 10.1371/journal.pone.0216935] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
395 Chung JC, Naik NK, Lewandowski RJ, Deng J, Mulcahy MF, Kulik LM, Sato KT, Ryu RK, Salem R, Larson AC, Omary RA. Diffusion-weighted magnetic resonance imaging to predict response of hepatocellular carcinoma to chemoembolization. World J Gastroenterol 2010;16:3161-7. [PMID: 20593501 DOI: 10.3748/wjg.v16.i25.3161] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
396 Qu L, Kuai X, Liu T, Chen T, Ni Z, Shen X. Pre-S deletion and complex mutations of hepatitis B virus related to young age hepatocellular carcinoma in Qidong, China. PLoS One 2013;8:e59583. [PMID: 23555717 DOI: 10.1371/journal.pone.0059583] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
397 Demerdash HM, Hussien HM, Hassouna E, Arida EA. Detection of MicroRNA in Hepatic Cirrhosis and Hepatocellular Carcinoma in Hepatitis C Genotype-4 in Egyptian Patients. Biomed Res Int 2017;2017:1806069. [PMID: 28642869 DOI: 10.1155/2017/1806069] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
398 Qiu YQ, Zhou J, Kang XS, Ding LM, Yu W, Tan FL, Deng DF. Effect of BZG-4000, a novel multi-targeted kinase inhibitor with potent anticancer activity, on a hepatocellular carcinoma xenograft model. Sci Rep 2014;4:4324. [PMID: 24632756 DOI: 10.1038/srep04324] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
399 Song P, Feng X, Zhang K, Song T, Ma K, Kokudo N, Dong J, Tang W. Perspectives on using des-γ-carboxyprothrombin (DCP) as a serum biomarker: facilitating early detection of hepatocellular carcinoma in China. Hepatobiliary Surg Nutr. 2013;2:227-231. [PMID: 24570947 DOI: 10.3978/j.issn.2304-3881.2013.08.11] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
400 Hiraoka N. Tumor-infiltrating lymphocytes and hepatocellular carcinoma: molecular biology. Int J Clin Oncol. 2010;15:544-551. [PMID: 20924634 DOI: 10.1007/s10147-010-0130-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
401 Paul SB, Sreenivas V, Gulati MS, Madan K, Gupta AK, Mukhopadhyay S, Acharya SK. Economic evaluation of a surveillance program of hepatocellular carcinoma (HCC) in India. Hepatol Int 2008;2:231-6. [PMID: 19669309 DOI: 10.1007/s12072-008-9054-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
402 Chen K, Zhang H, Zhang LN, Ju SQ, Qi J, Huang DF, Li F, Wei Q, Zhang J. Value of circulating cell-free DNA in diagnosis of hepatocelluar carcinoma. World J Gastroenterol. 2013;19:3143-3149. [PMID: 23716996 DOI: 10.3748/wjg.v19.i20.3143] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
403 Sun J, Zhou C, Ma Q, Chen W, Atyah M, Yin Y, Fu P, Liu S, Hu B, Ren N, Zhou H. High GCLC level in tumor tissues is associated with poor prognosis of hepatocellular carcinoma after curative resection. J Cancer 2019;10:3333-43. [PMID: 31293636 DOI: 10.7150/jca.29769] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
404 Li M, Xia S, Shi P. DPM1 expression as a potential prognostic tumor marker in hepatocellular carcinoma. PeerJ 2020;8:e10307. [PMID: 33282554 DOI: 10.7717/peerj.10307] [Reference Citation Analysis]
405 Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y, Lauwers GY, Thasler W, Lee JT, Avruch J, Bardeesy N. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell. 2009;16:425-438. [PMID: 19878874 DOI: 10.1016/j.ccr.2009.09.026] [Cited by in Crossref: 597] [Cited by in F6Publishing: 571] [Article Influence: 49.8] [Reference Citation Analysis]
406 Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY, Solé M, Thung S, Moyano S, Toffanin S, Mínguez B, Cabellos L, Peix J, Schwartz M, Mazzaferro V, Bruix J, Llovet JM. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol 2010;52:550-9. [PMID: 20206398 DOI: 10.1016/j.jhep.2010.01.015] [Cited by in Crossref: 156] [Cited by in F6Publishing: 144] [Article Influence: 14.2] [Reference Citation Analysis]
407 Shi J, Keller JM, Zhang J, Keller ET. A review on the diagnosis and treatment of hepatocellular carcinoma with a focus on the role of Wnts and the dickkopf family of Wnt inhibitors. J Hepatocell Carcinoma 2014;1:1-7. [PMID: 27508171 DOI: 10.2147/JHC.S44537] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
408 Gassmann P, Spieker T, Haier J, Schmidt F, Mardin WA, Senninger N. Prognostic impact of underlying liver fibrosis and cirrhosis after curative resection of hepatocellular carcinoma. World J Surg 2010;34:2442-51. [PMID: 20544346 DOI: 10.1007/s00268-010-0655-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
409 Murata S, Mine T, Ueda T, Nakazawa K, Onozawa S, Yasui D, Kumita S. Transcatheter arterial chemoembolization based on hepatic hemodynamics for hepatocellular carcinoma. ScientificWorldJournal 2013;2013:479805. [PMID: 23606815 DOI: 10.1155/2013/479805] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
410 Fuchs BC, Hoshida Y, Fujii T, Wei L, Yamada S, Lauwers GY, McGinn CM, DePeralta DK, Chen X, Kuroda T, Lanuti M, Schmitt AD, Gupta S, Crenshaw A, Onofrio R, Taylor B, Winckler W, Bardeesy N, Caravan P, Golub TR, Tanabe KK. Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology. 2014;59:1577-1590. [PMID: 24677197 DOI: 10.1002/hep.26898] [Cited by in Crossref: 195] [Cited by in F6Publishing: 174] [Article Influence: 27.9] [Reference Citation Analysis]
411 Mazioti A, Gatselis NK, Rountas C, Zachou K, Filippiadis DK, Tepetes K, Koukoulis GK, Fezoulidis I, Dalekos GN. Safety and efficacy of transcatheter arterial chemoemboliazation in the real-life management of unresectable hepatocellular carcinoma. Hepat Mon. 2013;13:e7070. [PMID: 24198841 DOI: 10.5812/hepatmon.7070] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
412 Siriwardana RC, Niriella MA, Dassanayake AS, Liyanage CA, Upasena A, Sirigampala C, de Silva HJ. Factors affecting post-embolization fever and liver failure after trans-arterial chemo-embolization in a cohort without background infective hepatitis- a prospective analysis. BMC Gastroenterol 2015;15:96. [PMID: 26239844 DOI: 10.1186/s12876-015-0329-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
413 Ognjanovic S, Yuan JM, Chaptman AK, Fan Y, Yu MC. Genetic polymorphisms in the cytokine genes and risk of hepatocellular carcinoma in low-risk non-Asians of USA. Carcinogenesis. 2009;30:758-762. [PMID: 19126646 DOI: 10.1093/carcin/bgn286] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 3.7] [Reference Citation Analysis]
414 Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan JA, Glickman JN, Ikeda K, Hashimoto M, Watanabe G, Daidone MG, Roayaie S, Schwartz M, Thung S, Salvesen HB, Gabriel S, Mazzaferro V, Bruix J, Friedman SL, Kumada H, Llovet JM, Golub TR. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008;359:1995-2004. [PMID: 18923165 DOI: 10.1056/nejmoa0804525] [Cited by in Crossref: 886] [Cited by in F6Publishing: 476] [Article Influence: 68.2] [Reference Citation Analysis]
415 Ueda T, Murata S, Mine T, Onozawa S, Onda M, Naito Z, Amano Y, Kumita S. Comparison of epirubicin-iodized oil suspension and emulsion for transcatheter arterial chemoembolization in VX2 tumor. ScientificWorldJournal 2012;2012:961986. [PMID: 22489208 DOI: 10.1100/2012/961986] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
416 Klein PJ, Schmidt CM, Wiesenauer CA, Choi JN, Gage EA, Yip-Schneider MT, Wiebke EA, Wang Y, Omer C, Sebolt-Leopold JS. The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer. Neoplasia 2006;8:1-8. [PMID: 16533420 DOI: 10.1593/neo.05373] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 3.3] [Reference Citation Analysis]
417 Yoo JJ, Lee JH, Lee SH, Lee M, Lee DH, Cho Y, Lee YB, Yu SJ, Kim HC, Kim YJ, Yoon JH, Kim CY, Lee HS. Comparison of the effects of transarterial chemoembolization for advanced hepatocellular carcinoma between patients with and without extrahepatic metastases. PLoS One. 2014;9:e113926. [PMID: 25427152 DOI: 10.1371/journal.pone.0113926] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
418 Zhong JH, Rodríguez AC, Ke Y, Wang YY, Wang L, Li LQ. Hepatic resection as a safe and effective treatment for hepatocellular carcinoma involving a single large tumor, multiple tumors, or macrovascular invasion. Medicine (Baltimore) 2015;94:e396. [PMID: 25621684 DOI: 10.1097/MD.0000000000000396] [Cited by in Crossref: 68] [Cited by in F6Publishing: 49] [Article Influence: 11.3] [Reference Citation Analysis]
419 Afzal M, Kazmi I, Gupta G, Rahman M, Kimothi V, Anwar F. Preventive effect of Metformin against N-nitrosodiethylamine-initiated hepatocellular carcinoma in rats. Saudi Pharm J 2012;20:365-70. [PMID: 23960811 DOI: 10.1016/j.jsps.2012.05.012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
420 Calvisi DF, Evert M, Dombrowski F. Pathogenetic and Prognostic Significance of Inactivation of RASSF Proteins in Human Hepatocellular Carcinoma. Mol Biol Int 2012;2012:849874. [PMID: 22548173 DOI: 10.1155/2012/849874] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
421 Yang HI, Lee MH, Liu J, Chen CJ. Risk calculators for hepatocellular carcinoma in patients affected with chronic hepatitis B in Asia. World J Gastroenterol 2014;20:6244-51. [PMID: 24876745 DOI: 10.3748/wjg.v20.i20.6244] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
422 Bissig KD, Wieland SF, Tran P, Isogawa M, Le TT, Chisari FV, Verma IM. Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest. 2010;120:924-930. [PMID: 20179355 DOI: 10.1172/jci40094] [Cited by in Crossref: 262] [Cited by in F6Publishing: 146] [Article Influence: 23.8] [Reference Citation Analysis]
423 Kanzaki H, Chiba T, Ao J, Koroki K, Kanayama K, Maruta S, Maeda T, Kusakabe Y, Kobayashi K, Kanogawa N, Kiyono S, Nakamura M, Kondo T, Saito T, Nakagawa R, Ogasawara S, Suzuki E, Ooka Y, Muroyama R, Nakamoto S, Yasui S, Tawada A, Arai M, Kanda T, Maruyama H, Mimura N, Kato J, Zen Y, Ohtsuka M, Iwama A, Kato N. The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma. Sci Rep 2021;11:5303. [PMID: 33674622 DOI: 10.1038/s41598-021-84117-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
424 Schröder PC, Segura V, Riezu JI, Sangro B, Mato JM, Prieto J, Santamaría E, Corrales FJ. A signature of six genes highlights defects on cell growth and specific metabolic pathways in murine and human hepatocellular carcinoma. Funct Integr Genomics 2011;11:419-29. [PMID: 21562899 DOI: 10.1007/s10142-011-0230-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
425 Li W, Li R, Zhao X, Lin X, Yu Y, Zhang J, Chen K, Chai W, Yan F. Differentiation of Hepatocellular Carcinoma from Hepatic Hemangioma and Focal Nodular Hyperplasia using Computed Tomographic Spectral Imaging. J Clin Transl Hepatol 2021;9:315-23. [PMID: 34221917 DOI: 10.14218/JCTH.2020.00173] [Reference Citation Analysis]
426 Hou KZ, Fu ZQ, Gong H. Chemokine ligand 20 enhances progression of hepatocellular carcinoma via epithelial-mesenchymal transition. World J Gastroenterol. 2015;21:475-483. [PMID: 25593462 DOI: 10.3748/wjg.v21.i2.475] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
427 Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. HPB (Oxford). 2005;7:35-41. [PMID: 18333159 DOI: 10.1080/13651820410024058] [Cited by in Crossref: 153] [Cited by in F6Publishing: 134] [Article Influence: 13.9] [Reference Citation Analysis]
428 Hong HP, Lee JY, Lee MY, Jung KU, Kim BI, Son BH, Shin JH, Lee SR. Early experience with laparoscopic treatment of liver tumors using a separable cluster electrode with a no-touch technique. Wideochir Inne Tech Maloinwazyjne 2021;16:76-82. [PMID: 33786119 DOI: 10.5114/wiitm.2020.95065] [Reference Citation Analysis]
429 Chau GY. Resection of hepatitis B virus-related hepatocellular carcinoma: evolving strategies and emerging therapies to improve outcome. World J Gastroenterol. 2014;20:12473-12484. [PMID: 25253947 DOI: 10.3748/wjg.v20.i35.12473] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
430 Liao WJ, Shi M, Chen JZ, Li AM. Local recurrence of hepatocellular carcinoma after radiofrequency ablation. World J Gastroenterol 2010;16:5135-8. [PMID: 20976853 DOI: 10.3748/wjg.v16.i40.5135] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
431 Choi SH, Park BK, Lee KW, Chang J, Lee Y, Kwon HJ. Effect of respiratory syncytial virus on the growth of hepatocellular carcinoma cell-lines. BMB Rep 2015;48:565-70. [PMID: 25739391 DOI: 10.5483/bmbrep.2015.48.10.268] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
432 Othman MS, Aref AM, Mohamed AA, Ibrahim WA. Serum Levels of Interleukin-6 and Interleukin-10 as Biomarkers for Hepatocellular Carcinoma in Egyptian Patients. ISRN Hepatol 2013;2013:412317. [PMID: 27335826 DOI: 10.1155/2013/412317] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
433 Hoshida Y, Villanueva A, Llovet JM. Molecular profiling to predict hepatocellular carcinoma outcome. Expert Rev Gastroenterol Hepatol 2009;3:101-3. [PMID: 19351279 DOI: 10.1586/egh.09.5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
434 Corey KE, Pratt DS. Current status of therapy for hepatocellular carcinoma. Therap Adv Gastroenterol. 2009;2:45-57. [PMID: 21180533 DOI: 10.1177/1756283X08100328] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
435 Jin YJ, Lee JW, Choi YJ, Chung HJ, Kim YS, Lee KY, Ahn SI, Shin WY, Cho SG, Jeon YS. Surgery versus transarterial chemoembolization for solitary large hepatocellular carcinoma of BCLC stage A. J Gastrointest Surg. 2014;18:555-561. [PMID: 24420729 DOI: 10.1007/s11605-013-2440-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
436 Mazioti A, Gatselis NK, Rountas C, Zachou K, Filippiadis DK, Tepetes K, Koukoulis GK, Fezoulidis I, Dalekos GN. Safety and efficacy of transcatheter arterial chemoemboliazation in the real-life management of unresectable hepatocellular carcinoma. Hepat Mon. 2013;13:e7070. [PMID: 24198841 DOI: 10.5812/hepatmon.7070.] [Reference Citation Analysis]
437 Stocker D, Marquez HP, Wagner MW, Raptis DA, Clavien PA, Boss A, Fischer MA, Wurnig MC. MRI texture analysis for differentiation of malignant and benign hepatocellular tumors in the non-cirrhotic liver. Heliyon 2018;4:e00987. [PMID: 30761374 DOI: 10.1016/j.heliyon.2018.e00987] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
438 Hung CS, Huang CY, Lee CH, Chen WY, Huang MT, Wei PL, Chang YJ. IGFBP2 plays an important role in heat shock protein 27-mediated cancer progression and metastasis. Oncotarget 2017;8:54978-92. [PMID: 28903396 DOI: 10.18632/oncotarget.18989] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
439 Liu H, Zhao P, Jin X, Zhao Y, Chen Y, Yan T, Wang J, Wu L, Sun Y. A 9‑lncRNA risk score system for predicting the prognosis of patients with hepatitis B virus‑positive hepatocellular carcinoma. Mol Med Rep 2019;20:573-83. [PMID: 31115573 DOI: 10.3892/mmr.2019.10262] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
440 Molvar C, Lewandowski R. Yttrium-90 Radioembolization of Hepatocellular Carcinoma-Performance, Technical Advances, and Future Concepts. Semin Intervent Radiol 2015;32:388-97. [PMID: 26622103 DOI: 10.1055/s-0035-1564704] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
441 Lin ZZ, Shau WY, Hsu C, Shao YY, Yeh YC, Kuo RN, Hsu CH, Yang JC, Cheng AL, Lai MS. Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size. PLoS One 2013;8:e80276. [PMID: 24244668 DOI: 10.1371/journal.pone.0080276] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
442 Lachenmayer A, Alsinet C, Chang CY, Llovet JM. Molecular approaches to treatment of hepatocellular carcinoma. Dig Liver Dis. 2010;42 Suppl 3:S264-S272. [PMID: 20547313 DOI: 10.1016/s1590-8658(10)60515-4] [Cited by in Crossref: 54] [Cited by in F6Publishing: 25] [Article Influence: 4.9] [Reference Citation Analysis]
443 Chen G, Qiu H, Ke S, Hu S, Yu S, Zou S. The fibroblast growth factor receptor 2-mediated extracellular signal-regulated kinase 1/2 signaling pathway plays is important in regulating excision repair cross-complementary gene 1 expression in hepatocellular carcinoma. Biomed Rep. 2013;1:604-608. [PMID: 24648994 DOI: 10.3892/br.2013.96] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
444 Crocetti L, Lencioni R. Thermal ablation of hepatocellular carcinoma. Cancer Imaging 2008;8:19-26. [PMID: 18331969 DOI: 10.1102/1470-7330.2008.0004] [Cited by in Crossref: 44] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
445 Kim MS, Jin YJ, Lee JW, Lee JI, Kim YS, Lee SY, Chae MH. Complete remission of advanced hepatocellular carcinoma by sorafenib: A case report. World J Gastrointest Oncol. 2013;5:38-42. [PMID: 23556056 DOI: 10.4251/wjgo.v5.i2.38] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
446 Deng X, Liang J, Jiang M, Zhou X, Liu H. Association between the C.1161G>A and C.1779C>G genetic variants of XRCC1 gene and hepatocellular carcinoma risk in Chinese population. Int J Biol Sci 2013;9:289-94. [PMID: 23493666 DOI: 10.7150/ijbs.5928] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
447 Cao ZY, Chen XZ, Liao LM, Peng J, Hu HX, Liu ZZ, Du J. Fuzheng Yiliu Granule inhibits the growth of hepatocellular cancer by regulating immune function and inducing apoptosis in vivo and in vitro. Chin J Integr Med. 2011;17:691-697. [PMID: 21910071 DOI: 10.1007/s11655-011-0847-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
448 Zhang H, Zhu C, Zhao Y, Li M, Wu L, Yang X, Wan X, Wang A, Zhang MQ, Sang X, Zhao H. Long non-coding RNA expression profiles of hepatitis C virus-related dysplasia and hepatocellular carcinoma. Oncotarget 2015;6:43770-8. [PMID: 26540467 DOI: 10.18632/oncotarget.6087] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 9.2] [Reference Citation Analysis]
449 Zhang QF, Yin WW, Xia Y, Yi YY, He QF, Wang X, Ren H, Zhang DZ. Liver-infiltrating CD11b-CD27- NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression. Cell Mol Immunol 2017;14:819-29. [PMID: 27321064 DOI: 10.1038/cmi.2016.28] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 11.8] [Reference Citation Analysis]
450 Shigesawa T, Suda G, Kimura M, Maehara O, Tokuchi Y, Kubo A, Yamada R, Furuya K, Baba M, Kitagataya T, Suzuki K, Ohara M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N. Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma. PLoS One 2021;16:e0247728. [PMID: 33647018 DOI: 10.1371/journal.pone.0247728] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
451 Valle JW, Dangoor A, Beech J, Sherlock DJ, Lee SM, Scarffe JH, Swindell R, Ranson M. Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study. Br J Cancer 2005;92:628-30. [PMID: 15700038 DOI: 10.1038/sj.bjc.6602394] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
452 Mir O, Coriat R, Blanchet B, Durand JP, Boudou-Rouquette P, Michels J, Ropert S, Vidal M, Pol S, Chaussade S, Goldwasser F. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One. 2012;7:e37563. [PMID: 22666367 DOI: 10.1371/journal.pone.0037563] [Cited by in Crossref: 180] [Cited by in F6Publishing: 163] [Article Influence: 20.0] [Reference Citation Analysis]
453 Kwon SK, Yun SS, Kim HJ, Lee DS. The risk factors of early recurrence after hepatectomy in hepatocellular carcinoma. Ann Surg Treat Res 2014;86:283-8. [PMID: 24949318 DOI: 10.4174/astr.2014.86.6.283] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
454 Morishita A, Iwama H, Fujihara S, Watanabe M, Fujita K, Tadokoro T, Ohura K, Chiyo T, Sakamoto T, Mimura S, Nomura T, Tani J, Yoneyama H, Okano K, Suzuki Y, Himoto T, Masaki T. Targeted sequencing of cancer-associated genes in hepatocellular carcinoma using next-generation sequencing. Oncol Lett 2018;15:528-32. [PMID: 29391887 DOI: 10.3892/ol.2017.7334] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
455 Yoshiji H, Noguchi R, Kitade M, Kaji K, Ikenaka Y, Namisaki T, Yoshii J, Yanase K, Yamazaki M, Tsujimoto T, Akahane T, Kawaratani H, Uemura M, Fukui H. Branched-chain amino acids suppress insulin-resistance-based hepatocarcinogenesis in obese diabetic rats. J Gastroenterol 2009;44:483-91. [DOI: 10.1007/s00535-009-0031-0] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 3.8] [Reference Citation Analysis]
456 Mehta N, Fidelman N, Sarkar M, Yao FY. Factors associated with outcomes and response to therapy in patients with infiltrative hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2013;11:572-578. [PMID: 23333661 DOI: 10.1016/j.cgh.2012.12.030] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
457 Khan R, Zahid S, Wan YJ, Forster J, Karim AB, Nawabi AM, Azhar A, Rahman MA, Ahmed N. Protein expression profiling of nuclear membrane protein reveals potential biomarker of human hepatocellular carcinoma. Clin Proteomics 2013;10:6. [PMID: 23724895 DOI: 10.1186/1559-0275-10-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
458 Berretta M, Rinaldi L, Di Benedetto F, Lleshi A, De Re V, Facchini G, De Paoli P, Di Francia R. Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma. Front Pharmacol 2016;7:428. [PMID: 27881963 DOI: 10.3389/fphar.2016.00428] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 6.4] [Reference Citation Analysis]
459 DeWall RJ, Varghese T, Madsen EL. Shear wave velocity imaging using transient electrode perturbation: phantom and ex vivo validation. IEEE Trans Med Imaging 2011;30:666-78. [PMID: 21075719 DOI: 10.1109/TMI.2010.2091412] [Cited by in Crossref: 27] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
460 Li N, Zheng D, Xue J, Guo W, Shi J, Sun J, Lu C, Zheng W, Wu M, Cheng S. Cidan inhibits liver cancer cell growth by reducing COX-2 and VEGF expression and cell cycle arrest. Exp Ther Med 2015;9:1709-18. [PMID: 26136881 DOI: 10.3892/etm.2015.2351] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
461 Mao S, Yu X, Yang Y, Shan Y, Mugaanyi J, Wu S, Lu C. Preoperative nomogram for microvascular invasion prediction based on clinical database in hepatocellular carcinoma. Sci Rep 2021;11:13999. [PMID: 34234239 DOI: 10.1038/s41598-021-93528-7] [Reference Citation Analysis]
462 Hargrove L, Francis T, Francis H. Vitamin D and GI cancers: shedding some light on dark diseases. Ann Transl Med. 2014;2:9. [PMID: 25332985 DOI: 10.3978/j.issn.2305-5839.2013.03.04] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
463 Lei JY, Wang WT, Yan LN, Wen TF, Li B. Radiofrequency ablation versus surgical resection for small unifocal hepatocellular carcinomas. Medicine (Baltimore) 2014;93:e271. [PMID: 25546668 DOI: 10.1097/MD.0000000000000271] [Cited by in Crossref: 20] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
464 Wang W, Huang P, Zhang L, Wei J, Xie Q, Sun Q, Zhou X, Xie H, Zhou L, Zheng S. Antitumor efficacy of C-X-C motif chemokine ligand 14 in hepatocellular carcinoma in vitro and in vivo. Cancer Sci. 2013;104:1523-1531. [PMID: 24033560 DOI: 10.1111/cas.12279] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
465 Yin H, Tan Z, Wu J, Zhu J, Shedden KA, Marrero J, Lubman DM. Mass-Selected Site-Specific Core-Fucosylation of Serum Proteins in Hepatocellular Carcinoma. J Proteome Res 2015;14:4876-84. [PMID: 26403951 DOI: 10.1021/acs.jproteome.5b00718] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
466 Wu LM, Xu JR, Gu HY, Hua J, Chen J, Zhu J, Zhang W, Hu J. Is liver-specific gadoxetic acid-enhanced magnetic resonance imaging a reliable tool for detection of hepatocellular carcinoma in patients with chronic liver disease? Dig Dis Sci. 2013;58:3313-3325. [PMID: 23884757 DOI: 10.1007/s10620-013-2790-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
467 Altomonte J, Marozin S, Schmid RM, Ebert O. Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma. Mol Ther 2010;18:275-84. [PMID: 19809404 DOI: 10.1038/mt.2009.231] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 4.8] [Reference Citation Analysis]
468 Miyahara K, Nouso K, Morimoto Y, Takeuchi Y, Hagihara H, Kuwaki K, Onishi H, Ikeda F, Miyake Y, Nakamura S, Shiraha H, Takaki A, Honda M, Kaneko S, Sato T, Sato S, Obi S, Iwadou S, Kobayashi Y, Takaguchi K, Kariyama K, Takuma Y, Takabatake H, Yamamoto K;  Okayama Liver Cancer Group. Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma. Br J Cancer. 2013;109:2072-2078. [PMID: 24045661 DOI: 10.1038/bjc.2013.554] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
469 Connolly GC, Chen R, Hyrien O, Mantry P, Bozorgzadeh A, Abt P, Khorana AA. Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma. Thromb Res. 2008;122:299-306. [PMID: 18045666 DOI: 10.1016/j.thromres.2007.10.009] [Cited by in Crossref: 63] [Cited by in F6Publishing: 61] [Article Influence: 4.5] [Reference Citation Analysis]
470 Jo IY, Son SH, Kim M, Sung SY, Won YK, Kang HJ, Lee SJ, Chung YA, Oh JK, Kay CS. Prognostic value of pretreatment (18)F-FDG PET-CT in radiotherapy for patients with hepatocellular carcinoma. Radiat Oncol J. 2015;33:179-187. [PMID: 26484301 DOI: 10.3857/roj.2015.33.3.179] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
471 Lang E, Schäfer M, Schwender H, Neumann NJ, Frank J. Occurrence of Malignant Tumours in the Acute Hepatic Porphyrias. JIMD Rep 2015;22:17-22. [PMID: 25701268 DOI: 10.1007/8904_2015_406] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
472 Hong Y, Huang J. Autoantibodies against tumor-associated antigens for detection of hepatocellular carcinoma. World J Hepatol. 2015;7:1581-1585. [PMID: 26085917 DOI: 10.4254/wjh.v7.i11.1581] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
473 Zhong NB, Lv GM, Chen ZH. Stereotactic body radiotherapy combined with transarterial chemoembolization for huge (≥10 cm) hepatocellular carcinomas: A clinical study. Mol Clin Oncol 2014;2:839-44. [PMID: 25054055 DOI: 10.3892/mco.2014.304] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
474 Carter LG, D'Orazio JA, Pearson KJ. Resveratrol and cancer: focus on in vivo evidence. Endocr Relat Cancer 2014;21:R209-25. [PMID: 24500760 DOI: 10.1530/ERC-13-0171] [Cited by in Crossref: 273] [Cited by in F6Publishing: 115] [Article Influence: 39.0] [Reference Citation Analysis]
475 Plentz RR, Boozari B, Malek NP. [Guideline compliant diagnostics of hepatocellular carcinoma]. Radiologe 2014;54:660-3. [PMID: 24981446 DOI: 10.1007/s00117-014-2651-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
476 Tsuchiya M, Parker JS, Kono H, Matsuda M, Fujii H, Rusyn I. Gene expression in nontumoral liver tissue and recurrence-free survival in hepatitis C virus-positive hepatocellular carcinoma. Mol Cancer. 2010;9:74. [PMID: 20380719 DOI: 10.1186/1476-4598-9-74] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 4.8] [Reference Citation Analysis]
477 Xu W, Huang JJ, Cheung PC. Extract of Pleurotus pulmonarius suppresses liver cancer development and progression through inhibition of VEGF-induced PI3K/AKT signaling pathway. PLoS One 2012;7:e34406. [PMID: 22470568 DOI: 10.1371/journal.pone.0034406] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 4.2] [Reference Citation Analysis]
478 Xu Y, Chenna V, Hu C, Sun HX, Khan M, Bai H, Yang XR, Zhu QF, Sun YF, Maitra A. Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma. Clin Cancer Res. 2012;18:1291-1302. [PMID: 21868763 DOI: 10.1158/1078-0432.CCR-11-0950] [Cited by in Crossref: 48] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
479 Hu Z, Li Z, Xiang J, Zhou J, Yan S, Wu J, Zhou L, Zheng S. Intent-to-treat analysis of liver transplant for hepatocellular carcinoma in the MELD era: impact of hepatitis C and advanced status. Dig Dis Sci 2014;59:3062-72. [PMID: 25008426 DOI: 10.1007/s10620-014-3266-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
480 Enooku K, Uranbileg B, Ikeda H, Kurano M, Sato M, Kudo H, Maki H, Koike K, Hasegawa K, Kokudo N, Yatomi Y. Higher LPA2 and LPA6 mRNA Levels in Hepatocellular Carcinoma Are Associated with Poorer Differentiation, Microvascular Invasion and Earlier Recurrence with Higher Serum Autotaxin Levels. PLoS One 2016;11:e0161825. [PMID: 27583415 DOI: 10.1371/journal.pone.0161825] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
481 Takeuchi S, Rohren EM, Abdel-Wahab R, Xiao L, Morris JS, Macapinlac HA, Hassan MM, Kaseb AO. Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers. Eur J Nucl Med Mol Imaging 2017;44:969-78. [PMID: 27942837 DOI: 10.1007/s00259-016-3583-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
482 Schwartz M, Dvorchik I, Roayaie S, Fiel MI, Finkelstein S, Marsh JW, Martignetti JA, Llovet JM. Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. J Hepatol. 2008;49:581-588. [PMID: 18602719 DOI: 10.1016/j.jhep.2008.03.032] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 4.8] [Reference Citation Analysis]
483 Mizuguchi T, Kawamoto M, Meguro M, Nakamura Y, Harada K, Kukita K, Hirata K. Prognostic impact of preoperative the branched-chain amino acid to the tyrosine ratio in hepatocellular carcinoma patients after initial hepatectomy. J Gastrointest Surg. 2011;15:1433-1439. [PMID: 21607795 DOI: 10.1007/s11605-011-1566-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
484 Zhao GS, Liu Y, Zhang Q, Li C, Zhang YW, Ren ZZ, Zhou J, Zhang M. Transarterial chemoembolization combined with Huaier granule for the treatment of primary hepatic carcinoma: Safety and efficacy. Medicine (Baltimore) 2017;96:e7589. [PMID: 28723799 DOI: 10.1097/MD.0000000000007589] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
485 Filmus J, Capurro M. Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma. Mol Diagn. 2004;8:207-212. [PMID: 15887976 DOI: 10.2165/00066982-200408040-00002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
486 Matsuda Y, Ichida T, Fukumoto M. Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies. Med Mol Morphol 2011;44:117-24. [PMID: 21922382 DOI: 10.1007/s00795-011-0547-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
487 Zhuang PY, Shen J, Zhu XD, Zhang JB, Tang ZY, Qin LX, Sun HC. Direct transformation of lung microenvironment by interferon-α treatment counteracts growth of lung metastasis of hepatocellular carcinoma. PLoS One 2013;8:e58913. [PMID: 23527047 DOI: 10.1371/journal.pone.0058913] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
488 Sadeghi M, Lahdou I, Oweira H, Daniel V, Terness P, Schmidt J, Weiss KH, Longerich T, Schemmer P, Opelz G, Mehrabi A. Serum levels of chemokines CCL4 and CCL5 in cirrhotic patients indicate the presence of hepatocellular carcinoma. Br J Cancer. 2015;113:756-762. [PMID: 26270232 DOI: 10.1038/bjc.2015.227] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
489 Tsunematsu S, Muto S, Oi H, Naka T, Kitagataya T, Sasaki R, Taya Y, Baba U, Tsukamoto Y, Uemura K, Kimura T, Ohara Y. Surgically Diagnosed Primary Hepatic Angiosarcoma. Intern Med 2018;57:687-91. [PMID: 29151516 DOI: 10.2169/internalmedicine.9318-17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
490 Coulouarn C, Factor VM, Thorgeirsson SS. Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology. 2008;47:2059-2067. [PMID: 18506891 DOI: 10.1002/hep.22283] [Cited by in Crossref: 227] [Cited by in F6Publishing: 215] [Article Influence: 17.5] [Reference Citation Analysis]
491 Reiter FP, Hadjamu NJ, Nagdyman N, Zachoval R, Mayerle J, De Toni EN, Kaemmerer H, Denk G. Congenital heart disease-associated liver disease: a narrative review. Cardiovasc Diagn Ther 2021;11:577-90. [PMID: 33968635 DOI: 10.21037/cdt-20-595] [Reference Citation Analysis]
492 Song JM, Lu M, Liu FF, Du XJ, Xing BC. AIB1 as an independent prognostic marker in hepatocellular carcinoma after hepatic resection. J Gastrointest Surg 2012;16:356-60. [PMID: 22052107 DOI: 10.1007/s11605-011-1762-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
493 Peveling-Oberhag J, Seiz A, Döring C, Hartmann S, Köberle V, Liese J, Zeuzem S, Hansmann ML, Piiper A. MicroRNA Profiling of Laser-Microdissected Hepatocellular Carcinoma Reveals an Oncogenic Phenotype of the Tumor Capsule. Transl Oncol 2014;7:672-80. [PMID: 25500075 DOI: 10.1016/j.tranon.2014.09.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
494 Mizuguchi Y, Mishima T, Yokomuro S, Arima Y, Kawahigashi Y, Shigehara K, Kanda T, Yoshida H, Uchida E, Tajiri T. Sequencing and bioinformatics-based analyses of the microRNA transcriptome in hepatitis B-related hepatocellular carcinoma. PLoS One. 2011;6:e15304. [PMID: 21283620 DOI: 10.1371/journal.pone.0015304] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 5.3] [Reference Citation Analysis]
495 Xu C, Shi L, Chen W, Fang P, Li J, Jin L, Pan Z, Pan C. MiR-106b inhibitors sensitize TRAIL-induced apoptosis in hepatocellular carcinoma through increase of death receptor 4. Oncotarget 2017;8:41921-31. [PMID: 28410209 DOI: 10.18632/oncotarget.16707] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
496 Wang P, Wang C, Li H, Shi B, Wang J, Zhong L. Impact of age on the prognosis after liver transplantation for patients with hepatocellular carcinoma: a single-center experience. Onco Targets Ther 2015;8:3775-81. [PMID: 26719705 DOI: 10.2147/OTT.S93939] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
497 Andersen JB, Factor VM, Marquardt JU, Raggi C, Lee YH, Seo D, Conner EA, Thorgeirsson SS. An integrated genomic and epigenomic approach predicts therapeutic response to zebularine in human liver cancer. Sci Transl Med 2010;2:54ra77. [PMID: 20962331 DOI: 10.1126/scitranslmed.3001338] [Cited by in Crossref: 62] [Cited by in F6Publishing: 67] [Article Influence: 6.2] [Reference Citation Analysis]
498 Hu JS, Wu DW, Liang S, Miao XY. GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population. Med Oncol. 2010;27:339-345. [PMID: 19399652 DOI: 10.1007/s12032-009-9215-y] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.1] [Reference Citation Analysis]
499 Belghiti J, Fuks D. Liver resection and transplantation in hepatocellular carcinoma. Liver Cancer. 2012;1:71-82. [PMID: 24159575 DOI: 10.1159/00034240] [Reference Citation Analysis]
500 Lu J, Xu L, Zou Y, Yang RX, Fan Y, Zhang W, Yu D, Yao YG. IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma. Med Sci Monit 2014;20:247-54. [PMID: 24531386 DOI: 10.12659/MSM.889891] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
501 Kato Y, Okamura Y, Omae K, Sugiura T, Ito T, Yamamoto Y, Ashida R, Sato R, Aramaki T, Uesaka K. Propensity score-matched comparison of non-anatomical resection and radiofrequency ablation for hepatocellular carcinoma in patients with up to three tumours, each measuring up to 3 cm in diameter. BJS Open 2018;2:213-9. [PMID: 30079390 DOI: 10.1002/bjs5.60] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
502 Rosen MD, Privalsky ML. Thyroid hormone receptor mutations in cancer and resistance to thyroid hormone: perspective and prognosis. J Thyroid Res 2011;2011:361304. [PMID: 21760978 DOI: 10.4061/2011/361304] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
503 Zhang W, Song TQ, Zhang T, Wu Q, Kong DL, Li Q, Sun HC. Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: A meta-analysis with comparison of different types of hepatitis. Mol Clin Oncol. 2014;2:1125-1134. [PMID: 25279210 DOI: 10.3892/mco.2014.386] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
504 Hoffmann K, Glimm H, Radeleff B, Richter G, Heining C, Schenkel I, Zahlten-Hinguranage A, Schirrmacher P, Schmidt J, Büchler MW. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. BMC Cancer. 2008;8:349. [PMID: 19036146 DOI: 10.1186/1471-2407-8-3491471-2407-8-349] [Reference Citation Analysis]
505 Zou Y, Xiong H, Xiong H, Lu T, Zhu F, Luo Z, Yuan X, Wang Y. A polysaccharide from mushroom Huaier retards human hepatocellular carcinoma growth, angiogenesis, and metastasis in nude mice. Tumour Biol 2015;36:2929-36. [PMID: 25492485 DOI: 10.1007/s13277-014-2923-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
506 Yang H, Zheng W, Shuai X, Chang RM, Yu L, Fang F, Yang LY. MicroRNA-424 inhibits Akt3/E2F3 axis and tumor growth in hepatocellular carcinoma. Oncotarget 2015;6:27736-50. [PMID: 26315541 DOI: 10.18632/oncotarget.4811] [Cited by in Crossref: 33] [Cited by in F6Publishing: 41] [Article Influence: 6.6] [Reference Citation Analysis]
507 Hamilton JP. Epigenetic mechanisms involved in the pathogenesis of hepatobiliary malignancies. Epigenomics 2010;2:233-43. [PMID: 20556199 DOI: 10.2217/epi.10.9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
508 Okamura Y, Sugiura T, Ito T, Yamamoto Y, Ashida R, Uesaka K. The optimal cut-off value of the preoperative prognostic nutritional index for the survival differs according to the TNM stage in hepatocellular carcinoma. Surg Today 2017;47:986-93. [PMID: 28315008 DOI: 10.1007/s00595-017-1491-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
509 Sagmeister S, Eisenbauer M, Pirker C, Mohr T, Holzmann K, Zwickl H, Bichler C, Kandioler D, Wrba F, Mikulits W, Gerner C, Shehata M, Majdic O, Streubel B, Berger W, Micksche M, Zatloukal K, Schulte-Hermann R, Grasl-Kraupp B. New cellular tools reveal complex epithelial-mesenchymal interactions in hepatocarcinogenesis. Br J Cancer 2008;99:151-9. [PMID: 18594539 DOI: 10.1038/sj.bjc.6604440] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
510 Kuramitsu K, Sverdlov DY, Liu SB, Csizmadia E, Burkly L, Schuppan D, Hanto DW, Otterbein LE, Popov Y. Failure of fibrotic liver regeneration in mice is linked to a severe fibrogenic response driven by hepatic progenitor cell activation. Am J Pathol. 2013;183:182-194. [PMID: 23680654 DOI: 10.1016/j.ajpath.2013.03.018] [Cited by in Crossref: 66] [Cited by in F6Publishing: 72] [Article Influence: 8.3] [Reference Citation Analysis]
511 Kamimura K, Suda T, Tamura Y, Takamura M, Yokoo T, Igarashi M, Kawai H, Yamagiwa S, Nomoto M, Aoyagi Y. Phase I study of miriplatin combined with transarterial chemotherapy using CDDP powder in patients with hepatocellular carcinoma. BMC Gastroenterol 2012;12:127. [PMID: 22994941 DOI: 10.1186/1471-230X-12-127] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
512 Tang CW, Zhu M, Feng WM, Bao Y, Zheng YY. Chinese herbal medicine, Jianpi Ligan decoction, improves prognosis of unresectable hepatocellular carcinoma after transarterial chemoembolization: a retrospective study. Drug Des Devel Ther 2016;10:2461-6. [PMID: 27536066 DOI: 10.2147/DDDT.S113295] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
513 Jin YJ, Aycheh HM, Han S, Chamberlin J, Shin J, Byun S, Lee Y. Differential alternative splicing between hepatocellular carcinoma with normal and elevated serum alpha-fetoprotein. BMC Med Genomics 2020;13:194. [PMID: 33371894 DOI: 10.1186/s12920-020-00836-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
514 Umeda Y, Matsuda H, Sadamori H, Matsukawa H, Yagi T, Fujiwara T. A prognostic model and treatment strategy for intrahepatic recurrence of hepatocellular carcinoma after curative resection. World J Surg. 2011;35:170-177. [PMID: 20922387 DOI: 10.1007/s00268-010-0794-8] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
515 Wang ZS, Wu LQ, Yi X, Geng C, Li YJ, Yao RY. Connexin-43 can delay early recurrence and metastasis in patients with hepatitis B-related hepatocellular carcinoma and low serum alpha-fetoprotein after radical hepatectomy. BMC Cancer 2013;13:306. [PMID: 23800357 DOI: 10.1186/1471-2407-13-306] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
516 Wang W, Feng X, Zhang T, Jin J, Wang S, Liu Y, Song Y, Liu X, Yu Z, Li Y. Prospective evaluation of microscopic extension using whole-mount preparation in patients with hepatocellular carcinoma: Definition of clinical target volume for radiotherapy. Radiat Oncol 2010;5:73. [PMID: 20731853 DOI: 10.1186/1748-717X-5-73] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
517 Miraglia R, Pietrosi G, Maruzzelli L, Petridis I, Caruso S, Marrone G, Mamone G, Vizzini G, Luca A, Gridelli B. Predictive factors of tumor response to trans-catheter treatment in cirrhotic patients with hepatocellular carcinoma: a multivariate analysis of pre-treatment findings. World J Gastroenterol 2007;13:6022-6. [PMID: 18023093 DOI: 10.3748/wjg.v13.45.6022] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
518 Zhang J, Yang JM, Wang HJ, Ru GQ, Fan DM. Synthesized multiple antigenic polypeptide vaccine based on B-cell epitopes of human heparanase could elicit a potent antimetastatic effect on human hepatocellular carcinoma in vivo. PLoS One 2013;8:e52940. [PMID: 23308126 DOI: 10.1371/journal.pone.0052940] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
519 Kudo M, Tateishi R, Yamashita T, Ikeda M, Furuse J, Ikeda K, Kokudo N, Izumi N, Matsui O. Current status of hepatocellular carcinoma treatment in Japan: case study and discussion-voting system. Clin Drug Investig 2012;32 Suppl 2:37-51. [PMID: 22873626 DOI: 10.1007/BF03265495] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
520 Yin JM, Sun LB, Zheng JS, Wang XX, Chen DX, Li N. Copper chelation by trientine dihydrochloride inhibits liver RFA-induced inflammatory responses in vivo. Inflamm Res 2016;65:1009-20. [PMID: 27613237 DOI: 10.1007/s00011-016-0986-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
521 Li JJ, Pan K, Gu MF, Chen MS, Zhao JJ, Wang H, Liang XT, Sun JC, Xia JC. Prognostic value of soluble MICA levels in the serum of patients with advanced hepatocellular carcinoma. Chin J Cancer. 2013;32:141-148. [PMID: 22704489 DOI: 10.5732/cjc.012.10025] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
522 Chen XL, Xu YY, Chen L, Wang GL, Shen Y. TLR3 Plays Significant Roles against HBV-Associated HCC. Gastroenterol Res Pract 2015;2015:572171. [PMID: 25983748 DOI: 10.1155/2015/572171] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
523 Liu PH, Su CW, Hsu CY, Hsia CY, Lee YH, Huang YH, Lee RC, Lin HC, Huo TI. Solitary Large Hepatocellular Carcinoma: Staging and Treatment Strategy. PLoS One. 2016;11:e0155588. [PMID: 27176037 DOI: 10.1371/journal.pone.0155588] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
524 Gong K, Chen C, Zhan Y, Chen Y, Huang Z, Li W. Autophagy-related gene 7 (ATG7) and reactive oxygen species/extracellular signal-regulated kinase regulate tetrandrine-induced autophagy in human hepatocellular carcinoma. J Biol Chem 2012;287:35576-88. [PMID: 22927446 DOI: 10.1074/jbc.M112.370585] [Cited by in Crossref: 89] [Cited by in F6Publishing: 42] [Article Influence: 9.9] [Reference Citation Analysis]
525 Salgia R, Mendiratta V. The Multidisciplinary Management of Hepatocellular Carcinoma. Clin Liver Dis (Hoboken) 2021;17:405-8. [PMID: 34386204 DOI: 10.1002/cld.1068] [Reference Citation Analysis]
526 Tang H, Lu W, Yang Z, Jiang K, Chen Y, Lu S, Dong J. Risk factors and long-term outcome for postoperative intra-abdominal infection after hepatectomy for hepatocellular carcinoma. Medicine (Baltimore) 2017;96:e6795. [PMID: 28445320 DOI: 10.1097/MD.0000000000006795] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
527 Wang C, Lu Y, Wang H, Gao X, Bai W, Qu J, Xu G, Zhang Z, Zeng Z, Zhou L, An L, Lv J, Yang Y. Transarterial chemoembolization with/without cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma. Exp Ther Med 2012;4:188-96. [PMID: 23139708 DOI: 10.3892/etm.2012.569] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
528 Kaseb AO, Morris JS, Iwasaki M, Al-Shamsi HO, Raghav KPS, Girard L, Cheung S, Nguyen V, Elsayes KM, Xiao L. Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma. OncoTargets and therapy. 2016;773-780. [PMID: 26929648 DOI: 10.2147/ott.s91977] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
529 Saito T, Chiba T, Suzuki E, Shinozaki M, Goto N, Kanogawa N, Motoyama T, Ogasawara S, Ooka Y, Tawada A. Effect of previous interferon-based therapy on recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. Int J Med Sci. 2014;11:707-712. [PMID: 24843320 DOI: 10.7150/ijms.8764] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
530 Liu W, Kang L, Han J, Wang Y, Shen C, Yan Z, Tai Y, Zhao C. miR-342-3p suppresses hepatocellular carcinoma proliferation through inhibition of IGF-1R-mediated Warburg effect. Onco Targets Ther 2018;11:1643-53. [PMID: 29615839 DOI: 10.2147/OTT.S161586] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 12.3] [Reference Citation Analysis]
531 Jiang Y, Yim SH, Xu HD, Jung SH, Yang SY, Hu HJ, Jung CK, Chung YJ. A potential oncogenic role of the commonly observed E2F5 overexpression in hepatocellular carcinoma. World J Gastroenterol 2011;17:470-7. [PMID: 21274376 DOI: 10.3748/wjg.v17.i4.470] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
532 Bartlett ASJR, McCall JL, Koea JB, Holden A, Yeong ML, Gurusinghe N, Gane E. Liver resection for hepatocellular carcinoma in a hepatitis B endemic area. World J Surg 2007;31:1775-81. [PMID: 17610112 DOI: 10.1007/s00268-007-9069-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
533 Chen L, Tian H, Li M, Ge C, Zhao F, Zhang L, Li H, Liu J, Wang T, Yao M, Li J. Derivate isocorydine inhibits cell proliferation in hepatocellular carcinoma cell lines by inducing G2/M cell cycle arrest and apoptosis. Tumour Biol 2016;37:5951-61. [PMID: 26596832 DOI: 10.1007/s13277-015-4362-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
534 Song DS, Choi JY, Yoo SH, Kim HY, Song MJ, Bae SH, Yoon SK, Chun HJ, Choi BG, Lee HG. DC Bead Transarterial Chemoembolization Is Effective in Hepatocellular Carcinoma Refractory to Conventional Transarteral Chemoembolization: A Pilot Study. Gut Liver 2013;7:89-95. [PMID: 23424047 DOI: 10.5009/gnl.2013.7.1.89] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
535 Qian WP, Tan YQ, Chen Y, Peng Y, Li Z, Lu GX, Lin MC, Kung HF, He ML, Shing LK. Rapid quantification of semen hepatitis B virus DNA by real-time polymerase chain reaction. World J Gastroenterol 2005;11:5385-9. [PMID: 16149152 DOI: 10.3748/wjg.v11.i34.5385] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
536 Ofosu A, Gurakar A. Current Concepts in Hepatocellular Carcinoma and Liver Transplantation: A Review and 2014 Update. Euroasian J Hepatogastroenterol 2015;5:19-25. [PMID: 29201680 DOI: 10.5005/jp-journals-10018-1123] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
537 Qi X, Schepers E, Avella D, Kimchi ET, Kaifi JT, Staveley-O'Carroll KF, Li G. An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis. J Vis Exp 2019. [PMID: 31566616 DOI: 10.3791/59368] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
538 Huang C, Zhu XD, Shen YH, Wu D, Ji Y, Ge NL, Chen LL, Tan CJ, Zhou J, Fan J, Sun HC. Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis. Biomark Res 2021;9:19. [PMID: 33743822 DOI: 10.1186/s40364-021-00274-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
539 Mazzoccoli G, Tarquini R, Valoriani A, Oben J, Vinciguerra M, Marra F. Management strategies for hepatocellular carcinoma: old certainties and new realities. Clin Exp Med 2016;16:243-56. [PMID: 26077653 DOI: 10.1007/s10238-015-0368-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
540 Liu M, Du L, He Z, Yan L, Shi Y, Shang J, Tang H. Increased ERp57 Expression in HBV-Related Hepatocellular Carcinoma: Possible Correlation and Prognosis. Biomed Res Int 2017;2017:1252647. [PMID: 28373975 DOI: 10.1155/2017/1252647] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
541 Yamashita T. Current status of hepatocellular carcinoma treatment in Japan: hepatic arterial infusion chemotherapy. Clin Drug Investig 2012;32 Suppl 2:15-23. [PMID: 22873624 DOI: 10.1007/BF03265493] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
542 Mitchell J, Tinkey PT, Avritscher R, Van Pelt C, Eskandari G, Konnath George S, Xiao L, Cressman E, Morris JS, Rashid A, Kaseb AO, Amin HM, Uthamanthil R. Validation of a Preclinical Model of Diethylnitrosamine-Induced Hepatic Neoplasia in Yucatan Miniature Pigs. Oncology 2016;91:90-100. [PMID: 27305144 DOI: 10.1159/000446074] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
543 Mínguez B, Hoshida Y, Villanueva A, Toffanin S, Cabellos L, Thung S, Mandeli J, Sia D, April C, Fan JB, Lachenmayer A, Savic R, Roayaie S, Mazzaferro V, Bruix J, Schwartz M, Friedman SL, Llovet JM. Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol 2011;55:1325-31. [PMID: 21703203 DOI: 10.1016/j.jhep.2011.02.034] [Cited by in Crossref: 93] [Cited by in F6Publishing: 87] [Article Influence: 9.3] [Reference Citation Analysis]
544 Bruno S, Savojardo D, Almasio PL, Mondelli MU. Critical reappraisal of risk factors for occurrence of hepatocellular carcinoma in patients with hepatitis C virus. Hepat Med 2011;3:21-8. [PMID: 24367218 DOI: 10.2147/HMER.S16991] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
545 Xia F, Wu LL, Lau WY, Huan HB, Wen XD, Ma KS, Li XW, Bie P. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients. World J Gastroenterol 2016;22:5384-92. [PMID: 27340354 DOI: 10.3748/wjg.v22.i23.5384] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
546 Nagaoki Y, Aikata H, Miyaki D, Murakami E, Hashimoto Y, Katamura Y, Azakami T, Kawaoka T, Takaki S, Hiramatsu A. Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy. J Gastroenterol. 2011;46:799-808. [PMID: 21373851 DOI: 10.1007/s00535-011-0384-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
547 Zhou Y, Zhao Y, Li B, Xu D, Yin Z, Xie F, Yang J. Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC Gastroenterol. 2010;10:78. [PMID: 20618937 DOI: 10.1186/1471-230x-10-78.] [Reference Citation Analysis]
548 Sarkar D. AEG-1/MTDH/LYRIC in liver cancer. Adv Cancer Res 2013;120:193-221. [PMID: 23889992 DOI: 10.1016/B978-0-12-401676-7.00007-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
549 Li W, Lebrun DG, Li M. The expression and functions of microRNAs in pancreatic adenocarcinoma and hepatocellular carcinoma. Chin J Cancer. 2011;30:540-550. [PMID: 21801602 DOI: 10.5732/cjc.011.10197] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
550 Filmus J, Capurro M. Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma. Mol Diagn. 2004;8:207-212. [PMID: 15887976 DOI: 10.1007/bf03260065] [Cited by in Crossref: 54] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
551 Fujita N, Nishie A, Kubo Y, Asayama Y, Ushijima Y, Takayama Y, Moirta K, Shirabe K, Aishima S, Honda H. Hepatocellular carcinoma: clinical significance of signal heterogeneity in the hepatobiliary phase of gadoxetic acid-enhanced MR imaging. Eur Radiol. 2015;25:211-220. [PMID: 25063395 DOI: 10.1007/s00330-014-3349-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
552 Inokawa Y, Nomoto S, Hishida M, Hayashi M, Kanda M, Nishikawa Y, Takeda S, Sugimoto H, Fujii T, Yamada S, Kodera Y. Detection of doublecortin domain-containing 2 (DCDC2), a new candidate tumor suppressor gene of hepatocellular carcinoma, by triple combination array analysis. J Exp Clin Cancer Res 2013;32:65. [PMID: 24034596 DOI: 10.1186/1756-9966-32-65] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
553 Alunni-Fabbroni M, Weber S, Öcal O, Seidensticker M, Mayerle J, Malfertheiner P, Ricke J. Circulating Cell-Free DNA Combined to Magnetic Resonance Imaging for Early Detection of HCC in Patients with Liver Cirrhosis. Cancers (Basel) 2021;13:521. [PMID: 33572923 DOI: 10.3390/cancers13030521] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
554 Tanaka S, Miyanishi K, Kobune M, Kawano Y, Hoki T, Kubo T, Hayashi T, Sato T, Sato Y, Takimoto R. Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. J Gastroenterol. 2013;48:1249-1258. [PMID: 23329365 DOI: 10.1007/s00535-012-0739-0] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 5.6] [Reference Citation Analysis]
555 Fages A, Duarte-Salles T, Stepien M, Ferrari P, Fedirko V, Pontoizeau C, Trichopoulou A, Aleksandrova K, Tjønneland A, Olsen A, Clavel-Chapelon F, Boutron-Ruault MC, Severi G, Kaaks R, Kuhn T, Floegel A, Boeing H, Lagiou P, Bamia C, Trichopoulos D, Palli D, Pala V, Panico S, Tumino R, Vineis P, Bueno-de-Mesquita HB, Peeters PH, Weiderpass E, Agudo A, Molina-Montes E, Huerta JM, Ardanaz E, Dorronsoro M, Sjöberg K, Ohlsson B, Khaw KT, Wareham N, Travis RC, Schmidt JA, Cross A, Gunter M, Riboli E, Scalbert A, Romieu I, Elena-Herrmann B, Jenab M. Metabolomic profiles of hepatocellular carcinoma in a European prospective cohort. BMC Med 2015;13:242. [PMID: 26399231 DOI: 10.1186/s12916-015-0462-9] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 8.8] [Reference Citation Analysis]
556 Samarakoon SR, Thabrew I, Galhena PB, De Silva D, Tennekoon KH. A comparison of the cytotoxic potential of standardized aqueous and ethanolic extracts of a polyherbal mixture comprised of Nigella sativa (seeds), Hemidesmus indicus (roots) and Smilax glabra (rhizome). Pharmacognosy Res 2010;2:335-42. [PMID: 21713135 DOI: 10.4103/0974-8490.75451] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
557 Chen D, Siddiq A, Emdad L, Rajasekaran D, Gredler R, Shen XN, Santhekadur PK, Srivastava J, Robertson CL, Dmitriev I. Insulin-like growth factor-binding protein-7 (IGFBP7): a promising gene therapeutic for hepatocellular carcinoma (HCC). Mol Ther. 2013;21:758-766. [PMID: 23319057 DOI: 10.1038/mt.2012.282] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
558 Villanueva A, Savic R, Llovet JM. Lymphotoxins: new targets for hepatocellular carcinoma. Cancer Cell 2009;16:272-3. [PMID: 19800570 DOI: 10.1016/j.ccr.2009.09.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
559 Colagrande S, Regini F, Taliani GG, Nardi C, Inghilesi AL. Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up. World J Hepatol. 2015;7:1041-1053. [PMID: 26052393 DOI: 10.4254/wjh.v7.i8.1041] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
560 Wang X, Xie G, Zhao A, Zheng X, Huang F, Wang Y, Yao C, Jia W, Liu P. Serum Bile Acids Are Associated with Pathological Progression of Hepatitis B-Induced Cirrhosis. J Proteome Res 2016;15:1126-34. [PMID: 25964117 DOI: 10.1021/acs.jproteome.5b00217] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 7.8] [Reference Citation Analysis]
561 Gao S, Yang RJ, Dong JH. Hepatocellular carcinoma with blood supply from parasitized omental artery: angiographic appearance and chemoembolization. Chin J Cancer Res 2012;24:207-12. [PMID: 23359452 DOI: 10.1007/s11670-012-0207-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
562 Huang JH, Gao F, Gu YK, Li WQ, Lu LW. Combined treatment of hepatocellular carcinoma with partial splenic embolization and transcatheter hepatic arterial chemoembolization. World J Gastroenterol 2007;13:6593-7. [PMID: 18161933 DOI: 10.3748/wjg.v13.i48.6593] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
563 Yin L, Wang Y, Guo X, Xu C, Yu G. Comparison of gene expression in liver regeneration and hepatocellular carcinoma formation. Cancer Manag Res 2018;10:5691-708. [PMID: 30532592 DOI: 10.2147/CMAR.S172945] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
564 Jin C, Li H, He Y, He M, Bai L, Cao Y, Song W, Dou K. Combination chemotherapy of doxorubicin and paclitaxel for hepatocellular carcinoma in vitro and in vivo. J Cancer Res Clin Oncol. 2010;136:267-274. [PMID: 19693537 DOI: 10.1007/500432-009-0658-5] [Reference Citation Analysis]
565 Ang SF, Ng ES, Li H, Ong YH, Choo SP, Ngeow J, Toh HC, Lim KH, Yap HY, Tan CK, Ooi LL, Cheow PC, Chung AY, Chow PK, Foo KF, Tan MH. The Singapore Liver Cancer Recurrence (SLICER) Score for relapse prediction in patients with surgically resected hepatocellular carcinoma. PLoS One. 2015;10:e0118658. [PMID: 25830231 DOI: 10.1371/journal.pone.0118658] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
566 Dong D, Mu Z, Zhao C, Sun M. ZFAS1: a novel tumor-related long non-coding RNA. Cancer Cell Int 2018;18:125. [PMID: 30186041 DOI: 10.1186/s12935-018-0623-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
567 Matsuda Y, Fukumoto M. Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled. Med Mol Morphol 2011;44:183-9. [PMID: 22179180 DOI: 10.1007/s00795-011-0558-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
568 Malek NP, Schmidt S, Huber P, Manns MP, Greten TF. The diagnosis and treatment of hepatocellular carcinoma. Dtsch Arztebl Int 2014;111:101-6. [PMID: 24622679 DOI: 10.3238/arztebl.2014.0101] [Cited by in Crossref: 5] [Cited by in F6Publishing: 30] [Article Influence: 0.8] [Reference Citation Analysis]
569 Swan RZ, Sindram D, Martinie JB, Iannitti DA. Operative microwave ablation for hepatocellular carcinoma: complications, recurrence, and long-term outcomes. J Gastrointest Surg. 2013;17:719-729. [PMID: 23404173 DOI: 10.1007/s11605-013-2164-y] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 6.1] [Reference Citation Analysis]
570 Hernandez-Gea V, Turon F, Berzigotti A, Villanueva A. Management of small hepatocellular carcinoma in cirrhosis: focus on portal hypertension. World J Gastroenterol. 2013;19:1193-1199. [PMID: 23482437 DOI: 10.3748/wjg.v19.i8.1193] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
571 Paul SB, Sharma H. Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma. J Clin Exp Hepatol 2014;4:S112-21. [PMID: 25755602 DOI: 10.1016/j.jceh.2014.03.048] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
572 Liu X, Zou L, Liu F, Zhou Y, Song B. Gadoxetic acid disodium-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: a meta-analysis. PLoS One. 2013;8:e70896. [PMID: 23967130 DOI: 10.1371/journal.pone.0070896.ecolletion] [Reference Citation Analysis]
573 Liu C, Xiao GQ, Yan LN, Li B, Jiang L, Wen TF, Wang WT, Xu MQ, Yang JY. Value of α-fetoprotein in association with clinicopathological features of hepatocellular carcinoma. World J Gastroenterol. 2013;19:1811-1819. [PMID: 23555170 DOI: 10.3748/wjg.v19.i11.1811] [Cited by in CrossRef: 64] [Cited by in F6Publishing: 61] [Article Influence: 8.0] [Reference Citation Analysis]
574 Matar P, Alaniz L, Rozados V, Aquino JB, Malvicini M, Atorrasagasti C, Gidekel M, Silva M, Scharovsky OG, Mazzolini G. Immunotherapy for liver tumors: present status and future prospects. J Biomed Sci. 2009;16:30. [PMID: 19272130 DOI: 10.1186/1423-0127-16-30] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
575 Park JG. Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy. Clin Mol Hepatol. 2015;21:287-294. [PMID: 26527250 DOI: 10.3350/cmh.2015.21.3.287] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
576 Bryant MK, Dorn DP, Zarzour J, Smith JK, Redden DT, Saddekni S, Abdel Aal AK, Gray SH, Eckhoff DE, Dubay DA. Computed tomography predictors of hepatocellular carcinoma tumour necrosis after chemoembolization. HPB (Oxford). 2014;16:327-335. [PMID: 23980917 DOI: 10.1111/hpb.12149] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
577 Han SX, Wang LJ, Zhao J, Zhang Y, Li M, Zhou X, Wang J, Zhu Q. 14-kDa Phosphohistidine phosphatase plays an important role in hepatocellular carcinoma cell proliferation. Oncol Lett 2012;4:658-64. [PMID: 23205079 DOI: 10.3892/ol.2012.802] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
578 Kim HC, Suk KT, Kim DJ, Yoon JH, Kim YS, Baik GH, Kim JB, Kim CH, Sung H, Choi JY, Han KH, Park SH. Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma. World J Gastroenterol 2014;20:745-54. [PMID: 24574748 DOI: 10.3748/wjg.v20.i3.745] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
579 Wang Q, An Y, Yuan Q, Qi Y, Ou Y, Chen J, Huang J. Identification of allelic expression imbalance genes in human hepatocellular carcinoma through massively parallel DNA and RNA sequencing. Med Oncol 2016;33:38. [PMID: 27000824 DOI: 10.1007/s12032-016-0751-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
580 Morise Z, Kawabe N, Tomishige H, Nagata H, Kawase J, Arakawa S, Yoshida R, Isetani M. Recent advances in liver resection for hepatocellular carcinoma. Front Surg. 2014;1:21. [PMID: 25593945 DOI: 10.3389/fsurg.2014.00021] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
581 Vincenzi B, Di Maio M, Silletta M, D'Onofrio L, Spoto C, Piccirillo MC, Daniele G, Comito F, Maci E, Bronte G, Russo A, Santini D, Perrone F, Tonini G. Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis. PLoS One 2015;10:e0133488. [PMID: 26230853 DOI: 10.1371/journal.pone.0133488] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 9.5] [Reference Citation Analysis]
582 He YF, Jin J, Wei W, Chang Y, Hu B, Ji CS, Jia WD, Wang XQ, Chen K, Chen J. Overexpression of cyclooxygenase-2 in noncancerous liver tissue increases the postoperative recurrence of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis. Can J Gastroenterol 2010;24:435-40. [PMID: 20652159 DOI: 10.1155/2010/872570] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
583 Wu J, Zhu P, Zhang Z, Zhang B, Shu C, Chen L, Feng R, Mba'nbo Koumpa AA, Li G, Ge Q. A new tumor-associated antigen prognostic scoring system for spontaneous ruptured hepatocellular carcinoma after partial hepatectomy. Cancer Biol Med 2018;15:415-24. [PMID: 30766751 DOI: 10.20892/j.issn.2095-3941.2018.0095] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
584 Welker MW, Trojan J. Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety. Cancer Manag Res 2013;5:337-47. [PMID: 24204170 DOI: 10.2147/CMAR.S35029] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
585 Fu YP, Ni XC, Yi Y, Cai XY, He HW, Wang JX, Lu ZF, Han X, Cao Y, Zhou J, Fan J, Qiu SJ. A Novel and Validated Inflammation-Based Score (IBS) Predicts Survival in Patients With Hepatocellular Carcinoma Following Curative Surgical Resection: A STROBE-Compliant Article. Medicine (Baltimore) 2016;95:e2784. [PMID: 26886627 DOI: 10.1097/MD.0000000000002784] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
586 Majumdar A, Roccarina D, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Management of people with early- or very early-stage hepatocellular carcinoma: An attempted network meta-analysis. Cochrane Database Syst Rev. 2017;3:CD011650. [PMID: 28351116 DOI: 10.1002/14651858.cd011650.pub2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
587 Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371:838-851. [PMID: 18328931 DOI: 10.1016/s0140-6736(08)60383-9] [Cited by in Crossref: 1212] [Cited by in F6Publishing: 501] [Article Influence: 93.2] [Reference Citation Analysis]
588 Bonzo JA, Ferry CH, Matsubara T, Kim JH, Gonzalez FJ. Suppression of hepatocyte proliferation by hepatocyte nuclear factor 4α in adult mice. J Biol Chem. 2012;287:7345-7356. [PMID: 22241473 DOI: 10.1074/jbc.m111.334599] [Cited by in Crossref: 127] [Cited by in F6Publishing: 85] [Article Influence: 14.1] [Reference Citation Analysis]
589 Gluer AM, Cocco N, Laurence JM, Johnston ES, Hollands MJ, Pleass HC, Richardson AJ, Lam VW. Systematic review of actual 10-year survival following resection for hepatocellular carcinoma. HPB (Oxford). 2012;14:285-290. [PMID: 22487065 DOI: 10.1111/j.1477-2574.2012.00446.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 64] [Article Influence: 6.8] [Reference Citation Analysis]
590 Liu X, Ren J, Luo N, Guo H, Zheng Y, Li J, Tang F, Wen L, Peng J. Comprehensive DNA methylation analysis of tissue of origin of plasma cell-free DNA by methylated CpG tandem amplification and sequencing (MCTA-Seq). Clin Epigenetics 2019;11:93. [PMID: 31234922 DOI: 10.1186/s13148-019-0689-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 11.5] [Reference Citation Analysis]
591 Tiwari AK, Laird-Fick HS, Wali RK, Roy HK. Surveillance for gastrointestinal malignancies. World J Gastroenterol 2012;18:4507-16. [PMID: 22969223 DOI: 10.3748/wjg.v18.i33.4507] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
592 Zidan A, Scheuerlein H, Schüle S, Settmacher U, Rauchfuss F. Epidemiological pattern of hepatitis B and hepatitis C as etiological agents for hepatocellular carcinoma in iran and worldwide. Hepat Mon. 2012;12:e6894. [PMID: 23233864 DOI: 10.5812/hepatmon.6894] [Cited by in Crossref: 17] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
593 Lupo L, Panzera P, Giannelli G, Memeo M, Gentile A, Memeo V. Single hepatocellular carcinoma ranging from 3 to 5 cm: radiofrequency ablation or resection? HPB (Oxford). 2007;9:429-434. [PMID: 18345289 DOI: 10.1080/13651820701713758] [Cited by in Crossref: 60] [Cited by in F6Publishing: 58] [Article Influence: 5.5] [Reference Citation Analysis]
594 Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M, Battiston C, Van Laarhoven S, Fiel MI, Di Feo A, Hoshida Y, Yea S, Toffanin S, Ramos A, Martignetti JA, Mazzaferro V, Bruix J, Waxman S, Schwartz M, Meyerson M, Friedman SL, Llovet JM. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 2008;135:1972-1983, 1983.e1-1983.11. [PMID: 18929564 DOI: 10.1053/j.gastro.2008.08.008] [Cited by in Crossref: 482] [Cited by in F6Publishing: 459] [Article Influence: 37.1] [Reference Citation Analysis]
595 Xu W, Kwon JH, Moon YH, Kim YB, Yu YS, Lee N, Choi KY, Kim YS, Park YK, Kim BW. Influence of preoperative transcatheter arterial chemoembolization on gene expression in the HIF-1α pathway in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol. 2014;140:1507-1515. [PMID: 24853275 DOI: 10.1007/s00432-014-1713-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
596 Shi M, Chen JA, Lin XJ, Guo RP, Yuan YF, Chen MS, Zhang YQ, Li JQ. Transarterial chemoembolization as initial treatment for unresectable hepatocellular carcinoma in southern China. World J Gastroenterol. 2010;16:264-269. [PMID: 20066748 DOI: 10.3748/wjg.v16.i2.264] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
597 Geier A, Macias RI, Bettinger D, Weiss J, Bantel H, Jahn D, Al-Abdulla R, Marin JJ. The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma. Oncotarget 2017;8:15846-57. [PMID: 28178663 DOI: 10.18632/oncotarget.15029] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
598 Kern MA, Breuhahn K, Schuchmann M, Schirmacher P. [Molecular pathogenesis of hepatocellular carcinoma: new therapeutic approaches and predictive pathology]. Pathologe 2007;28:261-8. [PMID: 17605064 DOI: 10.1007/s00292-007-0890-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
599 MacDonald DC, Nelson M, Bower M, Powles T. Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era. World J Gastroenterol 2008;14:1657-63. [PMID: 18350596 DOI: 10.3748/wjg.14.1657] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 40] [Article Influence: 3.2] [Reference Citation Analysis]
600 Wang Y, Speeg KV, Washburn WK, Halff G. Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: a case report. World J Gastroenterol 2010;16:5518-22. [PMID: 21086573 DOI: 10.3748/wjg.v16.i43.5518] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
601 Gao XD, Qu JH, Chang XJ, Lu YY, Bai WL, Wang H, Xu ZX, An LJ, Wang CP, Zeng Z, Yang YP. Hypomethylation of long interspersed nuclear element-1 promoter is associated with poor outcomes for curative resected hepatocellular carcinoma. Liver Int 2014;34:136-46. [PMID: 23875825 DOI: 10.1111/liv.12264] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
602 Yang H, Nie Y, Li Y, Wan YJ. Histone modification-mediated CYP2E1 gene expression and apoptosis of HepG2 cells. Exp Biol Med (Maywood) 2010;235:32-9. [PMID: 20404016 DOI: 10.1258/ebm.2009.009252] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
603 Costa FP, de Oliveira AC, Meirelles R, Machado MC, Zanesco T, Surjan R, Chammas MC, de Souza Rocha M, Morgan D, Cantor A, Zimmerman J, Brezovich I, Kuster N, Barbault A, Pasche B. Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields. Br J Cancer 2011;105:640-8. [PMID: 21829195 DOI: 10.1038/bjc.2011.292] [Cited by in Crossref: 45] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
604 Chen CT, Liao LZ, Lu CH, Huang YH, Lin YK, Lin JH, Chow LP. Quantitative phosphoproteomic analysis identifies the potential therapeutic target EphA2 for overcoming sorafenib resistance in hepatocellular carcinoma cells. Exp Mol Med 2020;52:497-513. [PMID: 32203105 DOI: 10.1038/s12276-020-0404-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
605 Sonohara F, Yamada S, Tanaka N, Suenaga M, Takami H, Hayashi M, Niwa Y, Sugimoto H, Hattori N, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Kodera Y. Perioperative and prognostic implication of albumin-bilirubin-TNM score in Child-Pugh class A hepatocellular carcinoma. Ann Gastroenterol Surg. 2019;3:65-74. [PMID: 30697612 DOI: 10.1002/ags3.12212] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
606 Zhao YL, Guo QQ, Yang GR, Wang QD. Early changes in apparent diffusion coefficient as an indicator of response to sorafenib in hepatocellular carcinoma. J Zhejiang Univ Sci B. 2014;15:713-719. [PMID: 25091989 DOI: 10.1631/jzus.B1400010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
607 Guo C, Liu S, Sun MZ. Novel insight into the role of GAPDH playing in tumor. Clin Transl Oncol. 2013;15:167-172. [PMID: 22911551 DOI: 10.1007/s12094-012-0924-x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 6.7] [Reference Citation Analysis]
608 Liu Y, Zhang A, Liu Y, Dong J. Association analysis between the c.1804C>A genetic polymorphism of XRCC1 gene and risk of hepatocellular carcinoma in Chinese population. Med Oncol 2014;31:854. [PMID: 24526467 DOI: 10.1007/s12032-014-0854-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
609 Lee JS, Kim JH, Park YY, Mills GB. Systems biology approaches to decoding the genome of liver cancer. Cancer Res Treat 2011;43:205-11. [PMID: 22247704 DOI: 10.4143/crt.2011.43.4.205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
610 Yang Y, Lu Y, Wang C, Bai W, Qu J, Chen Y, Chang X, An L, Zhou L, Zeng Z, Lou M, Lv J. Cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma. Exp Ther Med. 2012;3:171-180. [PMID: 22969864 DOI: 10.3892/etm.2011.398] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
611 Ryu JW, Kim SK, Son MY, Jeon SJ, Oh JH, Lim JH, Cho S, Jung CR, Hamamoto R, Kim DS, Cho HS. Novel prognostic marker PRMT1 regulates cell growth via downregulation of CDKN1A in HCC. Oncotarget 2017;8:115444-55. [PMID: 29383172 DOI: 10.18632/oncotarget.23296] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
612 Yang S, Lin Q, Lin W, Hu W, Wang G. Effect of adjuvant interferon therapy on hepatitis B virus-related hepatocellular carcinoma: a systematic review. World J Surg Oncol 2016;14:159. [PMID: 27282382 DOI: 10.1186/s12957-016-0912-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
613 Alberts SR, Fitch TR, Kim GP, Morlan BW, Dakhil SR, Gross HM, Nair S. Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group Clinical Trial. Am J Clin Oncol. 2012;35:329-333. [PMID: 21422991 DOI: 10.1097/coc.0b013e3182118cdf] [Cited by in Crossref: 38] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
614 Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015;12:408-424. [PMID: 26054909 DOI: 10.1038/nrclinonc.2015.103] [Cited by in Crossref: 260] [Cited by in F6Publishing: 242] [Article Influence: 43.3] [Reference Citation Analysis]
615 Erinjeri JP, Salhab HM, Covey AM, Getrajdman GI, Brown KT. Arterial patency after repeated hepatic artery bland particle embolization. J Vasc Interv Radiol. 2010;21:522-526. [PMID: 20188589 DOI: 10.1016/j.jvir.2009.12.390] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
616 Cai E, Song X, Han M, Yang L, Zhao Y, Li W, Han J, Tu S. Experimental study of the anti-tumour activity and pharmacokinetics of arctigenin and its valine ester derivative. Sci Rep 2018;8:3307. [PMID: 29459629 DOI: 10.1038/s41598-018-21722-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
617 Mahvash A, Murthy R, Odisio BC, Raghav KP, Girard L, Cheung S, Nguyen V, Ensor J, Gadani S, Elsayes KM, Abdel-Wahab R, Hassan M, Shalaby AS, Yao JC, Wallace MJ, Kaseb AO. Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatocell Carcinoma 2016;3:1-7. [PMID: 27574586 DOI: 10.2147/JHC.S62261] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
618 Vainshtein JM, Kabarriti R, Mehta KJ, Roy-Chowdhury J, Guha C. Bone marrow-derived stromal cell therapy in cirrhosis: clinical evidence, cellular mechanisms, and implications for the treatment of hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2014;89:786-803. [PMID: 24969793 DOI: 10.1016/j.ijrobp.2014.02.017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
619 Gabrielson A, Miller A, Banovac F, Kim A, He AR, Unger K. Outcomes and Predictors of Toxicity after Selective Internal Radiation Therapy Using Yttrium-90 Resin Microspheres for Unresectable Hepatocellular Carcinoma. Front Oncol 2015;5:292. [PMID: 26779437 DOI: 10.3389/fonc.2015.00292] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
620 Bouhlal H, Ouled-Haddou H, Debuysscher V, Singh AR, Ossart C, Reignier A, Hocini H, Fouquet G, Al Baghami M, Eugenio MS, Nguyen-Khac E, Regimbeau JM, Marcq I. RB/PLK1-dependent induced pathway by SLAMF3 expression inhibits mitosis and control hepatocarcinoma cell proliferation. Oncotarget 2016;7:9832-43. [PMID: 26799423 DOI: 10.18632/oncotarget.6954] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
621 Bruera G, Cannita K, Giordano AV, Manetta R, Vicentini R, Carducci S, Saltarelli P, Iapadre N, Coletti G, Ficorella C. Multidisciplinary management of hepatocellular carcinoma in clinical practice. Biomed Res Int. 2014;2014:806391. [PMID: 24900987 DOI: 10.1155/2014/806391] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
622 Greten TF, Manns MP, Reinisch I, Kaatsch P. Hepatocellular carcinoma occurring after successful treatment of childhood cancer with high dose chemotherapy and radiation. Gut. 2005;54:732. [PMID: 15831932 DOI: 10.1136/gut.2004.059352] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
623 Shinoda M, Kishida N, Itano O, Ei S, Ueno A, Kitago M, Abe Y, Hibi T, Yagi H, Masugi Y. Long-term complete response of advanced hepatocellular carcinoma treated with multidisciplinary therapy including reduced dose of sorafenib: case report and review of the literature. World J Surg Oncol. 2015;13:144. [PMID: 25889667 DOI: 10.1186/s12957-015-0559-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
624 Gauthier A, Ho M. Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update. Hepatol Res. 2013;43:147-154. [PMID: 23145926 DOI: 10.1111/j.1872-034x.2012.01113] [Reference Citation Analysis]
625 He W, Zeng Q, Zheng Y, Chen M, Shen J, Qiu J, Zou R, Liao Y, Li Q, Wu X, Li B, Yuan Y. The role of clinically significant portal hypertension in hepatic resection for hepatocellular carcinoma patients: a propensity score matching analysis. BMC Cancer. 2015;15:263. [PMID: 25886495 DOI: 10.1186/s12885-015-1280-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
626 Wang H, Pan K, Zhang HK, Weng DS, Zhou J, Li JJ, Huang W, Song HF, Chen MS, Xia JC. Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2008;134:535-541. [PMID: 17917742 DOI: 10.1007/s00432-007-0316-8] [Cited by in Crossref: 74] [Cited by in F6Publishing: 64] [Article Influence: 5.3] [Reference Citation Analysis]
627 Geissler EK, Schnitzbauer AA, Zülke C, Lamby PE, Proneth A, Duvoux C, Burra P, Jauch KW, Rentsch M, Ganten TM, Schmidt J, Settmacher U, Heise M, Rossi G, Cillo U, Kneteman N, Adam R, van Hoek B, Bachellier P, Wolf P, Rostaing L, Bechstein WO, Rizell M, Powell J, Hidalgo E, Gugenheim J, Wolters H, Brockmann J, Roy A, Mutzbauer I, Schlitt A, Beckebaum S, Graeb C, Nadalin S, Valente U, Turrión VS, Jamieson N, Scholz T, Colledan M, Fändrich F, Becker T, Söderdahl G, Chazouillères O, Mäkisalo H, Pageaux GP, Steininger R, Soliman T, de Jong KP, Pirenne J, Margreiter R, Pratschke J, Pinna AD, Hauss J, Schreiber S, Strasser S, Klempnauer J, Troisi RI, Bhoori S, Lerut J, Bilbao I, Klein CG, Königsrainer A, Mirza DF, Otto G, Mazzaferro V, Neuhaus P, Schlitt HJ. Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation 2016;100:116-25. [PMID: 26555945 DOI: 10.1097/TP.0000000000000965] [Cited by in Crossref: 189] [Cited by in F6Publishing: 78] [Article Influence: 37.8] [Reference Citation Analysis]
628 Zhao K, Xu L, Li F, Ao J, Jiang G, Shi R, Chen F, Luo Q. Identification of hepatocellular carcinoma prognostic markers based on 10-immune gene signature. Biosci Rep 2020;40:BSR20200894. [PMID: 32789471 DOI: 10.1042/BSR20200894] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
629 Hsu KY, Chau GY, Lui WY, Tsay SH, King KL, Wu CW. Predicting morbidity and mortality after hepatic resection in patients with hepatocellular carcinoma: the role of Model for End-Stage Liver Disease score. World J Surg. 2009;33:2412-2419. [PMID: 19756859 DOI: 10.1007/s00268-009-0202-4] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 5.0] [Reference Citation Analysis]
630 Yeh CC, Lin JT, Jeng LB, Charalampos I, Chen TT, Lee TY, Wu MS, Kuo KN, Liu YY, Wu CY. Hepatic resection for hepatocellular carcinoma patients on hemodialysis for uremia: a nationwide cohort study. World J Surg. 2013;37:2402-2409. [PMID: 23811792 DOI: 10.1007/s00268-013-2137-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
631 Choi HJ, Cho BC, Sohn JH, Shin SJ, Kim SH, Kim JH, Yoo NC. Brain metastases from hepatocellular carcinoma: prognostic factors and outcome: brain metastasis from HCC. J Neurooncol. 2009;91:307-313. [PMID: 18949445 DOI: 10.1007/s11060-008-9713-3] [Cited by in Crossref: 81] [Cited by in F6Publishing: 61] [Article Influence: 6.2] [Reference Citation Analysis]
632 Uemura T, Kirichenko A, Bunker M, Vincent M, Machado L, Thai N. Stereotactic Body Radiation Therapy: A New Strategy for Loco-Regional Treatment for Hepatocellular Carcinoma While Awaiting Liver Transplantation. World J Surg 2019;43:886-93. [PMID: 30361748 DOI: 10.1007/s00268-018-4829-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
633 Zhao H, Guo Y, Li S, Han R, Ying J, Zhu H, Wang Y, Yin L, Han Y, Sun L, Wang Z, Lin Q, Bi X, Jiao Y, Jia H, Zhao J, Huang Z, Li Z, Zhou J, Song W, Meng K, Cai J. A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway. Oncotarget 2015;6:31927-43. [PMID: 26376676 DOI: 10.18632/oncotarget.5578] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 11.8] [Reference Citation Analysis]
634 Wei S, Hao X, Zhan D, Xiong M, Li K, Chen X, Huang Z. Are surgical indications of Barcelona Clinic Liver Cancer staging classification justified? J Huazhong Univ Sci Technolog Med Sci. 2011;31:637-641. [PMID: 22038353 DOI: 10.1007/s11596-011-0574-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
635 Ju MJ, Qiu SJ, Fan J, Zhou J, Gao Q, Cai MY, Li YW, Tang ZY. Preoperative serum gamma-glutamyl transferase to alanine aminotransferase ratio is a convenient prognostic marker for Child-Pugh A hepatocellular carcinoma after operation. J Gastroenterol. 2009;44:635-642. [PMID: 19387533 DOI: 10.1007/s00535-009-0050-x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 3.2] [Reference Citation Analysis]
636 Zaltron S, Spinetti A, Biasi L, Baiguera C, Castelli F. Chronic HCV infection: epidemiological and clinical relevance. BMC Infect Dis. 2012;12 Suppl 2:S2. [PMID: 23173556 DOI: 10.1186/1471-2334-12-s2-s2] [Cited by in Crossref: 57] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
637 Cong WM, Wu MC. Small hepatocellular carcinoma: current and future approaches. Hepatol Int. 2013;7:805-812. [PMID: 26201917 DOI: 10.1007/s12072-013-9454-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
638 Perumpail RB, Wong RJ, Ahmed A, Harrison SA. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience. Dig Dis Sci. 2015;60:3142-3148. [PMID: 26250831 DOI: 10.1007/s10620-015-3821-7] [Cited by in Crossref: 63] [Cited by in F6Publishing: 54] [Article Influence: 10.5] [Reference Citation Analysis]
639 Gentschev I, Müller M, Adelfinger M, Weibel S, Grummt F, Zimmermann M, Bitzer M, Heisig M, Zhang Q, Yu YA, Chen NG, Stritzker J, Lauer UM, Szalay AA. Efficient colonization and therapy of human hepatocellular carcinoma (HCC) using the oncolytic vaccinia virus strain GLV-1h68. PLoS One 2011;6:e22069. [PMID: 21779374 DOI: 10.1371/journal.pone.0022069] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
640 Hu S, Liu J, Feng S, Wang Y, Liu H. LncRNA SUMO1P3 acts as a prognostic biomarker and promotes hepatocellular carcinoma growth and metastasis. Aging (Albany NY) 2021;13:12479-92. [PMID: 33902004 DOI: 10.18632/aging.202921] [Reference Citation Analysis]
641 Zugazagoitia J, Manzano A, Sastre J, Ladero JM, Puente J, Díaz-Rubio E. Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function. Clin Transl Oncol. 2013;15:146-153. [PMID: 22875650 DOI: 10.1007/s12094-012-0902-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
642 Pradhan-Sundd T, Monga SP. Blood-Bile Barrier: Morphology, Regulation, and Pathophysiology. Gene Expr 2019;19:69-87. [PMID: 30646969 DOI: 10.3727/105221619X15469715711907] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 6.5] [Reference Citation Analysis]
643 Walker M, El-Serag HB, Sada Y, Mittal S, Ying J, Duan Z, Richardson P, Davila JA, Kanwal F. Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer. Aliment Pharmacol Ther 2016;43:621-30. [PMID: 26784271 DOI: 10.1111/apt.13505] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
644 Zhou P, Liang P, Yu X, Wang Y, Dong B. Percutaneous microwave ablation of liver cancer adjacent to the gastrointestinal tract. J Gastrointest Surg. 2009;13:318-324. [PMID: 18825464 DOI: 10.1007/s11605-008-0710-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
645 Turato C, Vitale A, Fasolato S, Ruvoletto M, Terrin L, Quarta S, Ramirez Morales R, Biasiolo A, Zanus G, Zali N. SERPINB3 is associated with TGF-β1 and cytoplasmic β-catenin expression in hepatocellular carcinomas with poor prognosis. Br J Cancer. 2014;110:2708-2715. [PMID: 24809782 DOI: 10.1038/bjc.2014.246] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
646 Sukowati CH, Rosso N, Crocè LS, Tiribelli C. Hepatic cancer stem cells and drug resistance: Relevance in targeted therapies for hepatocellular carcinoma. World J Hepatol 2010;2:114-26. [PMID: 21160982 DOI: 10.4254/wjh.v2.i3.114] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
647 Li Y, Xu Y, Wang R, Li W, He W, Luo X, Ye Y. Expression of Notch-Hif-1α signaling pathway in liver regeneration of rats. J Int Med Res 2020;48:300060520943790. [PMID: 32967512 DOI: 10.1177/0300060520943790] [Reference Citation Analysis]
648 Mizuguchi T, Nagayama M, Meguro M, Shibata T, Kaji S, Nobuoka T, Kimura Y, Furuhata T, Hirata K. Prognostic Impact of Surgical Complications and Preoperative Serum Hepatocyte Growth Factor in Hepatocellular Carcinoma Patients After Initial Hepatectomy. J Gastrointest Surg 2009;13:325-33. [DOI: 10.1007/s11605-008-0711-8] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 3.0] [Reference Citation Analysis]
649 Nel I, Baba HA, Ertle J, Weber F, Sitek B, Eisenacher M, Meyer HE, Schlaak JF, Hoffmann AC. Individual profiling of circulating tumor cell composition and therapeutic outcome in patients with hepatocellular carcinoma. Transl Oncol 2013;6:420-8. [PMID: 23908685 DOI: 10.1593/tlo.13271] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
650 Shindoh J, Kawamura Y, Kobayashi Y, Akuta N, Kobayashi M, Suzuki Y, Ikeda K, Hashimoto M. Time-to-Interventional Failure as a New Surrogate Measure for Survival Outcomes after Resection of Hepatocellular Carcinoma. J Gastrointest Surg 2020;24:50-7. [PMID: 31190124 DOI: 10.1007/s11605-019-04277-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
651 Cherqui D, Laurent A, Tayar C, Chang S, Van Nhieu JT, Loriau J, Karoui M, Duvoux C, Dhumeaux D, Fagniez PL. Laparoscopic liver resection for peripheral hepatocellular carcinoma in patients with chronic liver disease: midterm results and perspectives. Ann Surg 2006;243:499-506. [PMID: 16552201 DOI: 10.1097/01.sla.0000206017.29651.99] [Cited by in Crossref: 229] [Cited by in F6Publishing: 206] [Article Influence: 15.3] [Reference Citation Analysis]
652 Zhang YC, Wang XP, Zhang LY, Song AL, Kou ZM, Li XS. Effect of blocking IGF-I receptor on growth of human hepatocellular carcinoma cells. World J Gastroenterol 2006;12:3977-82. [PMID: 16810743 DOI: 10.3748/wjg.v12.i25.3977] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
653 Wang R, Geller DA, Wink DA, Cheng B, Billiar TR. NO and hepatocellular cancer. Br J Pharmacol 2020;177:5459-66. [PMID: 31423564 DOI: 10.1111/bph.14838] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
654 Qu JH, Chang XJ, Lu YY, Bai WL, Chen Y, Zhou L, Zeng Z, Wang CP, An LJ, Hao LY, Xu GL, Gao XD, Lou M, Lv JY, Yang YP. Overexpression of metastasis-associated in colon cancer 1 predicts a poor outcome of hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol 2012;18:2995-3003. [PMID: 22736924 DOI: 10.3748/wjg.v18.i23.2995] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
655 Ueshima K, Kudo M, Tanaka M, Kumada T, Chung H, Hagiwara S, Inoue T, Yada N, Kitai S. Phase I/II Study of Sorafenib in Combination with Hepatic Arterial Infusion Chemotherapy Using Low-Dose Cisplatin and 5-Fluorouracil. Liver Cancer 2015;4:263-73. [PMID: 26734580 DOI: 10.1159/000367751] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
656 Zhang R, Lin HM, Broering R, Shi XD, Yu XH, Xu LB, Wu WR, Liu C. Dickkopf-1 contributes to hepatocellular carcinoma tumorigenesis by activating the Wnt/β-catenin signaling pathway. Signal Transduct Target Ther 2019;4:54. [PMID: 31839998 DOI: 10.1038/s41392-019-0082-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0]